

Advancing research diagnostic criteria for Alzheimer's d

Lancet Neurology, The

13, 614-629

DOI: 10.1016/s1474-4422(14)70090-0

Citation Report

#	ARTICLE	IF	CITATIONS
1	[ <sup>11</sup> C]( <i>R</i> )-PK11195 PET imaging of microglial activation in multiple system atrophy. <i>Neurology</i> , 2003, 61, 686-689.	1.5	229
2	General anesthetic and the risk of dementia in elderly patients: current insights. <i>Clinical Interventions in Aging</i> , 2014, 9, 1619.	1.3	67
3	Cerebrospinal Fluid Apolipoprotein E Concentration and Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 1229-1236.	1.2	9
4	Florbetaben for PET Imaging of Beta-Amyloid Plaques in the Brain. <i>Neurology and Therapy</i> , 2014, 3, 79-88.	1.4	19
5	Astrocytosis measured by <sup>11</sup> C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer's patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2120-2126.	3.3	53
6	Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human A $\beta$ -induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: rapid reversal by anti-A $\beta$ agents. <i>Acta Neuropathologica Communications</i> , 2014, 2, 175.	2.4	32
7	Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. <i>Croatian Medical Journal</i> , 2014, 55, 347-365.	0.2	34
9	New tools for the evaluation of patients with neurodegenerative diseases. <i>Neurodegenerative Disease Management</i> , 2014, 4, 403-405.	1.2	0
10	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. <i>NeuroImage: Clinical</i> , 2014, 6, 445-454.	1.4	172
11	Degradation of cognitive timing mechanisms in behavioural variant frontotemporal dementia. <i>Neuropsychologia</i> , 2014, 65, 88-101.	0.7	22
12	Imaging endpoints for clinical trials in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 87.	3.0	47
13	How to Diagnose and Define Alzheimer's. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2014, 14, 1.	0.0	0
14	Neutral polymers as coatings for high resolution electrophoretic separation of A $\beta$ peptides on glass microchips. <i>Analyst</i> , 2014, 139, 6547-6555.	1.7	13
15	Synthesis aided structural determination of amyloid- $\beta$ (1-15) glycopeptides, new biomarkers for Alzheimer's disease. <i>Chemical Communications</i> , 2014, 50, 15067-15070.	2.2	14
16	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. <i>Neurology</i> , 2014, 83, 1945-1953.	1.5	213
17	Neuropathological processes in sepsis. <i>Lancet Neurology</i> , 2014, 13, 534-536.	4.9	24
18	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
19	The Relationship between Amyloid Deposition, Neurodegeneration, and Cognitive Decline in Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 498.	2.0	13

#	ARTICLE	IF	CITATIONS
20	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014, 10, 808-817.	0.4	163
21	Age-specific population frequencies of cerebral $\beta$ -amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2014, 13, 997-1005.	4.9	297
22	Biomarkers in dementia: clinical utility and new directions. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1426-1434.	0.9	119
23	Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. <i>Molecular Brain</i> , 2014, 7, 40.	1.3	107
24	At the crossroads of preclinical AD and normal brain ageing. <i>Lancet Neurology</i> , The, 2014, 13, 965-966.	4.9	3
25	A population perspective on the IWG-2 research diagnostic criteria for Alzheimer's disease. <i>Lancet Neurology</i> , The, 2014, 13, 532-534.	4.9	25
26	Risk Factors and Screening Methods for Detecting Dementia: A Narrative Review. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S329-S338.	1.2	20
27	Automatic speech analysis for the assessment of patients with predementia and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 112-124.	1.2	217
28	Digital technologies for cognitive assessment to accelerate drug development in Alzheimer's disease. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 475-476.	2.3	15
29	Personalized health care beyond oncology: new indications for immunoassay-based companion diagnostics. <i>Annals of the New York Academy of Sciences</i> , 2015, 1346, 71-80.	1.8	15
30	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical <sc>AD</sc> subjects. <i>Human Brain Mapping</i> , 2015, 36, 5123-5136.	1.9	19
31	Elevation of the Plasma $A\beta_{40}/A\beta_{42}$ Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 1043-1050.	1.2	33
32	Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 945-959.	1.2	52
33	Exercise interventions for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. <i>The Cochrane Library</i> , 0, , .	1.5	10
34	Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography. <i>Scientific Reports</i> , 2015, 5, 16404.	1.6	110
35	Aberrant intra- and inter-network connectivity architectures in Alzheimer's disease and mild cognitive impairment. <i>Scientific Reports</i> , 2015, 5, 14824.	1.6	99
36	Alzheimer's disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15056.	18.1	1,210
37	Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer's Disease Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 187-199.	1.2	7

#	ARTICLE	IF	CITATIONS
38	Impaired Parahippocampus Connectivity in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1051-1064.	1.2	50
39	Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF $\beta$ 42 and Tau. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 883-887.	1.2	15
40	Prediction of Alzheimer's Disease Dementia: Data from the GuidAge Prevention Trial. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 793-804.	1.2	28
41	Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 817-836.	1.2	47
42	Identification of Conversion from Normal Elderly Cognition to Alzheimer's Disease using Multimodal Support Vector Machine. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 1057-1067.	1.2	16
43	Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 159-177.	1.2	32
44	Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2015, 50, 161-174.	1.2	8
45	Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 189-196.	1.2	4
46	A review of ethical issues in dementia. <i>International Psychogeriatrics</i> , 2015, 27, 1635-1647.	0.6	38
47	Fully Automated Atlas-Based Hippocampus Volumetry for Clinical Routine: Validation in Subjects with Mild Cognitive Impairment from the ADNI Cohort. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 199-209.	1.2	25
48	The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 17-32.	1.2	36
49	Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 729-740.	1.2	9
50	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	1.2	28
51	Clinical Evaluation of Brain Perfusion SPECT with Brodmann Areas Mapping in Early Diagnosis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 773-785.	1.2	20
52	Diffusion Kurtosis Imaging: A Possible MRI Biomarker for AD Diagnosis?. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 937-948.	1.2	50
53	The New Conceptualization of Alzheimer's Disease under the Microscope of Influential Definitions of Disease. <i>Psychopathology</i> , 2015, 48, 359-367.	1.1	9
54	Do cerebrospinal fluid transfer methods affect measured amyloid $\beta$ 42, total tau, and phosphorylated tau in clinical practice?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 380-384.	1.2	5
55	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 440-446.	1.2	16

#	ARTICLE	IF	CITATIONS
56	TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. <i>Annals of Neurology</i> , 2015, 78, 697-709.	2.8	96
57	Diagnostic value of cerebrospinal fluid A $\beta$ ratios in preclinical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 75.	3.0	47
58	Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 425-432.	1.2	16
59	Blood Protein Markers of Neocortical Amyloid- $\beta$ Burden: A Candidate Study Using SOMAscan Technology. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 947-961.	1.2	49
60	Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 617-631.	1.2	330
61	Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 205-214.	1.2	57
62	Cerebrospinal fluid A $\beta$ <sub>42</sub> levels and APP processing pathway genes in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 936-944.	2.2	14
63	Clinical Significance of Cerebrovascular Biomarkers and White Matter Tract Integrity in Alzheimer Disease. <i>Medicine (United States)</i> , 2015, 94, e1192.	0.4	15
64	Cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2015, 28, 402-409.	3.1	39
65	Corticobasal Syndrome in a Family with Early-Onset Alzheimer's Disease Linked to a Presenilin-1 Gene Mutation. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 388-394.	0.8	10
66	Nanotheranostics: Congo Red/Rutin-MNPs with Enhanced Magnetic Resonance Imaging and H <sub>2</sub> O <sub>2</sub> -Responsive Therapy of Alzheimer's Disease in APP <sup>swE</sup> /PS1 <sup>dE9</sup> Transgenic Mice. <i>Advanced Materials</i> , 2015, 27, 5499-5505.	11.1	120
67	Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 1230-1237.	1.3	29
68	Dietary interventions for prevention of dementia in people with mild cognitive impairment. <i>The Cochrane Library</i> , 2015, , .	1.5	7
69	In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2015, 28, 351-357.	1.8	14
70	Dissociating Statistically-Determined Alzheimer's Disease/Vascular Dementia Neuropsychological Syndromes Using White and Gray Neuroradiological Parameters. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 833-847.	1.2	13
71	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. <i>Current Alzheimer Research</i> , 2015, 12, 69-79.	0.7	22
72	Clinical trial design of serious gaming in mild cognitive impairment. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 26.	1.7	8
73	Reliability of a novel serious game using dual-task gait profiles to early characterize aMCI. <i>Frontiers in Aging Neuroscience</i> , 2015, 07, 50.	1.7	32

#	ARTICLE	IF	CITATIONS
74	Overestimating the Effects of Healthy Aging. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 164.	1.7	9
75	Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. <i>Frontiers in Neurology</i> , 2015, 6, 143.	1.1	23
76	Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. <i>Frontiers in Neurology</i> , 2015, 6, 186.	1.1	22
77	Cerebrospinal Fluid A $\beta$ 40 Improves the Interpretation of A $\beta$ 42 Concentration for Diagnosing Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 247.	1.1	49
78	Expanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted Approaches. <i>Frontiers in Neurology</i> , 2015, 6, 256.	1.1	16
79	The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events. <i>Frontiers in Neuroscience</i> , 2015, 9, 345.	1.4	66
80	Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 493-502.	1.2	12
81	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0136181.	1.1	129
82	Clinical Assessment of Cognitive Decline in Adults with Down Syndrome. <i>Current Alzheimer Research</i> , 2015, 13, 30-34.	0.7	31
83	FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects. <i>Current Radiopharmaceuticals</i> , 2015, 8, 69-75.	0.3	16
84	Aberrant Functional Connectivity Architecture in Alzheimer's Disease and Mild Cognitive Impairment: A Whole-Brain, Data-Driven Analysis. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	30
85	Precuneus and Cingulate Cortex Atrophy and Hypometabolism in Patients with Alzheimer's Disease and Mild Cognitive Impairment: MRI and <sup>18</sup> F-FDG PET Quantitative Analysis Using FreeSurfer. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	90
86	A normative study of the Italian printed word version of the free and cued selective reminding test. <i>Neurological Sciences</i> , 2015, 36, 1127-1134.	0.9	21
87	Apport de la scintigraphie de perfusion cérébrale dans l'exploration du syndrome cortico-basal. <i>Medecine Nucleaire</i> , 2015, 39, 81-89.	0.2	0
88	Progressive supranuclear palsy finally has a clinically measurable $\alpha$ abnormality. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 241-241.	0.9	0
89	Optimising the Cutoffs of Cognitive Screening Instruments in Pragmatic Diagnostic Accuracy Studies: Maximising Accuracy or the Youden Index?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 39, 167-175.	0.7	31
90	Preanalytical Variables and Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. <i>Clinical Chemistry</i> , 2015, 61, 686-688.	1.5	1
91	Amyloid Burden in the Hippocampus and Default Mode Network. <i>Medicine (United States)</i> , 2015, 94, e763.	0.4	34

#	ARTICLE	IF	CITATIONS
92	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
93	Advanced classification of Alzheimer's disease and healthy subjects based on EEG markers. , 2015, , .		10
94	Clinicopathological Correlations and Concomitant Pathologies in Rapidly Progressive Dementia: A Brain Bank Series. <i>Neurodegenerative Diseases</i> , 2015, 15, 350-360.	0.8	35
95	Independent information from cerebrospinal fluid amyloid- $\beta^2$ and florbetapir imaging in Alzheimer's disease. <i>Brain</i> , 2015, 138, 772-783.	3.7	200
96	Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. <i>NeuroImage: Clinical</i> , 2015, 7, 34-42.	1.4	85
97	Alzheimer's disease " Recent biomarker developments in relation to updated diagnostic criteria. <i>Clinica Chimica Acta</i> , 2015, 449, 3-8.	0.5	25
98	Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals. <i>Neuropsychopharmacology</i> , 2015, 40, 1794-1803.	2.8	55
99	Towards early diagnosis in Alzheimer disease. <i>Nature Reviews Neurology</i> , 2015, 11, 69-70.	4.9	59
100	White matter disruption at the prodromal stage of Alzheimer's disease: Relationships with hippocampal atrophy and episodic memory performance. <i>NeuroImage: Clinical</i> , 2015, 7, 482-492.	1.4	68
101	Phenotypical variation in Alzheimer's disease: insights from posterior cortical atrophy. <i>Practical Neurology</i> , 2015, 15, 2-4.	0.5	3
102	Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. <i>NeuroImage: Clinical</i> , 2015, 7, 187-194.	1.4	94
103	Diagnostic Values of Cerebrospinal Fluid T-Tau and A $\beta^{242}$ using Meso Scale Discovery Assays for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 709-719.	1.2	28
104	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. <i>Acta Neurologica Belgica</i> , 2015, 115, 547-555.	0.5	7
105	An Integrated Bioinformatics Approach for Identifying Genetic Markers that Predict Cerebrospinal Fluid Biomarker p-tau181/A $\beta^{1-42}$ Ratio in ApoE4-Negative Mild Cognitive Impairment Patients. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 1061-1076.	1.2	6
106	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015, 138, 1327-1338.	3.7	284
107	Amyloid- $\beta^2$ deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. <i>Brain</i> , 2015, 138, 1023-1035.	3.7	207
108	Enfermedad de Alzheimer. <i>Medicine</i> , 2015, 11, 4306-4315.	0.0	4
109	Mild cognitive impairment definitions: more evolution than revolution. <i>Neurodegenerative Disease Management</i> , 2015, 5, 11-17.	1.2	8

#	ARTICLE	IF	CITATIONS
110	Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. <i>Neurology</i> , 2015, 84, 1261-1268.	1.5	41
111	Dementia: timely diagnosis and early intervention. <i>BMJ, The</i> , 2015, 350, h3029-h3029.	3.0	315
112	Hemorrhagic stroke, cerebral amyloid angiopathy, Down syndrome and the Boston criteria. <i>Neurologia I Neurochirurgia Polska</i> , 2015, 49, 193-196.	0.6	15
113	Usefulness of data from magnetic resonance imaging to improve prediction of dementia: population based cohort study. <i>BMJ, The</i> , 2015, 350, h2863-h2863.	3.0	37
114	Plasma amyloid $\beta$ "quo vadis?". <i>Neurobiology of Aging</i> , 2015, 36, 2671-2673.	1.5	17
115	Le diagnostic prÃ©coce de la maladie d'Alzheimer: panacÃ©e ou catastrophe?. <i>Ethics, Medicine and Public Health</i> , 2015, 1, 151-154.	0.5	2
116	Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. <i>Alzheimer's and Dementia</i> , 2015, 11, 865-884.	0.4	181
117	The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. <i>Alzheimer's and Dementia</i> , 2015, 11, 772-791.	0.4	79
118	Sulcal morphology as a new imaging marker for the diagnosis of early onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2932-2939.	1.5	39
119	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. <i>Brain</i> , 2015, 138, 3110-3122.	3.7	94
120	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2340-2347.	1.5	49
121	Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1492-1506.	3.3	11
122	Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging correlates. <i>Neurobiology of Aging</i> , 2015, 36, 3108-3115.	1.5	32
123	Cerebrospinal fluid tau and amyloid- $\beta_{1-42}$ in patients with dementia. <i>Brain</i> , 2015, 138, 2716-2731.	3.7	152
124	Abnormalities of fixation, saccade and pursuit in posterior cortical atrophy. <i>Brain</i> , 2015, 138, 1976-1991.	3.7	74
125	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	3.7	397
126	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. <i>Cortex</i> , 2015, 69, 220-236.	1.1	133
127	Should we screen for cognitive decline and dementia?. <i>Maturitas</i> , 2015, 82, 28-35.	1.0	24



#	ARTICLE	IF	CITATIONS
128	Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. <i>Clinica Chimica Acta</i> , 2015, 449, 9-15.	0.5	66
129	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, <i>SveDem. Alzheimer's and Dementia</i> , 2015, 11, 1470-1479.	0.4	17
130	[18F]Florbetaben: A Review in $\beta$ -Amyloid PET Imaging in Cognitive Impairment. <i>CNS Drugs</i> , 2015, 29, 605-613.	2.7	24
131	Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2015, 35, 10402-10411.	1.7	117
132	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.4	142
133	A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1487-1491.	3.3	56
134	Advances in the prevention of Alzheimer's Disease. <i>F1000prime Reports</i> , 2015, 7, 50.	5.9	72
135	Amyloid Tracers. , 2015, , 633-639.		0
136	Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer's dementia. <i>Aging and Mental Health</i> , 2015, 19, 247-257.	1.5	32
137	Alzheimer's disease clinical trials: past failures and future opportunities. <i>Clinical Investigation</i> , 2015, 5, 297-309.	0.0	15
138	Imagerie multimodale TEP et IRM dans la prise en charge des démences. <i>Medecine Nucleaire</i> , 2015, 39, 268-278.	0.2	0
139	The use of amyloid imaging in clinical praxis: a critical review. <i>Clinical and Translational Imaging</i> , 2015, 3, 7-11.	1.1	5
140	Beta-amyloid imaging with florbetaben. <i>Clinical and Translational Imaging</i> , 2015, 3, 13-26.	1.1	120
141	New criteria for Alzheimer's disease: which, when and why?. <i>Brain</i> , 2015, 138, 1134-1137.	3.7	12
142	Glutamate receptors function as scaffolds for the regulation of $\beta$ -amyloid and cellular prion protein signaling complexes. <i>Molecular Brain</i> , 2015, 8, 18.	1.3	59
143	Early neurone loss in Alzheimer's disease: cortical or subcortical?. <i>Acta Neuropathologica Communications</i> , 2015, 3, 10.	2.4	150
144	Biochemical and Neuroimaging Studies in Subjective Cognitive Decline: Progress and Perspectives. <i>CNS Neuroscience and Therapeutics</i> , 2015, 21, 768-775.	1.9	50
145	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. <i>Brain</i> , 2015, 138, 761-771.	3.7	222

#	ARTICLE	IF	CITATIONS
146	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
147	Importance and Impact of Preanalytical Variables on Alzheimer Disease Biomarker Concentrations in Cerebrospinal Fluid. Clinical Chemistry, 2015, 61, 734-743.	1.5	53
148	Lifting the veil: how to use clinical neuropsychology to assess dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1216-1224.	0.9	16
149	Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurological Sciences, 2015, 36, 1075-1081.	0.9	35
150	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
151	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
152	The Impact of Age on Cognition. Seminars in Hearing, 2015, 36, 111-121.	0.5	782
153	Atrial Fibrillation and Cognition. Stroke, 2015, 46, 3316-3321.	1.0	56
154	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	1.8	39
155	MR spectroscopy, a new in vivo biomarker for dementia disorders?. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, jnnp-2015-311494.	0.9	3
156	Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report. BMC Neurology, 2015, 15, 152.	0.8	4
157	Benefits and risks of add-on therapies for Alzheimer's disease. Neurodegenerative Disease Management, 2015, 5, 445-462.	1.2	4
158	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
159	3D Shape Perception in Posterior Cortical Atrophy: A Visual Neuroscience Perspective. Journal of Neuroscience, 2015, 35, 12673-12692.	1.7	27
160	Alzheimer's disease in the 100 years since Alzheimer's death. Brain, 2015, 138, 3816-3821.	3.7	50
161	Cerebrospinal fluid A $\beta$ 40 is similarly reduced in patients with Frontotemporal Lobar Degeneration and Alzheimer's Disease. Journal of the Neurological Sciences, 2015, 358, 308-316.	0.3	25
163	Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Therapeutic Advances in Drug Safety, 2015, 6, 151-165.	1.0	32
164	Decision tree analysis of genetic risk for clinically heterogeneous Alzheimer's disease. BMC Neurology, 2015, 15, 47.	0.8	25

#	ARTICLE	IF	CITATIONS
165	Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: consensus proposal from the SEMNIM and SEN. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 303-313.	0.1	3
166	Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. <i>Neuroscience</i> , 2015, 309, 29-50.	1.1	265
167	The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment. <i>Social Science and Medicine</i> , 2015, 143, 117-127.	1.8	59
168	Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes. <i>JAMA Neurology</i> , 2015, 72, 1183.	4.5	57
169	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. <i>Acta Neuropathologica</i> , 2015, 130, 501-510.	3.9	35
170	Asymmetries of amyloid- $\beta^2$ burden and neuronal dysfunction are positively correlated in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3089-3099.	3.7	72
171	Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. <i>Clinical Therapeutics</i> , 2015, 37, 1632-1642.	1.1	35
172	Clinical use of amyloid- $\beta$ positron emission tomography neuroimaging: Practical and bioethical considerations. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 358-367.	1.2	33
173	Burden of Care and Patient's Neuropsychiatric Symptoms Influence Carer's Evaluation of Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 256-267.	0.7	22
174	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2015, 256, 168-183.	1.3	55
175	Conventional and robust norming in identifying preclinical dementia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2015, 37, 1098-1106.	0.8	12
176	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. <i>Brain</i> , 2015, 138, 3373-3385.	3.7	200
177	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. <i>Alzheimer's and Dementia</i> , 2015, 11, 964-974.	0.4	400
179	Recomendaciones para la utilizaci3n de biomarcadores de imagen PET en el proceso diagn3stico de las enfermedades neurodegenerativas que cursan con demencia: documento de consenso SEMNIM y SEN. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2015, 34, 303-313.	0.0	16
180	Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 83-105.	1.4	64
181	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
182	Hippocampal volume, early cognitive decline and gait variability: Which association?. <i>Experimental Gerontology</i> , 2015, 61, 98-104.	1.2	57
183	In search of innovative therapeutics for neuropsychiatric disorders: The case of neurodegenerative diseases. <i>Annales Pharmaceutiques Francaises</i> , 2015, 73, 3-12.	0.4	9

#	ARTICLE	IF	CITATIONS
184	Challenges of multimorbidity of the aging brain: a critical update. <i>Journal of Neural Transmission</i> , 2015, 122, 505-521.	1.4	115
185	An Emerging Model of Word Retrieval in Preclinical Alzheimer's Disease. , 2016, 06, .		0
186	Postoperative Cognitive Dysfunction. , 2016, , 411-427.		3
187	Mechanisms underlying Alzheimer's disease. <i>Neuropsychiatry I Neuropsychologia</i> , 2016, 3, 85-92.	0.3	1
189	Centered Kernel Alignment Enhancing Neural Network Pretraining for MRI-Based Dementia Diagnosis. <i>Computational and Mathematical Methods in Medicine</i> , 2016, 2016, 1-10.	0.7	17
190	Olfactory dysfunction in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 869.	1.0	127
191	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.3	33
192	Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1065-1080.	1.2	34
193	The New Criteria for Alzheimer's Disease - Implications for Geriatricians*. <i>Canadian Geriatrics Journal</i> , 2016, 19, 66-73.	0.7	14
194	Translational Approaches in Alzheimer's Disease. , 2016, , 157-173.		0
195	Expression of Phenotypic Astrocyte Marker Is Increased in a Transgenic Mouse Model of Alzheimer's Disease versus Age-Matched Controls: A Presymptomatic Stage Study. <i>International Journal of Alzheimer's Disease</i> , 2016, 2016, 1-12.	1.1	22
197	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid A $\beta$ 42 and the Ratios of A $\beta$ Isoforms Using Low Protein Binding Tubes. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1121-1132.	1.2	60
198	Abnormal Resting-State Functional Connectivity Strength in Mild Cognitive Impairment and Its Conversion to Alzheimer's Disease. <i>Neural Plasticity</i> , 2016, 2016, 1-12.	1.0	69
199	Cerebrospinal Fluid Levels of Amyloid Beta 1 $\beta$ 43 in Patients with Amnesic Mild Cognitive Impairment or Early Alzheimer's Disease: A 2-Year Follow-Up Study. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 30.	1.7	12
200	Exercise-Related Changes of Networks in Aging and Mild Cognitive Impairment Brain. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 47.	1.7	62
201	In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 108.	1.7	282
202	An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 276.	1.7	50
203	Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting State EEG Rhythms. <i>Frontiers in Neuroscience</i> , 2016, 10, 47.	1.4	73

#	ARTICLE	IF	CITATIONS
204	Early Dementia Screening. <i>Diagnostics</i> , 2016, 6, 6.	1.3	57
205	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. <i>Korean Journal of Radiology</i> , 2016, 17, 827.	1.5	61
206	What can imaging tell us about cognitive impairment and dementia?. <i>World Journal of Radiology</i> , 2016, 8, 240.	0.5	33
207	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. <i>Frontiers in Pharmacology</i> , 2016, 7, 88.	1.6	22
208	Methods for the Specific Detection and Quantitation of Amyloid- $\beta$ Oligomers in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 53-67.	1.2	26
209	The Correlation Study between Plasma A $\beta$ Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers. <i>Dementia and Neurocognitive Disorders</i> , 2016, 15, 122.	0.4	5
210	Performance of Cerebrospinal Fluid Biomarkers of Alzheimer Disease in a Memory Clinic in Norway. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 8-14.	0.6	4
211	Is there a significant interaction effect between apolipoprotein E rs405509 T/T and $\beta$ 4 genotypes on cognitive impairment and gray matter volume?. <i>European Journal of Neurology</i> , 2016, 23, 1415-1425.	1.7	20
212	MiR-214-3p attenuates cognition defects via the inhibition of autophagy in SAMP8 mouse model of sporadic Alzheimer's disease. <i>NeuroToxicology</i> , 2016, 56, 139-149.	1.4	61
213	Frontal Variant Alzheimer Disease or Frontotemporal Lobe Degeneration With Incidental Amyloidosis?. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 183-185.	0.6	8
214	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting. <i>Clinical Nuclear Medicine</i> , 2016, 41, e18-e23.	0.7	22
215	Arterial stiffness and medial temporal lobe atrophy in elders with memory disorders. <i>Journal of Hypertension</i> , 2016, 34, 1331-1337.	0.3	20
216	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
217	Cognitive Profiles on the Severe Impairment Battery Are Similar in Alzheimer Disease and Down Syndrome With Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2016, 30, 251-257.	0.6	19
218	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a "European ADNI" study. <i>Journal of Internal Medicine</i> , 2016, 279, 576-591.	2.7	64
219	The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 373-392.	1.2	7
220	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2016, 8, 1184-1196.	3.3	219
221	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2016, 6, 313-329.	0.6	12

#	ARTICLE	IF	CITATIONS
222	Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 97-106.	1.2	20
223	A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 383-395.	1.2	47
224	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913.	1.2	21
225	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 159-170.	1.2	23
226	Homotaurine Effects on Hippocampal Volume Loss and Episodic Memory in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 807-816.	1.2	15
227	EEG Dominant Frequency Peak Differentiates Between Alzheimer's Disease and Frontotemporal Lobar Degeneration. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 53-58.	1.2	13
228	Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 315-320.	1.2	47
229	Clinical and neuroimaging differences between posterior cortical atrophy and typical amnesic Alzheimer's disease patients at an early disease stage. <i>Scientific Reports</i> , 2016, 6, 29372.	1.6	21
230	Subjective Memory Impairment and Gait Variability in Cognitively Healthy Individuals: Results from a Cross-Sectional Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 965-971.	1.2	11
231	<sup>18</sup> F PET ligands for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 0, .	1.5	5
232	A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. <i>Nature Communications</i> , 2016, 7, 11398.	5.8	319
233	Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1099-1109.	1.2	146
234	Looking for Measures of Disease Severity in the Frontotemporal Dementia Continuum. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1227-1235.	1.2	17
235	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 41.	3.0	121
236	Longitudinal Study of Impaired Intra- and Inter-Network Brain Connectivity in Subjects at High Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 913-927.	1.2	54
237	Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1495-1508.	1.2	24
238	Atrophy in Alzheimer's Disease and Semantic Dementia: An ALE Meta-Analysis of Voxel-Based Morphometry Studies. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 941-955.	1.2	58
239	Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1011-1022.	1.2	60

#	ARTICLE	IF	CITATIONS
240	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 227-236.	1.2	14
241	Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 999-1010.	1.2	26
242	The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 283-293.	1.2	23
243	Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid- $\beta$ Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 691-705.	1.2	14
244	Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 179-190.	1.2	39
245	Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 359-371.	1.2	39
246	So Close Yet So Far: Executive Contribution to Memory Processing in Behavioral Variant Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1005-1014.	1.2	17
247	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496.	1.2	14
248	Recent advances in cerebrospinal fluid biomarkers for the detection of preclinical Alzheimer's disease. <i>Current Opinion in Neurology</i> , 2016, 29, 749-755.	1.8	10
249	Prediction of Alzheimer's Disease in Amnesic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1385-1401.	1.2	13
250	Are depressive symptoms in mild cognitive impairment predictive of conversion to dementia?. <i>International Psychogeriatrics</i> , 2016, 28, 921-928.	0.6	5
253	Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 51.	3.0	19
254	Analysis of Cerebrospinal Fluid and [11C]PIB PET Biomarkers for Alzheimer's Disease with Updated Protocols. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1403-1413.	1.2	17
255	Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 55-67.	1.2	27
256	The Clinical Use of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Diagnosis: The Italian Selfie. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1659-1666.	1.2	17
257	Hippocampus and Basal Forebrain Volumetry for Dementia and Mild Cognitive Impairment Diagnosis: Could It Be Useful in Primary Care?. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1379-1394.	1.2	11
258	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	1.5	34
259	Patterns of 11 C-PIB cerebral retention in mild cognitive impairment patients. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 171-174.	0.1	0

#	ARTICLE	IF	CITATIONS
260	Amyloid Imaging in Dementia and Related Disorders. , 2016, , 89-102.		0
261	Dual-phase amyloid PET: hitting two birds with one stone. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1300-1303.	3.3	22
262	Patterns of 11C-PIB cerebral retention in mild cognitive impairment patients. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2016, 35, 171-174.	0.0	3
263	Can patients without early, prominent visual deficits still be diagnosed of posterior cortical atrophy?. Journal of the Neurological Sciences, 2016, 367, 26-31.	0.3	4
264	Measuring Cortical Connectivity in Alzheimer's Disease as a Brain Neural Network Pathology: Toward Clinical Applications. Journal of the International Neuropsychological Society, 2016, 22, 138-163.	1.2	92
265	Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics. Annual Review of Neuroscience, 2016, 39, 57-79.	5.0	97
266	The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF- $\alpha$ , TGF- $\beta$ 2 and IFN- $\gamma$ 3. Translational Neurodegeneration, 2016, 5, 7.	3.6	211
267	Arterial spin labeling imaging reveals widespread and $\beta$ -independent reductions in cerebral blood flow in elderly apolipoprotein epsilon-4 carriers. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 581-595.	2.4	53
268	Familial early-onset dementia with complex neuropathologic phenotype and genomic background. Neurobiology of Aging, 2016, 42, 199-204.	1.5	16
269	Epigenetics of dementia: understanding the disease as a transformation rather than a state. Lancet Neurology, The, 2016, 15, 760-774.	4.9	116
270	Aberrant functional connectivity differentiates retrosplenial cortex from posterior cingulate cortex in prodromal Alzheimer's disease. Neurobiology of Aging, 2016, 44, 114-126.	1.5	63
271	Evaluation of DSM-5 and IWG-2 criteria for the diagnosis of Alzheimer's disease and dementia with Lewy bodies. Diagnosis, 2016, 3, 9-12.	1.2	5
272	Early [18F]florbetaben and [11C]PIB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1700-1709.	3.3	69
273	Strategy-Based Cognitive Training for Improving Executive Functions in Older Adults: a Systematic Review. Neuropsychology Review, 2016, 26, 252-270.	2.5	52
274	Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiology of Aging, 2016, 47, 149-156.	1.5	39
275	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. Neurobiology of Aging, 2016, 48, 122-134.	1.5	53
276	Electroencephalography Is a Good Complement to Currently Established Dementia Biomarkers. Dementia and Geriatric Cognitive Disorders, 2016, 42, 80-92.	0.7	30
277	CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease. Proteomics - Clinical Applications, 2016, 10, 1242-1253.	0.8	64



#	ARTICLE	IF	CITATIONS
278	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta^2$ in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
280	Biomarker-guided classification scheme of neurodegenerative diseases. <i>Journal of Sport and Health Science</i> , 2016, 5, 383-387.	3.3	22
281	Mnemonic strategy training of the elderly at risk for dementia enhances integration of information processing via cross-frequency coupling. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 241-249.	1.8	24
283	Insights into White Matter Damage in Alzheimer's Disease: From Postmortem to in vivo Diffusion Tensor MRI Studies. <i>Neurodegenerative Diseases</i> , 2016, 16, 26-33.	0.8	42
284	Diagnostic de la maladie d'Alzheimer: apport de l'imagerie au florbetapir et autres radiopharmaceutiques de la plaque amyloïde. <i>Medecine Nucleaire</i> , 2016, 40, 364-381.	0.2	2
285	Regional tau deposition measured by [18F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 38.	3.0	48
287	Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study. <i>Clinical Neurophysiology</i> , 2016, 127, 3455-3469.	0.7	4
288	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	4.4	9
289	Exploring anterograde memory: a volumetric MRI study in patients with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 26.	3.0	23
291	Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 1288-1296.	0.4	23
292	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 117-123.	3.0	8
293	Cerebrospinal fluid neurogranin and $\gamma$ -KL $\beta$ as biomarkers of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 12-20.	1.7	137
294	Alzheimer's disease prevention: A way forward. <i>Revista Clínica Española</i> , 2016, 216, 495-503.	0.3	3
295	Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder. <i>Bipolar Disorders</i> , 2016, 18, 71-77.	1.1	11
296	Reference measurement procedure for CSF amyloid beta ( $A\beta^2$ ) and the CSF $A\beta^2/A\beta^4$ ratio: a cross-validation study against amyloid PET. <i>Journal of Neurochemistry</i> , 2016, 139, 651-658.		78
297	Neural correlates of reduced awareness in instrumental activities of daily living in frontotemporal dementia. <i>Experimental Gerontology</i> , 2016, 83, 158-164.	1.2	19
298	Network-Based Statistic Show Aberrant Functional Connectivity in Alzheimer's Disease. <i>IEEE Journal on Selected Topics in Signal Processing</i> , 2016, 10, 1182-1188.	7.3	22
299	Longitudinal $\beta^2$ -Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. <i>JAMA Neurology</i> , 2016, 73, 1192.	4.5	77

#	ARTICLE	IF	CITATIONS
300	Introduction to Alzheimer's Disease Biomarkers. , 2016, , 3-23.		6
301	Clinical Diagnosis of Alzheimer's Disease. , 2016, , 27-48.		14
302	Neuroimaging Biomarkers in Alzheimer's Disease. , 2016, , 51-100.		8
303	Alzheimer's Disease Cerebrospinal Fluid (CSF) Biomarkers. , 2016, , 139-180.		4
304	The effects of healthy aging, amnesic mild cognitive impairment, and Alzheimer's disease on recollection, familiarity and false recognition, estimated by an associative process-dissociation recognition procedure. <i>Neuropsychologia</i> , 2016, 91, 29-35.	0.7	23
305	Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. <i>Neurology</i> , 2016, 87, 1235-1241.	1.5	34
306	Revisiting DLB Diagnosis. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 249-253.	1.2	92
307	Differential association of left and right hippocampal volumes with verbal episodic and spatial memory in older adults. <i>Neuropsychologia</i> , 2016, 93, 380-385.	0.7	108
309	Plasma $\beta$ -amyloid in Alzheimer's disease and vascular disease. <i>Scientific Reports</i> , 2016, 6, 26801.	1.6	442
310	Standardized Uptake Value Ratio-Independent Evaluation of Brain Amyloidosis. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1437-1457.	1.2	22
311	Performance of Hippocampus Volumetry with FSL-FIRST for Prediction of Alzheimer's Disease Dementia in at Risk Subjects with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 867-873.	1.2	19
312	Clinical PET/MR Imaging in Dementia and Neuro-Oncology. <i>PET Clinics</i> , 2016, 11, 441-452.	1.5	32
313	Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 3, 98-102.	1.2	62
314	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 39.	3.0	323
315	Classifying change and heterogeneity in amyotrophic lateral sclerosis. <i>Lancet Neurology</i> , The, 2016, 15, 1111-1112.	4.9	6
316	Looking but Not Seeing. <i>Current Directions in Psychological Science</i> , 2016, 25, 251-260.	2.8	8
317	Effect size for the main cognitive function determinants in a large cross-sectional study. <i>European Journal of Neurology</i> , 2016, 23, 1614-1626.	1.7	13
318	Feasibility and acceptance of simultaneous amyloid PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2236-2243.	3.3	25

#	ARTICLE	IF	CITATIONS
319	The Genetic Basis of Alzheimer's Disease. , 2016, , 547-571.		5
320	Self-awareness of cognitive efficiency: Differences between healthy elderly and patients with mild cognitive impairment (MCI). Journal of Clinical and Experimental Neuropsychology, 2016, 38, 1144-1157.	0.8	25
321	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1259-1272.	0.4	86
322	The clinical value of fluid biomarkers for dementia diagnosis – Authors' reply. Lancet Neurology, The, 2016, 15, 1204-1205.	4.9	7
323	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. Translational Psychiatry, 2016, 6, e952-e952.	2.4	46
324	Advances in A $\beta$ 2 plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. Neurodegenerative Disease Management, 2016, 6, 491-497.	1.2	3
325	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. Journal of Nuclear Medicine, 2016, 57, 1316-1322.	2.8	161
326	Impaired episodic memory network in subjects at high risk for Alzheimer's disease. , 2016, 2016, 4017-4020.		3
327	Reading impairment in neurodegenerative diseases: a multiple single-case study. Aphasiology, 0, , 1-23.	1.4	2
328	Extracellular vesicle-associated A $\beta$ 2 mediates trans-neuronal bioenergetic and Ca <sup>2+</sup> -handling deficits in Alzheimer's disease models. Npj Aging and Mechanisms of Disease, 2016, 2, .	4.5	102
329	Spontaneous confabulations in amnesic-mild cognitive impairment due to Alzheimer's disease: a new (yet old) atypical variant?. Neurocase, 2016, 22, 451-460.	0.2	4
330	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment. JAMA Neurology, 2016, 73, 1417.	4.5	84
331	Genetic Risk as a Marker of Amyloid- $\beta$ 2 and Tau Burden in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1417-1427.	1.2	16
332	Increased Cerebrospinal Fluid Levels of Ubiquitin Carboxyl-Terminal Hydrolase L1 in Patients with Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 283-294.	0.6	33
333	Functional Connectivity of Ventral and Dorsal Visual Streams in Posterior Cortical Atrophy. Journal of Alzheimer's Disease, 2016, 51, 1119-1130.	1.2	43
334	Is the left uncinatus fasciculus associated with verbal fluency decline in mild Alzheimer's disease?. Translational Neuroscience, 2016, 7, 89-91.	0.7	7
335	Pauses During Autobiographical Discourse Reflect Episodic Memory Processes in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 50, 687-698.	1.2	55
336	Rare TREM2 variants associated with Alzheimer's disease display reduced cell surface expression. Acta Neuropathologica Communications, 2016, 4, 98.	2.4	46

#	ARTICLE	IF	CITATIONS
337	Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnesic and nonamnesic mild cognitive impairment patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 1189-1196.	0.5	7
338	Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study. <i>BMC Neurology</i> , 2016, 16, 180.	0.8	22
339	No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF. <i>Molecular Neurodegeneration</i> , 2016, 11, 65.	4.4	16
340	Combination of Structural MRI and FDG-PET of the Brain Improves Diagnostic Accuracy in Newly Manifested Cognitive Impairment in Geriatric Inpatients. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1319-1331.	1.2	9
341	Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases: From pathophysiology to clinical practice. <i>Movement Disorders</i> , 2016, 31, 836-847.	2.2	54
342	PET Imaging as a Diagnostic Tool in Alzheimer's Disease. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 199-213.	0.1	0
343	Expanding the phenotypic associations of globular glial tau subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 4, 6-13.	1.2	23
344	Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond. <i>Lancet Neurology</i> , The, 2016, 15, 857-868.	4.9	241
345	The Genetic Basis of Alzheimer's Disease. , 2016, , 23-37.		5
346	Symptomatic Cognitive Enhancing Agents. , 2016, , 459-475.		4
347	Clinical Issues in Alzheimer Drug Development. , 2016, , 503-521.		1
348	Fluid Biomarkers and Diagnostics. , 2016, , 565-587.		0
349	Alzheimer's Disease Assessment Scale: Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 8.	3.0	69
350	The Prevalence and Incidence of Dementia Due to Alzheimer's Disease: a Systematic Review and Meta-Analysis. <i>Canadian Journal of Neurological Sciences</i> , 2016, 43, S51-S82.	0.3	194
351	Prevalencia de la enfermedad de Alzheimer: un camino a seguir. <i>Revista Clinica Espanola</i> , 2016, 216, 495-503.	0.2	6
352	Schizophrenia as a mimic of behavioral variant frontotemporal dementia. <i>Neurocase</i> , 2016, 22, 285-288.	0.2	12
354	Quantitative multimodal multiparametric imaging in Alzheimer's disease. <i>Brain Informatics</i> , 2016, 3, 29-37.	1.8	13
355	Reelin-immunoreactive neurons in entorhinal cortex layer II selectively express intracellular amyloid in early Alzheimer's disease. <i>Neurobiology of Disease</i> , 2016, 93, 172-183.	2.1	58

#	ARTICLE	IF	CITATIONS
356	Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy. <i>Neurobiology of Aging</i> , 2016, 44, 108-113.	1.5	11
357	Construct and diagnostic validities of the Free and Cued Selective Reminding Test in the Alzheimer's disease spectrum. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 913-924.	0.8	3
358	Quantitative MRI to understand Alzheimer's disease pathophysiology. <i>Current Opinion in Neurology</i> , 2016, 29, 437-444.	1.8	37
360	Amyloid and Amyloid Fibrils. Springer Theses, 2016, , 1-30.	0.0	0
361	Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry. <i>Clinical Proteomics</i> , 2016, 13, 4.	1.1	22
362	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 4.	3.0	134
363	Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 3.	4.4	236
365	Two-stage screening for early dementia in primary care. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 1038-1049.	0.8	12
366	Neuropsychological predictors of conversion to probable Alzheimer disease in elderly with mild cognitive impairment. <i>Journal of Neuropsychology</i> , 2016, 10, 239-255.	0.6	23
367	Cerebral amyloid burden and Alzheimer's disease subtypes " does localization information matter?. <i>European Journal of Neurology</i> , 2016, 23, 233-234.	1.7	2
368	Dementia beyond 2025: Knowledge and uncertainties. <i>Dementia</i> , 2016, 15, 6-21.	1.0	48
369	Tracer Kinetic Analysis of [ <sup>18</sup> F]-THK5117 as a PET Tracer for Assessing Tau Pathology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 574-581.	2.8	51
370	Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 546-555.	0.4	25
371	Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. <i>Brain</i> , 2016, 139, 922-936.	3.7	235
372	Emerging amyloid disease-modifying drugs for Alzheimer's disease. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 5-7.	1.0	10
373	The rising global tide of cognitive impairment. <i>Nature Reviews Neurology</i> , 2016, 12, 131-132.	4.9	40
374	Suspected non-Alzheimer disease pathophysiology " concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
375	Cascading network failure across the Alzheimer's disease spectrum. <i>Brain</i> , 2016, 139, 547-562.	3.7	401

#	ARTICLE	IF	CITATIONS
376	Increased CSF neurogranin concentration is specific to Alzheimer disease. <i>Neurology</i> , 2016, 86, 829-835.	1.5	170
377	Correlated patterns of neuropsychological and behavioral symptoms in frontal variant of Alzheimer disease and behavioral variant frontotemporal dementia: a comparative case study. <i>Neurological Sciences</i> , 2016, 37, 797-803.	0.9	11
378	Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Neurodegenerative Diseases</i> , 2016, 16, 69-76.	0.8	36
379	Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 68-79.	0.7	11
380	Dkk1: A promising molecule to connect Alzheimer's disease and osteoporosis. <i>Medical Hypotheses</i> , 2016, 88, 30-32.	0.8	15
381	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 57-87.	2.5	16
382	Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study. <i>Lancet Neurology</i> , The, 2016, 15, 56-64.	4.9	104
383	Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 374-385.	3.3	182
384	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
385	The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study. <i>Alzheimer's and Dementia</i> , 2016, 12, 786-795.	0.4	28
386	Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 40, 120-126.	1.5	96
387	ERP C250 shows the elderly (cognitively normal, Alzheimer's disease) store more stimuli in short-term memory than Young Adults do. <i>Clinical Neurophysiology</i> , 2016, 127, 2423-2435.	0.7	4
388	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1686-1699.	3.3	114
389	Amyloid biomarkers: pushing the limits of early detection. <i>Brain</i> , 2016, 139, 1008-1010.	3.7	5
390	Cerebrospinal Biomarkers in Alzheimer Disease—Potential Roles as Markers of Prognosis and Neuroplasticity. <i>JAMA Neurology</i> , 2016, 73, 508.	4.5	3
391	Apolipoprotein E (APOE) $\epsilon$ 4 and episodic memory decline in Alzheimer's disease: A review. <i>Ageing Research Reviews</i> , 2016, 27, 15-22.	5.0	70
392	Brain fluorodeoxyglucose (FDG) PET in dementia. <i>Ageing Research Reviews</i> , 2016, 30, 73-84.	5.0	175
393	The substantia nigra and ventral tegmental dopaminergic neurons from development to degeneration. <i>Journal of Chemical Neuroanatomy</i> , 2016, 76, 98-107.	1.0	54

#	ARTICLE	IF	CITATIONS
394	Network-selective vulnerability of the human cerebellum to Alzheimer's disease and frontotemporal dementia. <i>Brain</i> , 2016, 139, 1527-1538.	3.7	168
395	The Cellular Phase of Alzheimer's Disease. <i>Cell</i> , 2016, 164, 603-615.	13.5	1,346
396	Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 49-57.	1.2	32
397	The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. <i>Neurobiology of Aging</i> , 2016, 41, 115-121.	1.5	11
398	Poor Gait Performance and Prediction of Dementia: Results From a Meta-Analysis. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 482-490.	1.2	206
399	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016, 38, 47-55.	1.5	54
400	Defeating Alzheimer's disease and other dementias: a priority for European science and society. <i>Lancet Neurology</i> , 2016, 15, 455-532.	4.9	1,242
401	Comparison of Early-Phase <sup>11</sup> C-Deuterium-l-Deprenyl and <sup>11</sup> C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1071-1077.	2.8	63
402	Alzheimer's disease. <i>Lancet</i> , 2016, 388, 505-517.	6.3	2,430
403	Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 499-508.	3.3	66
404	Association of Motoric Cognitive Risk Syndrome With Brain Volumes: Results From the GAIT Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 1081-1088.	1.7	58
405	Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. <i>Brain</i> , 2016, 139, 1551-1567.	3.7	833
406	Comparison of the Psychometric Properties of the Word and Picture Versions of the Free and Cued Selective Reminding Test in a Spanish-Speaking Cohort of Patients with Mild Alzheimer's Disease and Cognitively Healthy Controls. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, acv107.	0.3	19
407	Cortical connectivity and memory performance in cognitive decline: A study via graph theory from EEG data. <i>Neuroscience</i> , 2016, 316, 143-150.	1.1	95
408	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , 2016, 37, 208.e11-208.e17.	1.5	38
409	Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly. <i>Ageing Research Reviews</i> , 2016, 25, 1-12.	5.0	17
410	Pro-inflammatory S100A9 Protein as a Robust Biomarker Differentiating Early Stages of Cognitive Impairment in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 34-39.	1.7	60
411	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of amyloid (1 <sup>42</sup> ) in human cerebrospinal fluid. <i>Alzheimer's and Dementia</i> , 2016, 12, 517-526. <sup>0.4</sup>		254

#	ARTICLE	IF	CITATIONS
412	Hair sterol signatures coupled to multivariate data analysis reveal an increased 7 $\beta$ -hydroxycholesterol production in cognitive impairment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 9-17.	1.2	14
413	The role of cerebrovascular disease when there is concomitant Alzheimer disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 952-956.	1.8	41
414	Altered Blood Gene Expression of Tumor-Related Genes (PRKCB, BECN1, and CDKN2A) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 5902-5911.	1.9	15
415	Assessing the commutability of reference material formats for the harmonization of amyloid- $\beta^2$ measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1177-1191.	1.4	49
416	Brain Amyloid Deposition Is Associated With Lower Instrumental Activities of Daily Living Abilities in Older Adults. Results From the MAPT Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 391-397.	1.7	19
417	Alzheimer's as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks. <i>Methods in Molecular Biology</i> , 2016, 1303, 3-48.	0.4	33
418	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179
419	Neuropsychiatric Symptoms in Posterior Cortical Atrophy and Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 65-71.	1.2	35
420	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. <i>European Journal of Human Genetics</i> , 2016, 24, 710-716.	1.4	77
421	Using prior knowledge from cellular pathways and molecular networks for diagnostic specimen classification. <i>Briefings in Bioinformatics</i> , 2016, 17, 440-452.	3.2	25
422	"Small World" architecture in brain connectivity and hippocampal volume in Alzheimer's disease: a study via graph theory from EEG data. <i>Brain Imaging and Behavior</i> , 2017, 11, 473-485.	1.1	85
423	Biomarcadores por tomografía por emisión de positrones (PET): imagen de la patología de Alzheimer y la neurodegeneración al servicio del diagnóstico clínico. <i>Neurología</i> , 2017, 32, 275-277.	0.3	5
424	Montreal cognitive assessment (MoCA): Normative data for old and very old Czech adults. <i>Applied Neuropsychology Adult</i> , 2017, 24, 23-29.	0.7	73
425	Disease-specific patterns of cortical and subcortical degeneration in a longitudinal study of Alzheimer's disease and behavioural-variant frontotemporal dementia. <i>NeuroImage</i> , 2017, 151, 72-80.	2.1	89
426	Subtle visuomotor difficulties in preclinical Alzheimer's disease. <i>Journal of Neuropsychology</i> , 2017, 11, 56-73.	0.6	13
427	The free and cued selective reminding test for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: A prospective longitudinal study. <i>Journal of Neuropsychology</i> , 2017, 11, 40-55.	0.6	13
428	Construct validity of the Free and Cued Selective Reminding Test in older adults with memory complaints. <i>Journal of Neuropsychology</i> , 2017, 11, 238-251.	0.6	10
429	Early-Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 146-151.	0.6	12



#	ARTICLE	IF	CITATIONS
430	Typical and atypical appearance of early-onset Alzheimer's disease: A clinical, neuroimaging and neuropathological study. <i>Neuropathology</i> , 2017, 37, 150-173.	0.7	29
431	Validation of 18F-FDG-PET Single-Subject Optimized SPM Procedure with Different PET Scanners. <i>Neuroinformatics</i> , 2017, 15, 151-163.	1.5	35
432	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2017, 641, 101-106.	1.0	14
433	Ischemic optic neuropathy as a model of neurodegenerative disorder: A review of pathogenic mechanism of axonal degeneration and the role of neuroprotection. <i>Journal of the Neurological Sciences</i> , 2017, 375, 430-441.	0.3	27
434	Cortical Thickness and Microstructural White Matter Changes Detect Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 415-428.	1.2	21
435	The <i>APOE</i> $\epsilon$ 4 genotype modulates CSF $\beta$ 42 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 50-59.	1.2	36
436	Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease. <i>Journal of the Neurological Sciences</i> , 2017, 373, 295-302.	0.3	81
437	Major Shifts in Glial Regional Identity Are a Transcriptional Hallmark of Human Brain Aging. <i>Cell Reports</i> , 2017, 18, 557-570.	2.9	326
438	Plasma concentrations of free amyloid $\beta$ 2 cannot predict the development of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 778-782.	0.4	70
439	CSF biomarkers for Alzheimer disease "approaching consensus. <i>Nature Reviews Neurology</i> , 2017, 13, 131-132.	4.9	26
440	Co-occurring frontal variant Alzheimer's dementia and carrier of Huntington's disease allele with reduced penetrance. <i>Psychogeriatrics</i> , 2017, 17, 488-490.	0.6	1
441	Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. <i>Translational Psychiatry</i> , 2017, 7, e995-e995.	2.4	56
442	Selecting $A\beta$ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel. <i>Biomarkers in Medicine</i> , 2017, 11, 169-178.	0.6	11
443	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. <i>Journal of Psychopharmacology</i> , 2017, 31, 147-168.	2.0	198
444	Free and Cued Selective Reminding Test "accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD). <i>Alzheimer's and Dementia</i> , 2017, 13, 913-923.	0.4	75
445	Tau PET imaging: present and future directions. <i>Molecular Neurodegeneration</i> , 2017, 12, 19.	4.4	220
446	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , 2017, 13, 903-912.	0.4	32
447	Cognition in non-demented Parkinson's disease vs essential tremor: A population-based study. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 393-400.	1.0	18

#	ARTICLE	IF	CITATIONS
448	Sharpening a classic scalpel to face the growth of Alzheimer's dementia. <i>Clinical Neurophysiology</i> , 2017, 128, 658-659.	0.7	0
449	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2017, 14, 285-299.	1.3	78
450	Unbiased estimates of cerebrospinal fluid $\beta$ -amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 8.	3.0	60
451	Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 203-211.	2.0	91
452	Neural Basis of Cognitive Assessment in Alzheimer Disease, Amnesic Mild Cognitive Impairment, and Subjective Memory Complaints. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 730-740.	0.6	24
453	Sleep EEG Detects Epileptiform Activity in Alzheimer's Disease with High Sensitivity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1175-1183.	1.2	50
454	$\beta$ -amyloid PET neuroimaging: A review of radiopharmaceutical development. <i>Medecine Nucleaire</i> , 2017, 41, 27-35.	0.2	7
455	A cognitive electrophysiological signature differentiates amnesic mild cognitive impairment from normal aging. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 3.	3.0	26
456	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
457	High-Field 3 T Imaging of Alzheimer's Disease. , 2017, , 255-269.		1
458	Consensus classification of posterior cortical atrophy. <i>Alzheimer's and Dementia</i> , 2017, 13, 870-884.	0.4	423
459	Two-level diagnostic classification using cerebrospinal fluid YKL-40 in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 993-1003.	0.4	39
460	Consent for the diagnosis of preclinical dementia states: A review. <i>Maturitas</i> , 2017, 98, 30-34.	1.0	45
461	Emerging biomarkers and screening for cognitive frailty. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1075-1086.	1.4	39
462	A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. <i>Climacteric</i> , 2017, 20, 107-118.	1.1	112
463	Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 197-204.	1.2	7
464	Objective measurement of gait parameters in healthy and cognitively impaired elderly using the dual-task paradigm. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 1181-1189.	1.4	33
465	Multicenter stability of resting state fMRI in the detection of Alzheimer's disease and amnesic MCI. <i>NeuroImage: Clinical</i> , 2017, 14, 183-194.	1.4	49

#	ARTICLE	IF	CITATIONS
466	Penalized Nonlinear Mixed Effects Model to Identify Biomarkers That Predict Disease Progression. <i>Biometrics</i> , 2017, 73, 1343-1354.	0.8	5
467	Is sporadic Alzheimer's disease a developmental disorder?. <i>Journal of Neurochemistry</i> , 2017, 143, 396-408.	2.1	61
468	The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly. <i>Neurologic Clinics</i> , 2017, 35, 231-262.	0.8	5
469	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. <i>IEEE Transactions on Medical Imaging</i> , 2017, 36, 1758-1768.	5.4	85
470	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017, 55, 143-158.	1.5	76
471	Applying fluid biomarkers to Alzheimer's disease. <i>American Journal of Physiology - Cell Physiology</i> , 2017, 313, C3-C10.	2.1	46
472	APOE Genotype Effects on Intrinsic Brain Network Connectivity in Patients with Amnesic Mild Cognitive Impairment. <i>Scientific Reports</i> , 2017, 7, 397.	1.6	23
473	Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No?. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 323-335.	1.2	11
474	The need for harmonisation and innovation of neuropsychological assessment in neurodegenerative dementias in Europe: consensus document of the Joint Program for Neurodegenerative Diseases Working Group. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 27.	3.0	66
475	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017, 32, 995-1005.	2.2	121
476	Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. <i>Movement Disorders</i> , 2017, 32, 1025-1034.	2.2	75
477	Accelerating drug development for Alzheimer's disease through the use of data standards. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 273-283.	1.8	10
478	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.	0.9	78
479	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
480	Neuro-degeneration profile of Alzheimer's patients: A brain morphometry study. <i>NeuroImage: Clinical</i> , 2017, 15, 15-24.	1.4	56
481	Age-specific and sex-specific prevalence of cerebral $\beta$ -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
482	Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study. <i>Alzheimer's and Dementia</i> , 2017, 13, 1307-1316.	0.4	49
483	The impact of $\beta$ -amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts. <i>Neurodegenerative Disease Management</i> , 2017, 7, 107-117.	1.2	1

#	ARTICLE	IF	CITATIONS
484	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. <i>Neurochemistry International</i> , 2017, 108, 355-360.	1.9	46
485	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	1.2	28
486	Subclinical white matter lesions and medial temporal lobe atrophy are associated with EEG slowing in a memory clinic cohort. <i>Clinical Neurophysiology</i> , 2017, 128, 1575-1582.	0.7	5
487	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
488	Applicability of [ 11 C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model. <i>Neurobiology of Aging</i> , 2017, 57, 84-94.	1.5	17
489	Cerebrospinal Fluid Biomarkers for the Diagnosis of Alzheimer Disease in South Korea. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 13-18.	0.6	21
491	Multiparametric MRI to distinguish early onset Alzheimer's disease and behavioural variant of frontotemporal dementia. <i>NeuroImage: Clinical</i> , 2017, 15, 428-438.	1.4	49
492	Functional Disintegration of the Default Mode Network in Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 169-187.	1.2	81
493	Framingham Risk Score and the Risk of Progression from Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 67-75.	1.2	33
494	Assessing the "social brain" in dementia: Applying TASIT-S. <i>Cortex</i> , 2017, 93, 166-177.	1.1	46
495	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
496	Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 771-780.	1.5	23
497	Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 182-187.	1.2	23
498	Patient and caregiver reactions to clinical amyloid imaging. <i>Alzheimer's and Dementia</i> , 2017, 13, 924-932.	0.4	30
499	Amyloidosis and neurodegeneration result in distinct structural connectivity patterns in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2017, 55, 177-189.	1.5	20
500	CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2017, 2017, CD010803.	1.5	110
501	Early classification of Alzheimer's disease using hippocampal texture from structural MRI. <i>Proceedings of SPIE</i> , 2017, .	0.8	2
502	Cognitive Efficiency in Alzheimer's Disease is Associated with Increased Occipital Connectivity. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 541-556.	1.2	15

#	ARTICLE	IF	CITATIONS
503	Incidental and Intentional Memory: Their Relation with Attention and Executive Functions. Archives of Clinical Neuropsychology, 2017, 32, 519-532.	0.3	24
504	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
505	Color perception differentiates Alzheimer's Disease (AD) from Vascular Dementia (VaD) patients. International Psychogeriatrics, 2017, 29, 1355-1361.	0.6	11
506	Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population. Alzheimer's Research and Therapy, 2017, 9, 21.	3.0	15
507	Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. Journal of Alzheimer's Disease, 2017, 57, 645-665.	1.2	139
508	Alzheimer's disease: The next frontier"Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.4	88
509	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 167-182.e1.	1.5	60
510	Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. Neurobiology of Aging, 2017, 52, 119-131.	1.5	23
511	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 153-166.	1.5	49
512	Clinical validity of cerebrospinal fluid A $\beta$ 242, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
513	Alzheimer's disease biomarker development: a call to funding bodies. Neurobiology of Aging, 2017, 52, 117-118.	1.5	3
514	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 183-195.	1.5	85
515	Clinical validity of presynaptic dopaminergic imaging with $^{123}\text{I}$ -ioflupane and noradrenergic imaging with $^{123}\text{I}$ -MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 228-242.	1.5	34
516	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 214-227.	1.5	67
517	The biomarker-based diagnosis of Alzheimer's disease. 2"lessons from oncology. Neurobiology of Aging, 2017, 52, 141-152.	1.5	38
518	MACE versus MoCA: equivalence or superiority? Pragmatic diagnostic test accuracy study. International Psychogeriatrics, 2017, 29, 931-937.	0.6	37
519	Estimating personalized diagnostic rules depending on individualized characteristics. Statistics in Medicine, 2017, 36, 1099-1117.	0.8	5
520	Introduction to Cognitive Screening Instruments: Rationale and Desiderata. , 2017, , 3-13.		11

#	ARTICLE	IF	CITATIONS
521	The Usage of Cognitive Screening Instruments: Test Characteristics and Suspected Diagnosis. , 2017, , 315-339.		4
522	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
523	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
524	Imaging biomarkers of dementia: recommended visual rating scales with teaching cases. Insights Into Imaging, 2017, 8, 79-90.	1.6	67
525	The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer's and Dementia, 2017, 13, 624-633.	0.4	143
526	Physical Activity and Alzheimer's Disease: A Systematic Review. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw251.	1.7	117
527	Subjective Memory Complaints in healthy older adults: Fewer complaints associated with depression and perceived health, more complaints also associated with lower memory performance. Archives of Gerontology and Geriatrics, 2017, 70, 28-37.	1.4	37
528	Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 733-742.	1.2	31
529	White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy. Hippocampus, 2017, 27, 249-262.	0.9	62
530	Molecular Diagnostics of Ageing and Tackling Age-related Disease. Trends in Pharmacological Sciences, 2017, 38, 67-80.	4.0	7
531	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
532	Alzheimer's disease prevention: from risk factors to early intervention. Alzheimer's Research and Therapy, 2017, 9, 71.	3.0	424
533	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	0.8	28
534	Plasma amyloid $\beta$ 42/40 ratios as biomarkers for amyloid $\beta$ cerebral deposition in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 179-187.	1.2	129
535	Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. Journal of Alzheimer's Disease, 2017, 60, 1477-1487.	1.2	31
536	Task-evoked pupil dilation and BOLD variance as indicators of locus coeruleus dysfunction. Cortex, 2017, 97, 60-69.	1.1	45
537	Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer's disease: an update. Expert Review of Proteomics, 2017, 14, 1007-1020.	1.3	21
539	Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline. Brain and Behavior, 2017, 7, e00776.	1.0	34

#	ARTICLE	IF	CITATIONS
540	Pathology and hippocampal atrophy in Alzheimer's disease. <i>Lancet Neurology</i> , The, 2017, 16, 862-864.	4.9	87
541	Weighting and standardization of frequencies to determine prevalence of AD imaging biomarkers. <i>Neurology</i> , 2017, 89, 2039-2048.	1.5	15
542	A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 603-614.	1.2	48
543	Cerebrospinal Fluid Amyloid- $\beta$ 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 183-200.	1.2	31
544	Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1327-1334.	1.2	35
545	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13333.	1.6	45
546	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 339-358.	1.2	45
547	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. <i>Brain</i> , 2017, 140, 3286-3300.	3.7	472
548	Effectiveness of Flortetapir PET Imaging in Changing Patient Management. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 129-143.	0.7	35
549	A case of reversible anti-NMDA-receptor encephalitis: neuropsychological and neuroradiological features. <i>Neurological Sciences</i> , 2017, 38, 2231-2236.	0.9	2
550	A Cytomic Approach Towards Genomic Individuality of Neurons. <i>Neuromethods</i> , 2017, , 81-106.	0.2	1
551	The Alzheimer's disease metabolic brain pattern in mild cognitive impairment. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 3643-3648.	2.4	29
552	A specific pattern of gray matter atrophy in Alzheimer's disease with depression. <i>Journal of Neurology</i> , 2017, 264, 2101-2109.	1.8	12
554	A single center study: A $\beta$ 42/p-Tau181 CSF ratio to discriminate AD from FTD in clinical setting. <i>Neurological Sciences</i> , 2017, 38, 1791-1797.	0.9	16
555	Dementia prevention, intervention, and care. <i>Lancet</i> , The, 2017, 390, 2673-2734.	6.3	4,228
556	Henry, where have you lost your Self?. <i>Cortex</i> , 2017, 95, 37-50.	1.1	5
557	Assessment of amyloid $\beta$ in pathologically confirmed frontotemporal dementia syndromes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 10-20.	1.2	38
558	Increasing Precision of Clinical Diagnosis of Alzheimer's Disease Using a Combined Algorithm Incorporating Clinical and Novel Biomarker Data. <i>Neurology and Therapy</i> , 2017, 6, 83-95.	1.4	61

#	ARTICLE	IF	CITATIONS
559	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <i>Neurology and Therapy</i> , 2017, 6, 15-24.	1.4	211
560	Alzheimer's disease markers in the aged sheep ( <i>Ovis aries</i> ). <i>Neurobiology of Aging</i> , 2017, 58, 112-119.	1.5	30
561	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. <i>Neurobiology of Aging</i> , 2017, 59, 1-9.	1.5	84
562	PET biomarkers: Use of imaging techniques in Alzheimer disease and neurodegeneration clinical diagnosis. <i>Neurologia (English Edition)</i> , 2017, 32, 275-277.	0.2	2
563	Lumbar puncture in patients with neurologic conditions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 108-110.	1.2	12
564	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <i>Acta Neurologica Belgica</i> , 2017, 117, 591-602.	0.5	90
565	Transcranial magnetic stimulation distinguishes Alzheimer disease from frontotemporal dementia. <i>Neurology</i> , 2017, 89, 665-672.	1.5	95
566	<sup>18</sup> F-AV-1451 and CSF $\tau$ and $A\beta$ as biomarkers in Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2017, 9, 1212-1223.	3.3	156
567	Absolute Quantification of $A\beta_{1-42}$ in CSF Using a Mass Spectrometric Reference Measurement Procedure. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	3
568	Commentary on: Association of imaging abnormalities of the subcallosal septal area with Alzheimer's disease and mild cognitive impairment. <i>Clinical Radiology</i> , 2017, 72, 923-924.	0.5	0
569	Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 6517.	1.6	64
570	<sup>18</sup> F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2073-2083.	3.3	29
571	Use of Imaging for Preclinical Evaluation. , 2017, , 921-938.		0
572	Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> , 2017, 6, 1-4.	1.4	2
573	A randomized, exploratory molecular imaging study targeting amyloid $\beta$ with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-04 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 622-635.	1.8	59
575	Prediction of Alzheimer's Dementia in Patients with Amnesic Mild Cognitive Impairment in Clinical Routine: Incremental Value of Biomarkers of Neurodegeneration and Brain Amyloidosis Added Stepwise to Cognitive Status. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 373-388.	1.2	15
576	<sup>18</sup> F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2017, 2017, CD012216.	1.5	32
577	<sup>18</sup> F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2017, 2017, CD012884.	1.5	29



#	ARTICLE	IF	CITATIONS
578	Effects of Physical Exercise on Alzheimer's Disease Biomarkers: A Systematic Review of Intervention Studies. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 359-372.	1.2	60
579	Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 135-143.	1.2	15
580	Word and Picture Version of the Free and Cued Selective Reminding Test (FCSRT): Is There Any Difference?. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 47-52.	1.2	8
581	Comparison between FCSRT and LASSI-L to Detect Early Stage Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 103-111.	1.2	27
582	Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1641-1652.	1.2	16
583	S3-Leitlinie Demenzen. , 2017, , .		17
584	Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1267-1274.	1.2	57
585	An Opportunity to Definitively Evaluate the Theoretical Risks of Neprilysin Inhibition. <i>JACC: Heart Failure</i> , 2017, 5, 851-852.	1.9	0
586	Reply. <i>JACC: Heart Failure</i> , 2017, 5, 851.	1.9	0
587	Recent Progress in the Pharmacotherapy of Alzheimer's Disease. <i>Drugs and Aging</i> , 2017, 34, 811-820.	1.3	46
588	The effect of diagnostic criteria on outcome measures in preclinical and prodromal Alzheimer's disease: Implications for trial design. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 513-523.	1.8	17
589	EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. <i>Neurobiology of Aging</i> , 2017, 57, 133-142.	1.5	91
590	Parietal white matter lesions in Alzheimer's disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. <i>Acta Neuropathologica</i> , 2017, 134, 459-473.	3.9	180
591	Visual Evaluation of Medial Temporal Lobe Atrophy as a Clinical Marker of Conversion from Mild Cognitive Impairment to Dementia and for Predicting Progression in Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 12-24.	0.7	13
592	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464
593	A clinicopathological approach to the diagnosis of dementia. <i>Nature Reviews Neurology</i> , 2017, 13, 457-476.	4.9	233
594	Performance comparison of 10 different classification techniques in segmenting white matter hyperintensities in aging. <i>NeuroImage</i> , 2017, 157, 233-249.	2.1	79
595	Clinical Aspects of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2017, 15, 31-53.	1.3	10

#	ARTICLE	IF	CITATIONS
596	Revolution of Resting-State Functional Neuroimaging Genetics in Alzheimer's Disease. Trends in Neurosciences, 2017, 40, 469-480.	4.2	34
597	Chinese herbal medicine for Alzheimer's disease: Clinical evidence and possible mechanism of neurogenesis. Biochemical Pharmacology, 2017, 141, 143-155.	2.0	103
598	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	0.8	64
599	Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - A consensus report. BMC Neurology, 2017, 17, 102.	0.8	65
600	Retinal vascular and structural changes are associated with amyloid burden in the elderly: ophthalmic biomarkers of preclinical Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 13.	3.0	88
601	Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimer's Research and Therapy, 2017, 9, 32.	3.0	56
602	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, $\beta$ -synuclein, and total tau in combination with A $\beta$ (1-42)/A $\beta$ (1-40). Alzheimer's Research and Therapy, 2017, 9, 40.	3.0	17
603	Early identification of MCI converting to AD: a FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2042-2052.	3.3	83
604	Correlation of florbetaben PET imaging and the amyloid peptide A $\beta$ 42 in cerebrospinal fluid. Psychiatry Research - Neuroimaging, 2017, 265, 98-101.	0.9	11
605	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. Brain Research, 2017, 1655, 23-32.	1.1	29
606	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. Molecular Diagnosis and Therapy, 2017, 21, 13-22.	1.6	29
607	Visual short-term memory binding deficits in Alzheimer's disease: a reply to Parra's commentary.. Cortex, 2017, 88, 201-204.	1.1	5
608	Functional and effective brain connectivity for discrimination between Alzheimer's patients and healthy individuals: A study on resting state EEG rhythms. Clinical Neurophysiology, 2017, 128, 667-680.	0.7	79
609	Amyloid pet in primary progressive aphasia: case series and systematic review of the literature. Journal of Neurology, 2017, 264, 121-130.	1.8	24
610	A $\beta$ -amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	2.5	96
611	Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution?. Brain Pathology, 2017, 27, 603-611.	2.1	21
612	Amyloid Imaging: Poised for Integration into Medical Practice. Neurotherapeutics, 2017, 14, 54-61.	2.1	32
613	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 205-216.	0.4	581

#	ARTICLE	IF	CITATIONS
614	Pupillary responses and memory-guided visual search reveal age-related and Alzheimer's-related memory decline. <i>Behavioural Brain Research</i> , 2017, 322, 351-361.	1.2	22
615	Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 419-430.	0.4	31
616	Hybrid Antioxidant and Metal Sequestering Small Molecules Targeting the Molecular Features of Alzheimer's Disease. <i>Comments on Inorganic Chemistry</i> , 2017, 37, 146-167.	3.0	2
618	Alpha-2 macroglobulin in Alzheimer's disease: a marker of neuronal injury through the RCAN1 pathway. <i>Molecular Psychiatry</i> , 2017, 22, 13-23.	4.1	100
619	On-going electroencephalographic rhythms related to cortical arousal in wild-type mice: the effect of aging. <i>Neurobiology of Aging</i> , 2017, 49, 20-30.	1.5	11
620	Low Flortetapir PET Uptake and Normal A $\beta$ <sub>1-42</sub> Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 697-703.	1.2	5
621	Incident Cerebral Microbleeds Detected by Susceptibility Weight-Imaging Help to Identify Patients with Mild Cognitive Impairment Progressing to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 253-262.	1.2	12
622	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid- $\beta$ Concentration. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 885-891.	1.2	6
623	Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 761-772.	1.2	21
624	The Cerebrospinal Fluid A $\beta$ <sub>1-42</sub> /A $\beta$ <sub>1-40</sub> Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 561-576.	1.2	82
625	Sample Preparation for Endopeptidomic Analysis in Human Cerebrospinal Fluid. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	1
626	Factors Influencing Successful Lumbar Puncture in Alzheimer Research. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 287-294.	0.6	18
627	Neuroanatomical Comparison of the "Word" and "Picture" Versions of the Free and Cued Selective Reminding Test in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 589-600.	1.2	17
628	The Distinction of Amyloid- $\beta$ Protein Precursor (A $\beta$ PP) Ratio in Platelet Between Alzheimer's Disease Patients and Controls: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1037-1044.	1.2	8
629	Alzheimer's Disease Diagnosis Relies on a Twofold Clinical-Biological Algorithm: Three Memory Clinic Case Reports. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 577-583.	1.2	2
630	Fully Automatic MRI-Based Hippocampus Volumetry Using FSL-FIRST: Intra-Scanner Test-Retest Stability, Inter-Field Strength Variability, and Performance as Enrichment Biomarker for Clinical Trials Using Prodromal Target Populations at Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 151-164.	1.2	7
632	Mathematical and Theoretical Neuroscience. Springer INdAM Series, 2017, , .	0.4	0
633	18F PET with flortetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2017, 2017, CD012883.	1.5	23

#	ARTICLE	IF	CITATIONS
634	Translational Correlation. , 2017, , 709-714.		0
635	Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population. <i>Oncotarget</i> , 2017, 8, 24077-24087.	0.8	39
637	Localized Accumulation of Tau without Amyloid-Beta in Aged Brains Measured with [11C]PBB3 and [11C]Pib Positron Emission Tomography. , 2017, 07, .		3
638	Genetic Biomarkers on Age-Related Cognitive Decline. <i>Frontiers in Psychiatry</i> , 2017, 8, 247.	1.3	33
639	Korsakoff's syndrome: a critical review. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2875-2890.	1.0	188
640	Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis. , 2017, , 17-26.		0
641	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 695-705.	1.2	44
642	The Gut Microbial Metabolite Trimethylamine-N-Oxide Is Present in Human Cerebrospinal Fluid. <i>Nutrients</i> , 2017, 9, 1053.	1.7	108
643	Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2128.	1.8	69
644	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease "From Brain Starch to Bench and Bedside. <i>Diagnostics</i> , 2017, 7, 42.	1.3	19
645	Neuropsychological Correlates of Pre-Frailty in Neurocognitive Disorders: A Possible Role for Metacognitive Dysfunction and Mood Changes. <i>Frontiers in Medicine</i> , 2017, 4, 199.	1.2	22
646	Alzheimer's Disease Diagnosis: Discrepancy between Clinical, Neuroimaging, and Cerebrospinal Fluid Biomarkers Criteria in an Italian Cohort of Geriatric Outpatients: A Retrospective Cross-sectional Study. <i>Frontiers in Medicine</i> , 2017, 4, 203.	1.2	8
647	Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 114.	1.7	31
648	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 117.	1.7	71
649	Frequency-Dependent Altered Functional Connections of Default Mode Network in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 259.	1.7	30
650	Strengthening of Existing Episodic Memories Through Non-invasive Stimulation of Prefrontal Cortex in Older Adults with Subjective Memory Complaints. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 401.	1.7	29
651	The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease. <i>Frontiers in Neuroanatomy</i> , 2017, 11, 80.	0.9	44
652	Multicenter Analytical Validation of A $\beta$ 240 Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	1.1	10

#	ARTICLE	IF	CITATIONS
653	Eyetracking Metrics in Young Onset Alzheimer's Disease: A Window into Cognitive Visual Functions. <i>Frontiers in Neurology</i> , 2017, 8, 377.	1.1	50
654	Visual Dysfunction in Posterior Cortical Atrophy. <i>Frontiers in Neurology</i> , 2017, 8, 389.	1.1	43
655	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. <i>Frontiers in Neuroscience</i> , 2016, 10, 604.	1.4	51
656	Ensemble Classification of Alzheimer's Disease and Mild Cognitive Impairment Based on Complex Graph Measures from Diffusion Tensor Images. <i>Frontiers in Neuroscience</i> , 2017, 11, 56.	1.4	52
657	PET/MR Imaging: New Frontier in Alzheimer's Disease and Other Dementias. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 343.	1.4	47
658	Optimizing Neuropsychological Assessments for Cognitive, Behavioral, and Functional Impairment Classification: A Machine Learning Study. <i>Behavioural Neurology</i> , 2017, 2017, 1-19.	1.1	76
659	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnesic Mild Cognitive Impairment-Storage Subtype. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 447-459.	1.2	26
660	The Ambivalence of Early Diagnosis "Returning Results in Current Alzheimer Research. <i>Current Alzheimer Research</i> , 2017, 15, 28-37.	0.7	8
661	Increased levels of plasma total tau in adult Down syndrome. <i>PLoS ONE</i> , 2017, 12, e0188802.	1.1	36
662	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 201-210.	1.2	11
663	Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients. <i>BMC Geriatrics</i> , 2017, 17, 210.	1.1	9
664	Drug candidates in clinical trials for Alzheimer's disease. <i>Journal of Biomedical Science</i> , 2017, 24, 47.	2.6	330
665	Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. <i>Molecular Neurodegeneration</i> , 2017, 12, 63.	4.4	202
666	No added diagnostic value of non-phosphorylated tau fraction (p-tau <sub>rel</sub> ) in CSF as a biomarker for differential dementia diagnosis. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 49.	3.0	11
667	Differential role of CSF fatty acid binding protein 3, $\beta$ -synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 52.	3.0	101
668	On the path to 2025: understanding the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 60.	3.0	316
669	Amnesic MCI patients' experiences after disclosure of their amyloid PET result in a research context. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 92.	3.0	25
670	Aging and Alzheimer's Disease. , 2017, , 311-340.		0

#	ARTICLE	IF	CITATIONS
671	Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1045-1054.	1.2	22
672	Imaging biomarkers in Alzheimer's disease: added value in the clinical setting. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 360-371.	0.4	10
673	Brazilian transcultural adaptation of an instrument on communicative strategies of caregivers of elderly with dementia. <i>Dementia E Neuropsychologia</i> , 2017, 11, 242-248.	0.3	4
674	The emerging role of PET imaging in dementia. <i>F1000Research</i> , 2017, 6, 1830.	0.8	43
675	Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics. <i>Psychiatry Investigation</i> , 2017, 14, 851.	0.7	75
676	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 247-268.	1.2	50
677	Cerebrospinal Fluid Biomarkers of Preclinical Alzheimer's Disease. <i>Neuroinformatics</i> , 2018, , 93-106.	0.2	1
678	Amyloid PET Positivity in Different Primary Progressive Aphasia Phenotypes. <i>Clinical Nuclear Medicine</i> , 2018, 43, e103-e108.	0.7	3
679	Biomarkers for Preclinical Alzheimer's Disease. <i>Neuroinformatics</i> , 2018, , .	0.2	5
680	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , 2018, 90, e1231-e1239.	1.5	94
681	Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1470-1485.	3.7	109
682	Evolution of diagnostic criteria and assessments for Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 503-510.	2.2	52
683	Validation of the Delayed Matching-to-Sample Task 48 (DMS48) in Elderly Chinese. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1611-1618.	1.2	2
684	Cognitive and neuroimaging features and brain $\beta$ -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study. <i>Lancet Neurology</i> , The, 2018, 17, 335-346.	4.9	161
685	CSF biomarkers of Alzheimer's disease concord with amyloid $\beta$ PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. <i>Alzheimer's and Dementia</i> , 2018, 14, 1470-1481.	0.4	468
686	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	1.2	37
687	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S3-S22.	1.2	108
688	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. <i>Journal of Neurotrauma</i> , 2018, 35, 2015-2024.	1.7	25

#	ARTICLE	IF	CITATIONS
689	Patrones de retención de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presión normal idiopática. Un análisis visual. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 87-93.	0.1	0
690	Neuropsychological Predictors of Long-Term (10 Years) Mild Cognitive Impairment Stability. Journal of Alzheimer's Disease, 2018, 62, 1703-1711.	1.2	14
691	Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness Analysis. Pharmacoeconomics - Open, 2018, 2, 309-323.	0.9	8
692	Diagnostic Âtologique des troubles cognitifsÂet biomarqueurs. Dans quelles situations lâ™utilisation de lâ™imagerie molÂculaire est-elle indiquÂeÂ?. Medecine Nucleaire, 2018, 42, 185-189.	0.2	2
693	Amyloid blood biomarker detects Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	145
694	Plasma Amyloid-Î² (AÎ²42) Correlates with Cerebrospinal Fluid AÎ²42 in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1857-1863.	1.2	100
695	NIAâ€™AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
696	Tau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers. Journal of Alzheimer's Disease, 2018, 63, 13-33.	1.2	111
697	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
698	The Rationale Behind the New Alzheimerâ€™s Disease Conceptualization: Lessons Learned During the Last Decades. Journal of Alzheimer's Disease, 2018, 62, 1067-1077.	1.2	19
699	The Past and the Future of Alzheimerâ€™s Disease Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 62, 1125-1140.	1.2	106
700	Update on Vascular Cognitive Impairment Associated with Subcortical Small-Vessel Disease. Journal of Alzheimer's Disease, 2018, 62, 1417-1441.	1.2	90
701	Prevalence of preclinical Alzheimer disease. Neurology, 2018, 90, e1682-e1691.	1.5	82
702	Biomarkers study in atypical dementia: proof of a diagnostic work-up. Neurological Sciences, 2018, 39, 1203-1210.	0.9	3
703	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
704	FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. NeuroImage: Clinical, 2018, 18, 167-177.	1.4	108
705	Melatonin as an endogenous regulator of diseases: The role of autophagy. Pharmacological Research, 2018, 133, 265-276.	3.1	47
706	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimerâ€™s and Parkinsonâ€™s diseases. Clinical Neurophysiology, 2018, 129, 766-782.	0.7	45

#	ARTICLE	IF	CITATIONS
707	Concordance between brain 18 F-FDG PET and cerebrospinal fluid biomarkers in diagnosing Alzheimer's disease. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 3-8.	0.1	2
708	Plasma A $\beta$ 2 analysis using magnetically-labeled immunoassays and PET 18F-florbetapir binding in non-demented patients with major depressive disorder. <i>Scientific Reports</i> , 2018, 8, 2739.	1.6	5
709	Imaging tau and amyloid- $\beta$ 2 proteinopathies in Alzheimer disease and other conditions. <i>Nature Reviews Neurology</i> , 2018, 14, 225-236.	4.9	321
710	T1- or T2-weighted magnetic resonance imaging: what is the best choice to evaluate atrophy of the hippocampus?. <i>European Journal of Neurology</i> , 2018, 25, 775-781.	1.7	3
711	Impact of diabetes on caregiver stress in patients with Alzheimer's disease: data from the ICTUS study. <i>International Psychogeriatrics</i> , 2018, 30, 1109-1117.	0.6	3
712	Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. <i>Cortex</i> , 2018, 99, 358-374.	1.1	42
713	Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 907-912.	1.2	23
714	Neurotransmitter Pathway Genes in Cognitive Decline During Aging: Evidence for <i>GNG4</i> and <i>KCNQ2</i> Genes. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 153-165.	0.9	24
716	Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease. <i>ACS Nano</i> , 2018, 12, 1321-1338.	7.3	205
717	Cerebral Perfusion Insufficiency and Relationships with Cognitive Deficits in Alzheimer's Disease: A Multiparametric Neuroimaging Study. <i>Scientific Reports</i> , 2018, 8, 1541.	1.6	32
718	Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 1500-1515.	1.9	21
719	Proper name retrieval and structural integrity of cerebral cortex in midlife: A cross-sectional study. <i>Brain and Cognition</i> , 2018, 120, 26-33.	0.8	8
720	Free and Cued Selective Reminding Test sensitivity. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 75-75.	1.2	3
721	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018, 65, 18-40.	1.5	61
722	Associations between [ <sup>18</sup> F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. <i>Neurology</i> , 2018, 90, e282-e290.	1.5	113
723	Anesthesia and Alzheimer disease – Current perceptions. <i>Brazilian Journal of Anesthesiology (Elsevier)</i> , 2018, 68, 174-182.	0.2	2
724	Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau deposition in Alzheimer's disease. , 2018, 14, 652-663.		18
725	Comparing <sup>18</sup> F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. <i>Neurology</i> , 2018, 90, e388-e395.	1.5	83



#	ARTICLE	IF	CITATIONS
726	A wrapped multi-label classifier for the automatic diagnosis and prognosis of Alzheimer's disease. Journal of Neuroscience Methods, 2018, 302, 58-65.	1.3	27
727	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	1.7	30
728	[ <sup>18</sup> F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Annals of Neurology, 2018, 83, 248-257.	2.8	67
729	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A $\beta$ <sub>42</sub> , total tau, phosphorylated tau, NFL, neurogranin, and YKL40. Alzheimer's and Dementia, 2018, 14, 492-501.	0.4	91
730	Rapidly Progressive Alzheimer's Disease: Contributions to Clinical-Pathological Definition and Diagnosis. Journal of Alzheimer's Disease, 2018, 63, 887-897.	1.2	16
731	Alzheimer's disease drug development pipeline: 2018. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 195-214.	1.8	469
732	Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration. Alzheimer's Research and Therapy, 2018, 10, 31.	3.0	42
733	Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD). Alzheimer's Research and Therapy, 2018, 10, 35.	3.0	22
734	Biomarkers in Cerebrospinal Fluid: Analysis of Cell-Free Circulating Mitochondrial DNA by Digital PCR. Methods in Molecular Biology, 2018, 1768, 111-126.	0.4	12
735	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1470-1486.	3.3	19
736	Major or Mild Neurocognitive Disorder Due to Alzheimer Disease. , 2018, , 369-401.		1
737	Diagnosis of Alzheimer's Disease Typical and Atypical Forms. , 2018, , 21-28.		4
738	The Progressive Acalculia Presentation of Parietal Variant Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 63, 941-948.	1.2	10
739	Clinical utility of FDG-PET for the clinical diagnosis in MCI. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1497-1508.	3.3	61
740	Amyloid $\beta$ peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 311-321.	1.2	21
741	Simultaneous resting-state FDG-PET/fMRI in Alzheimer Disease: Relationship between glucose metabolism and intrinsic activity. NeuroImage, 2018, 176, 246-258.	2.1	105
742	Characterization of brain anatomical patterns by comparing region intensity distributions: Applications to the description of Alzheimer's disease. Brain and Behavior, 2018, 8, e00942.	1.0	10
743	Resistance vs resilience to Alzheimer disease. Neurology, 2018, 90, 695-703.	1.5	227

#	ARTICLE	IF	CITATIONS
744	SMAC: Spatial multi-category angle-based classifier for high-dimensional neuroimaging data. <i>NeuroImage</i> , 2018, 175, 230-245.	2.1	4
745	A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward. <i>Journal of Huntington's Disease</i> , 2018, 7, 109-135.	0.9	38
746	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1005-1014.	0.4	80
747	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1199-1209.	1.2	69
748	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S281-S287.	1.2	6
749	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ 2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
750	Fluid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
751	Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the prodementia phase of Alzheimer's disease: Implications for clinical trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 161-171.	1.2	36
752	Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 172-181.	1.2	16
753	Gatekeeping and trailblazing: The role of biomarkers in novel guidelines for diagnosing Alzheimer's disease. <i>BioSocieties</i> , 2018, 13, 213-231.	0.8	11
754	REM Sleep Behavior Disorder and Alzheimer's Disease: Definitely No Relationship?. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1-11.	1.2	35
755	Intrahippocampal injection of a lentiviral vector expressing neurogranin enhances cognitive function in 5XFAD mice. <i>Experimental and Molecular Medicine</i> , 2018, 50, e461-e461.	3.2	22
756	Apolipoprotein E genotypes and longevity across dementia disorders. <i>Alzheimer's and Dementia</i> , 2018, 14, 895-901.	0.4	8
757	Hippocampal Proteomic Analysis Reveals Distinct Pathway Deregulation Profiles at Early and Late Stages in a Rat Model of Alzheimer's-Like Amyloid Pathology. <i>Molecular Neurobiology</i> , 2018, 55, 3451-3476.	1.9	21
758	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. <i>Molecular Psychiatry</i> , 2018, 23, 1666-1673.	4.1	88
759	Structural Anatomical Investigation of Long-Term Memory Deficit in Behavioral Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1887-1900.	1.2	22
760	Plasma levels of soluble amyloid precursor protein $\beta$ 2 in symptomatic Alzheimer's disease. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 519-524.	1.8	11
761	Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a033118.	2.3	616

#	ARTICLE	IF	CITATIONS
762	Concordancia entre la PET cerebral con 18 F-FDG y los biomarcadores en LÃquido cefalorraquÃdeo en el diagnÃstico de enfermedad de Alzheimer. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 3-8.	0.0	6
763	The Emergence of a New Conceptual Framework for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2018, 62, 1059-1066.	1.2	56
764	Visuospatial Functioning in the Primary Progressive Aphasias. Journal of the International Neuropsychological Society, 2018, 24, 259-268.	1.2	53
765	Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimerâ€™s disease patients: A CSF and FDG PET study. Brain Research, 2018, 1678, 116-122.	1.1	30
766	Î²APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimerâ€™s Disease. Cerebral Cortex, 2018, 28, 3976-3993.	1.6	13
767	CSF Î²-amyloid and white matter damage: a new perspective on Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 352-357.	0.9	36
768	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
769	Fully Bayesian Spectral Methods for Imaging Data. Biometrics, 2018, 74, 645-652.	0.8	6
770	Patrones de retenciÃ³n de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presiÃ³n normal idiopÃ¡tica. Un anÃ¡lisis visual. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 87-93.	0.0	1
771	CSF AÎ²1â€“42, but not p-Tau181, differentiates aMCI from SCI. Brain Research, 2018, 1678, 27-31.	1.1	9
772	Clinical utility of amyloid PET imaging with (18)F-florbetapir: a retrospective study of 100 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 294-299.	0.9	44
773	The lines are open: An artistâ€™s experience of working with dementia research. Dementia, 2018, 17, 755-762.	1.0	2
774	A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease. Proteomics - Clinical Applications, 2018, 12, 1700131.	0.8	87
775	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. NeuroImage: Clinical, 2018, 17, 452-464.	1.4	126
776	Single-step immunoassays and microfluidic droplet operation: Towards a versatile approach for detection of amyloid-Î² peptide-based biomarkers of Alzheimerâ€™s disease. Sensors and Actuators B: Chemical, 2018, 255, 2126-2135.	4.0	53
777	Alzheimer's disease. European Journal of Neurology, 2018, 25, 59-70.	1.7	1,624
778	Mean diffusivity in cortical gray matter in Alzheimer's disease: The importance of partial volume correction. NeuroImage: Clinical, 2018, 17, 579-586.	1.4	40
780	No association of cortical amyloid load and EEG connectivity in older people with subjective memory complaints. NeuroImage: Clinical, 2018, 17, 435-443.	1.4	19

#	ARTICLE	IF	CITATIONS
781	Validation of T1-weighted based segmentations of white matter hyperintensity volumes in large-scale datasets of aging. <i>Human Brain Mapping</i> , 2018, 39, 1093-1107.	1.9	65
782	Spousal recollections of early signs of primary progressive aphasia. <i>International Journal of Language and Communication Disorders</i> , 2018, 53, 282-293.	0.7	16
783	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 63, 75-87.	1.5	61
784	Cerebrospinal fluid in the dementias. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2018, 146, 85-97.	1.0	9
785	Amyloid- $\beta$ and tau complexity " towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303
786	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
787	Multiple neuronal pathologies are common in young patients with pathologically proven Frontotemporal lobar degeneration. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 522-532.	1.8	9
788	Can visuospatial measures improve the diagnosis of Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 66-74.	1.2	63
789	Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 193-201.	1.4	5
790	Alterations of Effective Connectivity Patterns in Mild Cognitive Impairment: An MEG Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 843-854.	1.2	12
791	Predicting progression of amnesic MCI: The integration of episodic memory impairment with perfusion SPECT. <i>Psychiatry Research - Neuroimaging</i> , 2018, 271, 43-49.	0.9	15
792	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , 2018, 11, 147-152.	1.5	224
794	Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 125.	3.0	20
795	The Precuneus " A Witness for Excessive $\text{A}\beta$ Gathering in Alzheimer's Disease Pathology. <i>Neurodegenerative Diseases</i> , 2018, 18, 302-309.	0.8	13
796	Systematic assessment of the rehabilitation needs in early stage dementia for home-dwelling people: a scoping review protocol. <i>JB International Database of Systematic Reviews and Implementation Reports</i> , 2018, 16, 1947-1958.	1.7	2
797	Antemortem CSF $\text{A}\beta_{42}/\text{A}\beta_{40}$ ratio predicts Alzheimer's disease pathology better than $\text{A}\beta_{42}$ in rapidly progressive dementias. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 263-273.	1.7	31
798	Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 373-381.	1.2	12
799	Down syndrome with posterior cortical atrophy. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223108.	0.2	2

#	ARTICLE	IF	CITATIONS
801	Common Variants in PLXNA4 and Correlation to CSF-related Phenotypes in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 946.	1.4	14
802	5. Ethik und rechtliche Fragen. , 2018, , 157-186.		0
803	6 .Diagnostische Methoden. , 2018, , 187-352.		0
804	Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1105-1116.	1.2	20
805	Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer's Disease: A Case Report. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1363-1369.	1.2	5
806	Detection of Early Stage Alzheimer's Disease using EEG Relative Power with Deep Neural Network. , 2018, 2018, 352-355.		41
807	Identification of Optimum Panel of Blood-based Biomarkers for Alzheimer's Disease Diagnosis Using Machine Learning. , 2018, 2018, 3991-3994.		10
808	The D'Épistage Cognitif de Qu'Ébec: A New Clinician's Tool for Early Recognition of Atypical Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 46, 310-321.	0.7	13
809	Beta-amyloid PET imaging for Alzheimer's dementia diagnosis. <i>Progress in Neurology and Psychiatry</i> , 2018, 22, 31-35.	0.4	0
810	Functional Decline in Alzheimer's Disease: A Continuum. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2239-2240.	1.3	0
811	CSF sTREM2 in delirium's relation to Alzheimer's disease CSF biomarkers A $\beta$ 42, t-tau and p-tau. <i>Journal of Neuroinflammation</i> , 2018, 15, 304.	3.1	36
812	Amnesic Mild Cognitive Impairment Is Associated With Frequency-Specific Brain Network Alterations in Temporal Poles. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 400.	1.7	29
813	PET amiloide en enfermedades neurodegenerativas que cursan con demencia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 397-406.	0.0	2
814	European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol. <i>BMJ Open</i> , 2018, 8, e021017.	0.8	72
815	Updating Our Definitions of Parkinson's Disease for a Molecular Age. <i>Journal of Parkinson's Disease</i> , 2018, 8, S53-S57.	1.5	7
816	Multivariate Deep Learning Classification of Alzheimer's Disease Based on Hierarchical Partner Matching Independent Component Analysis. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 417.	1.7	26
817	Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 669-676.	1.8	9
818	Advances in Resting State Neuroimaging of Mild Cognitive Impairment. <i>Frontiers in Psychiatry</i> , 2018, 9, 671.	1.3	14

#	ARTICLE	IF	CITATIONS
819	Speech Analysis by Natural Language Processing Techniques: A Possible Tool for Very Early Detection of Cognitive Decline?. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 369.	1.7	91
820	Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 459.	1.8	98
821	Ethical Arguments Concerning the Use of Alzheimer's Disease Biomarkers in Individuals with No or Mild Cognitive Impairment: A Systematic Review and Framework for Discussion. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1309-1322.	1.2	27
822	Current state of Alzheimer's fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
823	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 563-572.	1.2	52
824	Patterns of Cerebellar Gray Matter Atrophy Across Alzheimer's Disease Progression. <i>Frontiers in Cellular Neuroscience</i> , 2018, 12, 430.	1.8	48
825	White matter hyperintensities are linked to future cognitive decline in de novo Parkinson's disease patients. <i>NeuroImage: Clinical</i> , 2018, 20, 892-900.	1.4	53
826	Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. <i>Nature Reviews Neurology</i> , 2018, 14, 639-652.	4.9	434
827	Temporospatial components of brain ERPs as biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 604-614.	1.2	3
828	Clinical Progression in Four Cases of Primary Progressive Apraxia of Speech. <i>American Journal of Speech-Language Pathology</i> , 2018, 27, 1303-1318.	0.9	36
829	Speech Registration in Symptomatic Memory Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 201.	1.7	2
830	Parietal Involvement in the Semantic Variant of Primary Progressive Aphasia with Alzheimer's Disease Cerebrospinal Fluid Profile. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 271-280.	1.2	5
831	Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. <i>Nature Reviews Neurology</i> , 2018, 14, 653-666.	4.9	687
832	Naming and verbal learning in adults with Alzheimer's disease, mild cognitive impairment and in healthy aging, with low educational levels. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 93-99.	0.3	2
833	Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional A $\beta$ 2 deposition rate and plaque burden at treatment initiation. <i>Theranostics</i> , 2018, 8, 4957-4968.	4.6	22
834	CSF A $\beta$ 1-42, but not p-Tau181, Predicted Progression from Amnesic MCI to Alzheimer's Disease Dementia. <i>NeuroMolecular Medicine</i> , 2018, 20, 491-497.	1.8	4
835	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
836	Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment. <i>Disease Markers</i> , 2018, 2018, 1-26.	0.6	195

#	ARTICLE	IF	CITATIONS
837	Impaired Spike Timing Dependent Cortico-Cortical Plasticity in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 983-991.	1.2	43
838	Conceptualising and Understanding Artistic Creativity in the Dementias: Interdisciplinary Approaches to Research and Practise. <i>Frontiers in Psychology</i> , 2018, 9, 1842.	1.1	27
839	Questions concerning the role of amyloid- $\beta^2$ in the definition, aetiology and diagnosis of Alzheimer's disease. <i>Acta Neuropathologica</i> , 2018, 136, 663-689.	3.9	151
840	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
842	Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 551-563.	1.2	46
843	Inhibition of miR-128 Abates $A\beta^2$ -Mediated Cytotoxicity by Targeting PPAR- $\beta^3$ via NF- $\kappa^B$ Inactivation in Primary Mouse Cortical Neurons and Neuro2a Cells. <i>Yonsei Medical Journal</i> , 2018, 59, 1096.	0.9	51
844	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides $A\beta^1$ and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 297.	1.7	10
845	Diagnosis of neurodegenerative dementia: where do we stand, now?. <i>Annals of Translational Medicine</i> , 2018, 6, 340-340.	0.7	24
846	Atrophy, metabolism and cognition in the posterior cortical atrophy spectrum based on Alzheimer's disease cerebrospinal fluid biomarkers. <i>NeuroImage: Clinical</i> , 2018, 20, 1018-1025.	1.4	21
847	Glial responses during epileptogenesis in <i>Mus musculus</i> point to potential therapeutic targets. <i>PLoS ONE</i> , 2018, 13, e0201742.	1.1	24
848	CSF pro-orexin and amyloid- $\beta^238$ expression in Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 72, 171-176.	1.5	25
849	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 87.	3.0	13
850	Hallucinations in Neurological Disorders. , 2018, , 99-130.		0
851	The impact of transcranial magnetic stimulation on diagnostic confidence in patients with Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 94.	3.0	37
852	Diagnostic challenges in rapidly progressive dementia. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 761-772.	1.4	29
853	Nonlinear model with random inflection points for modeling neurodegenerative disease progression. <i>Statistics in Medicine</i> , 2018, 37, 4721-4742.	0.8	3
855	Study of altered functional connectivity in individuals at risk for Alzheimer's Disease. <i>Technology and Health Care</i> , 2018, 26, 103-111.	0.5	7
856	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48

#	ARTICLE	IF	CITATIONS
857	The Combination of Functional and Structural MRI Is a Potential Screening Tool in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 251.	1.7	4
858	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	4.9	140
859	On the personal utility of Alzheimer's disease-related biomarker testing in the research context. <i>Journal of Medical Ethics</i> , 2018, 44, 830-834.	1.0	27
860	Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 765-779.	1.2	14
861	Alzheimer's Dementia due to Suspected CTE from Subconcussive Head Impact. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-4.	0.3	2
862	Geriatric Psychiatry Study Guide. , 2018, , .		0
863	Common Major and Mild Neurocognitive Disorders: Alzheimer Disease, Frontotemporal, Lewy Body, and Vascular Types. , 2018, , 203-242.		0
864	Callosal circularity as an early marker for Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 516-526.	1.4	12
865	Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233.	1.8	23
866	Use of Flutemetamol F 18 Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnesic Mild Cognitive Impairment. <i>JAMA Neurology</i> , 2018, 75, 1114.	4.5	75
867	Music models aberrant rule decoding and reward valuation in dementia. <i>Social Cognitive and Affective Neuroscience</i> , 2018, 13, 192-202.	1.5	18
868	From Cerebrospinal Fluid to Blood: The Third Wave of Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S271-S279.	1.2	66
869	Cerebrospinal Fluid BACE1 Activity and sA $\beta$ 2PP $\beta$ 2 as Biomarker Candidates of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 152-161.	0.7	18
870	A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1347-1360.	1.2	55
871	Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1605-1617.	3.3	36
872	Neuropsychological correlates of instrumental activities of daily living in neurocognitive disorders: a possible role for executive dysfunction and mood changes. <i>International Psychogeriatrics</i> , 2018, 30, 1871-1881.	0.6	22
873	Potential value of soluble APP $\beta$ 1 and APP $\beta$ 2 in CSF as biomarkers of dementia disorders: Unresolved issues and perspectives. <i>Neurology and Clinical Neuroscience</i> , 2018, 6, 89-93.	0.2	2
874	Test-retest variability of resting-state networks in healthy aging and prodromal Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 948-962.	1.4	24



#	ARTICLE	IF	CITATIONS
875	Dissection of prodromal Alzheimer's disease. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 1272-1291.	3.0	8
876	Comparative study of microRNA profiling in one Chinese Family with PSEN1 G378E mutation. <i>Metabolic Brain Disease</i> , 2018, 33, 1711-1720.	1.4	18
877	Clinical Research on Alzheimer's Disease: Progress and Perspectives. <i>Neuroscience Bulletin</i> , 2018, 34, 1111-1118.	1.5	100
878	Commutability of the certified reference materials for the standardization of $\beta$ -amyloid 1-42 assay in human cerebrospinal fluid: lessons for tau and $\beta$ -amyloid 1-40 measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 2058-2066.	1.4	27
879	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
880	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain $^{18}$ F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , 2018, 25, 1201-1217.	1.7	153
881	Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 181-191.	1.2	15
882	Biomarkers and the diagnosis of preclinical dementia. <i>BJ Psych Advances</i> , 2018, 24, 422-430.	0.5	5
883	Exploring the Profile of Incidental Memory in Patients with Amnesic Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 617-627.	1.2	7
884	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	3.0	34
885	Validity of the QUADAS-2 in Assessing Risk of Bias in Alzheimer's Disease Diagnostic Accuracy Studies. <i>Frontiers in Psychiatry</i> , 2018, 9, 221.	1.3	10
886	Phenotypic Heterogeneity in Dementia: A Challenge for Epidemiology and Biomarker Studies. <i>Frontiers in Public Health</i> , 2018, 6, 181.	1.3	55
887	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1509-1522.	1.2	17
888	Amsterdam Dementia Cohort: Performing Research to Optimize Care. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1091-1111.	1.2	228
889	A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 783-796.	1.2	50
890	Biomarkers for Alzheimer's disease: current status and prospects for the future. <i>Journal of Internal Medicine</i> , 2018, 284, 643-663.	2.7	550
891	Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 71.	3.0	216
892	PICALM Gene Methylation in Blood of Alzheimer's Disease Patients Is Associated with Cognitive Decline. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 283-292.	1.2	18

#	ARTICLE	IF	CITATIONS
893	Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment. <i>Neurological Sciences</i> , 2018, 39, 1867-1875.	0.9	26
894	Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 60.	3.0	19
895	The Heart-Brain Continuum: A New Way of Looking at Heart Failure Therapy. <i>Journal of Cardiac Failure</i> , 2018, 24, 537-539.	0.7	0
896	Relevance of A $\beta$ 42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 138.	1.7	59
897	Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 188.	1.7	52
898	The Quest for an Alzheimer Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 108.	1.1	19
899	An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 275.	1.4	38
900	Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 362.	1.4	12
901	Spatial navigation deficits " overlooked cognitive marker for preclinical Alzheimer disease?. <i>Nature Reviews Neurology</i> , 2018, 14, 496-506.	4.9	293
902	Prosodic and phonetic subtypes of primary progressive apraxia of speech. <i>Brain and Language</i> , 2018, 184, 54-65.	0.8	106
904	Sex differences in Alzheimer disease " the gateway to precision medicine. <i>Nature Reviews Neurology</i> , 2018, 14, 457-469.	4.9	573
905	What Happens with the Circuit in Alzheimer's Disease in Mice and Humans?. <i>Annual Review of Neuroscience</i> , 2018, 41, 277-297.	5.0	154
906	TDP-43 and Alzheimer's Disease Pathologic Subtype in Non-Amnesic Alzheimer's Disease Dementia. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1227-1233.	1.2	20
907	Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease with Transcranial Magnetic Stimulation. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 221-230.	1.2	44
908	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018, 14, 1522-1552.	0.4	68
909	Psychometric properties and reference data for Danish versions of Free and Cued Selective Reminding Test, Category Cued Memory Test and Logical Memory. <i>Scandinavian Journal of Psychology</i> , 2018, 59, 496-502.	0.8	11
910	How the Brain Is Affected. , 2018, , 3-21.		0
911	Transcranial magnetic stimulation predicts cognitive decline in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1237-1242.	0.9	64

#	ARTICLE	IF	CITATIONS
912	Alzheimer disease pathology and the cerebrospinal fluid proteome. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 66.	3.0	67
913	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 5.	3.0	94
914	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1509-1525.	3.3	81
915	Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. <i>BMC Neurology</i> , 2018, 18, 4.	0.8	99
916	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 32.	3.0	79
917	Standardization and validation of a parallel form of the verbal and non-verbal recognition memory test in an Italian population sample. <i>Neurological Sciences</i> , 2018, 39, 1391-1399.	0.9	14
918	Molecular biomarkers of Alzheimer's disease: progress and prospects. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	163
919	Comparison of $\beta$ -2-microglobulin serum level between Alzheimer's patients, cognitive healthy and mild cognitive impaired individuals. <i>Biomarkers</i> , 2018, 23, 603-608.	0.9	20
920	Differentiation of neuropsychological features between posterior cortical atrophy and early onset Alzheimer's disease. <i>BMC Neurology</i> , 2018, 18, 65.	0.8	16
921	A biomarker study in long-lasting amnesic mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 42.	3.0	26
922	Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data. <i>NeuroImage</i> , 2018, 183, 504-521.	2.1	132
923	Diagnosing dementia with Lewy bodies: new diagnostic criteria. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2018, 48, 44-45.	0.2	2
924	Involvement of the Cingulate Cortex in Anosognosia: A Multimodal Neuroimaging Study in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 443-453.	1.2	28
925	Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification. <i>NeuroImage: Clinical</i> , 2018, 20, 153-160.	1.4	21
926	The genetic risk of Alzheimer's disease beyond APOE $\epsilon$ 4: systematic review of Alzheimer's genetic risk scores. <i>Translational Psychiatry</i> , 2018, 8, 166.	2.4	76
927	Can a Novel High-Density EEG Approach Disentangle the Differences of Visual Event Related Potential (N170), Elicited by Negative Facial Stimuli, in People with Subjective Cognitive Impairment?. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 543-575.	1.2	14
928	Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1147-1157.	1.2	17
929	Neuroinflammation is increased in the parietal cortex of atypical Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2018, 15, 170.	3.1	30

#	ARTICLE	IF	CITATIONS
930	How early can we diagnose Alzheimer disease (and is it sufficient)?. <i>Neurology</i> , 2018, 91, 395-402.	1.5	60
931	Different Abnormalities of Cortical Neural Synchronization Mechanisms in Patients with Mild Cognitive Impairment due to Alzheimer's and Chronic Kidney Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 897-915.	1.2	12
932	Amyloid PET in neurodegenerative diseases with dementia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 397-406.	0.1	0
933	A Pilot Study Investigating a Novel Non-Linear Measure of Eyes Open versus Eyes Closed EEG Synchronization in People with Alzheimer's Disease and Healthy Controls. <i>Brain Sciences</i> , 2018, 8, 134.	1.1	29
934	The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. <i>Scientific Reports</i> , 2018, 8, 8431.	1.6	55
935	Alzheimer's disease. <i>Current Biology</i> , 2018, 28, R645-R649.	1.8	45
936	Diagnostic and prognostic role of semantic processing in preclinical Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 637-651.	0.6	32
937	Plasma $\beta$ -amyloid 1-42 reference values in cognitively normal subjects. <i>Journal of the Neurological Sciences</i> , 2018, 391, 120-126.	0.3	19
938	Multicenter Resting State Functional Connectivity in Prodromal and Dementia Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 801-813.	1.2	19
939	Update on biomarkers for amyloid pathology in Alzheimer's disease. <i>Biomarkers in Medicine</i> , 2018, 12, 799-812.	0.6	59
940	Functional MRI technologies in the study of medication treatment effect on Alzheimer's disease. <i>Aging Medicine (Milton (N S W))</i> , 2018, 1, 75-95.	0.9	8
941	Diagnosis (2): Disorders Causing Dementia and Cognitive Impairment. , 2018, , 279-296.		0
942	The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0193707.	1.1	30
943	Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model. <i>Cell Death and Disease</i> , 2018, 9, 685.	2.7	120
944	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	4.5	102
945	The Patient with Cognitive Impairment. , 0, , 52-80.		1
947	Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study. <i>Molecular Imaging and Biology</i> , 2019, 21, 140-148.	1.3	13
948	Cortical Network Topology in Prodromal and Mild Dementia Due to Alzheimer's Disease: Graph Theory Applied to Resting State EEG. <i>Brain Topography</i> , 2019, 32, 127-141.	0.8	40

#	ARTICLE	IF	CITATIONS
949	Biomarkers for Alzheimer's Disease Defined by a Novel Brain Functional Network Measure. IEEE Transactions on Biomedical Engineering, 2019, 66, 41-49.	2.5	28
950	Cognitive heterogeneity in probable Alzheimer disease. Neurology, 2019, 93, e778-e790.	1.5	27
951	Quantum capacitance-limited MoS <sub>2</sub> biosensors enable remote label-free enzyme measurements. Nanoscale, 2019, 11, 15622-15632.	2.8	13
952	Gracilin A Derivatives Target Early Events in Alzheimer's Disease: in Vitro Effects on Neuroinflammation and Oxidative Stress. ACS Chemical Neuroscience, 2019, 10, 4102-4111.	1.7	14
953	Neuropsychiatric Symptoms as Predictors of Clinical Course in Neurodegeneration. A Longitudinal Study. Frontiers in Aging Neuroscience, 2019, 11, 176.	1.7	27
954	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.4	34
955	Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimer's and Dementia, 2019, 15, 1208-1217.	0.4	45
956	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. NeuroImage: Clinical, 2019, 24, 101949.	1.4	14
957	Regulation of Brain Cholesterol: What Role Do Liver X Receptors Play in Neurodegenerative Diseases?. International Journal of Molecular Sciences, 2019, 20, 3858.	1.8	42
958	Systemic Inflammatory Markers in Age-Associated Cognitive Impairment and Alzheimer's Disease. Neuroscience and Behavioral Physiology, 2019, 49, 352-356.	0.2	4
959	Radiomics approach in the neurodegenerative brain. Aging Clinical and Experimental Research, 2021, 33, 1709-1711.	1.4	31
961	The role of Locus Coeruleus in neuroinflammation occurring in Alzheimer's disease. Brain Research Bulletin, 2019, 153, 47-58.	1.4	35
962	Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, jnnp-2019-321111.	0.9	80
963	IS A LARGE-SCALE SCREENING FOR ALZHEIMER'S DISEASE POSSIBLE? YES, IN A FEW YEARS. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-2.	1.5	3
965	Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. Alzheimer's Research and Therapy, 2019, 11, 67.	3.0	28
966	Does the Right Focal Variant of Alzheimer's Disease Really Exist? A Literature Analysis. Journal of Alzheimer's Disease, 2019, 71, 405-420.	1.2	6
967	Cortical auditory evoked potentials in mild cognitive impairment: Evidence from a temporal-spatial principal component analysis. Psychophysiology, 2019, 56, e13466.	1.2	8
968	Current radiotracers to image neurodegenerative diseases. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 17.	1.8	28

#	ARTICLE	IF	CITATIONS
969	AD biomarker discovery in CSF and in alternative matrices. <i>Clinical Biochemistry</i> , 2019, 72, 52-57.	0.8	15
970	Brain Molecular Connectivity in Neurodegenerative Diseases: Recent Advances and New Perspectives Using Positron Emission Tomography. <i>Frontiers in Neuroscience</i> , 2019, 13, 617.	1.4	54
971	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. <i>Clinical Mass Spectrometry</i> , 2019, 14, 74-82.	1.9	9
973	Retinal thickness as potential biomarker in posterior cortical atrophy and typical Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 62.	3.0	40
974	Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnesic Subtype of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1051-1058.	1.2	21
975	Transcranial Magnetic and Electrical Stimulation in Alzheimer's Disease and Mild Cognitive Impairment: A Review of Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 776-780.	2.3	42
976	Neuronal chemoarchitecture of the entorhinal cortex: A comparative review. <i>European Journal of Neuroscience</i> , 2019, 50, 3627-3662.	1.2	28
978	Alzheimer Disease Pathogenesis: Insights From Molecular and Cellular Biology Studies of Oligomeric A $\beta$ and Tau Species. <i>Frontiers in Neuroscience</i> , 2019, 13, 659.	1.4	198
979	Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India. <i>Asian Journal of Psychiatry</i> , 2019, 44, 99-105.	0.9	10
980	The Use of Biomarkers and Genetic Screening to Diagnose Frontotemporal Dementia: Evidence and Clinical Implications. <i>Frontiers in Neuroscience</i> , 2019, 13, 757.	1.4	22
981	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
982	Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of Aging. <i>JAMA Neurology</i> , 2019, 76, 1340.	4.5	156
983	Validation of neuropsychological tests for the China Health and Retirement Longitudinal Study Harmonized Cognitive Assessment Protocol. <i>International Psychogeriatrics</i> , 2019, 31, 1709-1719.	0.6	53
984	Potential Clinical Applications and Future Prospect of Wireless and Mobile Electroencephalography on the Assessment of Cognitive Impairment. <i>Bioelectricity</i> , 2019, 1, 105-112.	0.6	5
985	Which Episodic Memory Performance is Associated with Alzheimer's Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD). <i>Journal of Alzheimer's Disease</i> , 2019, 70, 811-824.	1.2	16
986	Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults. <i>Clinical Neurophysiology</i> , 2019, 130, 1488-1498.	0.7	10
987	Towards a unified protocol for handling of CSF before $\beta$ -amyloid measurements. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 63.	3.0	38
988	A case of ALS with posterior cortical atrophy. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 506-510.	1.1	2

#	ARTICLE	IF	CITATIONS
989	Sulcal morphology in Alzheimer's disease: an effective marker of diagnosis and cognition. <i>Neurobiology of Aging</i> , 2019, 84, 41-49.	1.5	23
990	Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 64.	3.0	47
991	Staging the cognitive continuum in prodromal Alzheimer's disease with episodic memory. <i>Neurobiology of Aging</i> , 2019, 84, 1-8.	1.5	22
992	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101954.	1.4	42
993	The complexities of behavioural assessment in neurodegenerative disorders: A focus on Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 147, 104363.	3.1	9
994	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	0.8	16
995	Alzheimer's disease clinical variants show distinct regional patterns of neurofibrillary tangle accumulation. <i>Acta Neuropathologica</i> , 2019, 138, 597-612.	3.9	75
996	Early detection of Alzheimer's disease by peptides from phage display screening. <i>Brain Research</i> , 2019, 1721, 146306.	1.1	7
997	The overlap between epilepsy and Alzheimer's disease and the consequences for treatment. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 653-661.	1.4	16
998	The Who, When, Why, and How of PET Amyloid Imaging in Management of Alzheimer's Disease—Review of Literature and Interesting Images. <i>Diagnostics</i> , 2019, 9, 65.	1.3	63
999	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
1000	Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 747-756.	1.2	26
1001	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019, 79, 716-737.	1.5	30
1002	Astrocytic Tau Deposition Is Frequent in Typical and Atypical Alzheimer Disease Presentations. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1112-1123.	0.9	34
1003	Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 84.	3.0	28
1004	<p>The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer's disease?</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 1481-1492.	1.3	14
1005	Posterior Cortical Atrophy: Does Complaint Match the Impairment? A Neuropsychological and FDG-PET Study. <i>Frontiers in Neurology</i> , 2019, 10, 1010.	1.1	5
1006	Brain Amyloid- $\beta^2$ Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 169-178.	1.2	28

#	ARTICLE	IF	CITATIONS
1007	Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America. <i>Pharmaceutical Medicine</i> , 2019, 33, 511-518.	1.0	2
1008	Diagnosis of Dementia and Cognitive Impairment. <i>Diagnostics</i> , 2019, 9, 180.	1.3	3
1009	Methodological Issues in the Clinical Validation of Biomarkers for Alzheimer's Disease: The Paradigmatic Example of CSF. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 282.	1.7	8
1010	Practical algorithms for amyloid $\beta$ probability in subjective or mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 710-720.	1.2	8
1011	Diagnosis of mild cognitive impairment using multiple neuroimaging modalities in addition to the Mini-Mental State Examination. <i>Geriatrics and Gerontology International</i> , 2019, 19, 1193-1197.	0.7	3
1012	Global Clinical Dementia Rating Score of 0.5 May Not Be an Accurate Criterion to Identify Individuals with Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease Reports</i> , 2019, 3, 233-239.	1.2	17
1013	Age-Related Changes of the Neurovascular Unit in the Cerebral Cortex of Alzheimer Disease Mouse Models: A Neuroanatomical and Molecular Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 101-112.	0.9	15
1014	Hibernation Impairs Odor Discrimination – Implications for Alzheimer's Disease. <i>Frontiers in Neuroanatomy</i> , 2019, 13, 69.	0.9	5
1015	Brain Iron Metabolism and CNS Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	11
1016	Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 364-373.	1.8	11
1017	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. <i>Brain Sciences</i> , 2019, 9, 213.	1.1	15
1018	In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 47, 289-296.	0.7	9
1019	Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 74.	3.0	28
1020	Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET. <i>Japanese Journal of Radiology</i> , 2019, 37, 735-749.	1.0	35
1021	The –rights– of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	3.0	148
1022	Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 382-387.	1.8	34
1023	The Executive Checklist (EC-10) – a new rating instrument for clinicians assessing dysexecutive behavior. <i>Applied Neuropsychology Adult</i> , 2021, 28, 525-534.	0.7	1
1024	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1233-1243.	1.2	28



#	ARTICLE	IF	CITATIONS
1025	Discordant amyloid- $\beta$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 78.	3.0	40
1026	Biomarker-guided clustering of Alzheimer's disease clinical syndromes. <i>Neurobiology of Aging</i> , 2019, 83, 42-53.	1.5	48
1027	Cerebrospinal fluid biomarkers and cognitive status in differential diagnosis of frontotemporal dementia and Alzheimer's disease. <i>Journal of International Medical Research</i> , 2019, 47, 4968-4980.	0.4	13
1028	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 82.	3.0	51
1029	Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"? <i>Alzheimer's and Dementia</i> , 2019, 15, 1348-1356.	0.4	20
1030	Permutation Entropy and Irreversibility in Gait Kinematic Time Series from Patients with Mild Cognitive Decline and Early Alzheimer's Dementia. <i>Entropy</i> , 2019, 21, 868.	1.1	15
1031	Plasma A $\beta$ 42 and Total Tau Predict Cognitive Decline in Amnesic Mild Cognitive Impairment. <i>Scientific Reports</i> , 2019, 9, 13984.	1.6	38
1032	Identification of a rare presenilin 1 single amino acid deletion mutation (F175del) with unusual amyloid- $\beta$ processing effects. <i>Neurobiology of Aging</i> , 2019, 84, 241.e5-241.e11.	1.5	9
1033	Age-Dependent Relationship Between Plasma A $\beta$ 40 and A $\beta$ 42 and Total Tau Levels in Cognitively Normal Subjects. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 222.	1.7	29
1034	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 69-73.	1.2	13
1035	Perception of Benefits and Risks of Neurocognitive Disorders Diagnosis: A French National Survey. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1267-1275.	1.2	7
1036	The Incremental Diagnostic Value of [18F]Florbetaben PET and the Pivotal Role of the Neuropsychological Assessment in Clinical Practice. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1235-1244.	1.2	5
1037	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019, 77, 112-127.	1.5	33
1038	Clinical, neuropsychological and imaging characteristics of Alzheimer's disease patients presenting as corticobasal syndrome. <i>Journal of the Neurological Sciences</i> , 2019, 398, 142-147.	0.3	9
1039	$^{18}\text{F}$ -Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification. <i>Journal of Neuroimaging</i> , 2019, 29, 383-393.	1.0	19
1040	Apolipoprotein E gene in physiological and pathological aging. <i>Mechanisms of Ageing and Development</i> , 2019, 178, 41-45.	2.2	15
1041	Early pathological gambling in co-occurrence with semantic variant primary progressive aphasia: a case report. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 727-733.	1.3	3
1042	Cognitive impairment in depression: recent advances and novel treatments. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1249-1258.	1.0	196

#	ARTICLE	IF	CITATIONS
1043	Elecsys <sup>®</sup> Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , 2019, 72, 30-38.	0.8	60
1044	Method comparison study of the Elecsys <sup>®</sup> $\beta$ -Amyloid (1 $\times$ 42) CSF assay versus comparator assays and LC-MS/MS. <i>Clinical Biochemistry</i> , 2019, 72, 7-14.	0.8	30
1045	A new diagnostic approach for the identification of patients with neurodegenerative cognitive complaints. <i>PLoS ONE</i> , 2019, 14, e0217388.	1.1	26
1046	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
1047	Early detection and risk assessment for chronic disease with irregular longitudinal data analysis. <i>Journal of Biomedical Informatics</i> , 2019, 96, 103231.	2.5	14
1048	A new perspective for advanced positron emission tomography <sup>®</sup> -based molecular imaging in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia</i> , 2019, 15, 1081-1103.	0.4	16
1049	Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia. <i>NeuroImage: Clinical</i> , 2019, 23, 101902.	1.4	9
1050	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	0.8	17
1051	ABCA1- and ABCG1-mediated cholesterol efflux capacity of cerebrospinal fluid is impaired in Alzheimer's disease. <i>Journal of Lipid Research</i> , 2019, 60, 1449-1456.	2.0	44
1052	Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 663-669.	1.2	21
1053	Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid A $\beta$ 242 and T-Tau assays for Alzheimer <sup>®</sup> 's disease diagnosis. <i>Journal of Neurology</i> , 2019, 266, 2304-2311.	1.8	34
1054	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	0.9	19
1055	Diagnosis and treatment of cognitive impairment. <i>Zeitschrift Fur Gerontologie Und Geriatrie</i> , 2019, 52, 309-315.	0.8	14
1056	Subtypes of Alzheimer's Disease Display Distinct Network Abnormalities Extending Beyond Their Pattern of Brain Atrophy. <i>Frontiers in Neurology</i> , 2019, 10, 524.	1.1	52
1058	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer <sup>®</sup> 's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 1213-1220.	1.2	12
1059	A frontline defense against neurodegenerative diseases:the development of early disease detection methods. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 559-563.	1.5	12
1060	The neuroinflammatory biomarker YKL-40 for neurodegenerative diseases: advances in development. <i>Expert Review of Proteomics</i> , 2019, 16, 593-600.	1.3	41
1061	Physician's Field Guide to Neuropsychology. , 2019, , .		2

#	ARTICLE	IF	CITATIONS
1062	Altered microbiomes distinguish Alzheimer's disease from amnesic mild cognitive impairment and health in a Chinese cohort. <i>Brain, Behavior, and Immunity</i> , 2019, 80, 633-643.	2.0	358
1063	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. <i>Lancet Neurology</i> , 2019, 18, 519-520.	4.9	0
1064	Where words meet numbers: Comprehension of measurement unit terms in posterior cortical atrophy. <i>Neuropsychologia</i> , 2019, 131, 216-222.	0.7	8
1065	Attention network dysfunction underlies memory impairment in posterior cortical atrophy. <i>NeuroImage: Clinical</i> , 2019, 22, 101773.	1.4	27
1066	TMA-93 for Diagnosing Amnesic Mild Cognitive Impairment: A Comparison With the Free and Cued Selective Reminding Test. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 322-328.	0.9	7
1067	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 327-332.	1.2	9
1068	Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid® Treatment on Cognition and 18F-FDG PET Scans. <i>Journal of Alzheimer's Disease Reports</i> , 2019, 3, 95-102.	1.2	8
1069	Semi-quantification and grading of amyloid PET: A project of the European Alzheimer's Disease Consortium (EADC). <i>NeuroImage: Clinical</i> , 2019, 23, 101846.	1.4	18
1070	Timely Detection of Mild Cognitive Impairment in Italy: An Expert Opinion. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1401-1414.	1.2	11
1071	Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9285-9292.	3.3	118
1072	Visuospatial dysfunction in Alzheimer's disease and behavioural variant frontotemporal dementia. <i>Journal of the Neurological Sciences</i> , 2019, 402, 74-80.	0.3	27
1073	A brief history of "Alzheimer disease". <i>Neurology</i> , 2019, 92, 1053-1059.	1.5	52
1074	ASAF: altered spontaneous activity fingerprinting in Alzheimer's disease based on multisite fMRI. <i>Science Bulletin</i> , 2019, 64, 998-1010.	4.3	24
1075	Epilepsy and other neurological disorders. , 2019, , 221-244.		0
1076	Longitudinal progression of grey matter atrophy in non-amnesic Alzheimer's disease. <i>Brain</i> , 2019, 142, 1701-1722.	3.7	37
1077	Development of memory clinics in the Netherlands over the last 20 years. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1267-1274.	1.3	30
1078	Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient. <i>Neurochemistry International</i> , 2019, 128, 154-162.	1.9	14
1079	Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 211-220.	1.2	14

#	ARTICLE	IF	CITATIONS
1080	Neuroimaging and Neurolaw: Drawing the Future of Aging. <i>Frontiers in Endocrinology</i> , 2019, 10, 217.	1.5	5
1081	Plasma Levels of Soluble A $\beta$ 1-42 as a Biomarker for Alzheimer's Disease with Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 83-90.	1.2	0
1082	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019, 9, e024498.	0.8	18
1083	Assessment of 18F-Florbetaben Amyloid PET Imaging in Patients with Suspected Alzheimer's Disease and Isolated Increase in Cerebrospinal Fluid Tau Proteins. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1061-1069.	1.2	6
1084	Development of parallel reaction monitoring assays for cerebrospinal fluid proteins associated with Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019, 494, 79-93.	0.5	30
1085	Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1151-1159.	1.2	9
1086	Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 723-733.	1.2	21
1087	Effects of CD33 Variants on Neuroimaging Biomarkers in Non-Demented Elders. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 757-766.	1.2	6
1088	Novelty processing and memory impairment in Alzheimer's disease: A review. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 100, 237-249.	2.9	26
1089	Multiple Visual Rating Scales Based on Structural MRI and a Novel Prediction Model Combining Visual Rating Scales and Age Stratification in the Diagnosis of Alzheimer's Disease in the Chinese Population. <i>Frontiers in Neurology</i> , 2019, 10, 93.	1.1	13
1090	BIOLOGICAL AND COGNITIVE MARKERS OF PRESENILIN1 E280A AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW OF THE COLOMBIAN KINDRED. <i>Journal of Prevention of Alzheimer's Disease</i> , 2019, 6, 1-9.	1.5	31
1091	CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. <i>Acta Neurologica Belgica</i> , 2019, 119, 445-452.	0.5	18
1092	An Impairment of Prospective Memory in Mild Alzheimer's Disease: A Ride in a Virtual Town. <i>Frontiers in Psychology</i> , 2019, 10, 241.	1.1	39
1093	Potential Diagnostic Value of Red Blood Cells $\alpha$ -Synuclein Heteroaggregates in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 6451-6459.	1.9	24
1094	Primary progressive aphasia: a model for neurodegenerative disease. <i>Current Opinion in Neurology</i> , 2019, 32, 255-265.	1.8	50
1095	18F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease. , 2019, , 37-48.		1
1096	The difference of mild cognitive impairment in Parkinson's disease from amnesic mild cognitive impairment: Deeper power decrement and no phase-locking in visual event-related responses. <i>International Journal of Psychophysiology</i> , 2019, 139, 48-58.	0.5	16
1097	Evolution of brain atrophy subtypes during aging predicts long-term cognitive decline and future Alzheimer's clinical syndrome. <i>Neurobiology of Aging</i> , 2019, 79, 22-29.	1.5	13

#	ARTICLE	IF	CITATIONS
1098	Comparison between a Paper-Pencil Version and Computerized Version for the Realization of a Neuropsychological Test: The Example of the Trail Making Test. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1657-1666.	1.2	14
1099	Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 164-169.	1.2	11
1100	Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1369-1382.	3.3	74
1101	Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus. <i>Journal of Clinical Medicine</i> , 2019, 8, 319.	1.0	43
1102	Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. <i>Neuroradiology</i> , 2019, 61, 633-642.	1.1	50
1103	From brain collections to modern brain banks: A historical perspective. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 52-60.	1.8	21
1105	Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnesic Mild Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2019, 9, 100-113.	0.6	28
1106	A $\beta$ <sup>2</sup> and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 257-263.	1.2	40
1107	The added value of A $\beta$ <sup>242</sup> /A $\beta$ <sup>240</sup> in the CSF signature for routine diagnostics of Alzheimer's disease. <i>Clinica Chimica Acta</i> , 2019, 494, 71-73.	0.5	26
1108	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 591-608.	1.2	7
1109	Preanalytical sample handling recommendations for Alzheimer's disease plasma biomarkers. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 291-300.	1.2	56
1110	Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 213-225.	1.2	0
1111	Combined Biomarker Prognosis of Mild Cognitive Impairment: An 11-Year Follow-Up Study in the Alzheimer's Disease Neuroimaging Initiative. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1549-1559.	1.2	9
1112	Extracellular Vesicle as a Source of Alzheimer's Biomarkers: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1728.	1.8	86
1113	Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and 18F-FDG-PET imaging. <i>NeuroImage: Clinical</i> , 2019, 22, 101771.	1.4	108
1114	CSF level of $\beta$ <sup>2</sup> -amyloid peptide predicts mortality in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 29.	3.0	19
1115	Alzheimer's Disease Including Focal Presentations. <i>Seminars in Neurology</i> , 2019, 39, 213-226.	0.5	72
1116	Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 79, 131-141.	1.5	23

#	ARTICLE	IF	CITATIONS
1117	Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1276-1286.	3.3	38
1118	The Relationship Between Hippocampal Volumes and Delayed Recall Is Modified by APOE $\epsilon$ 4 in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 36.	1.7	10
1119	A Dementia Classification Framework Using Frequency and Time-Frequency Features Based on EEG Signals. <i>IEEE Transactions on Neural Systems and Rehabilitation Engineering</i> , 2019, 27, 826-835.	2.7	76
1120	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 49-58.	1.2	8
1121	Late Effects. , 2019, , 496-554.		0
1122	Synaptic vesicle protein 2A as a potential biomarker in synaptopathies. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 34-42.	1.0	55
1123	Quantifying memory deficits in amnestic mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 108-114.	1.2	14
1124	Statistical considerations in a delayed-start design to demonstrate disease modification effect in neurodegenerative disorders. <i>Pharmaceutical Statistics</i> , 2019, 18, 407-419.	0.7	3
1125	What happens when nothing happens? An investigation of pauses as a compensatory mechanism in early Alzheimer's disease. <i>Neuropsychologia</i> , 2019, 124, 133-143.	0.7	37
1126	Transcranial Direct Current Stimulation in Psychiatric Disorders: A Comprehensive Review of Recent Advances. <i>Current Psychiatry Reviews</i> , 2019, 14, 230-238.	0.9	1
1127	Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 18.	3.0	36
1128	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1833-1863.	2.4	75
1129	The functional neuroanatomy of musical memory in Alzheimer's disease. <i>Cortex</i> , 2019, 115, 357-370.	1.1	20
1130	Is Alzheimer's Disease Risk Modifiable?. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 795-819.	1.2	73
1131	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. <i>Current Alzheimer Research</i> , 2019, 16, 91-101.	0.7	23
1132	Head-to-Head Comparison among Semi-Quantification Tools of Brain FDG-PET to Aid the Diagnosis of Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 383-394.	1.2	14
1133	Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	6
1134	Imaging beta amyloid aggregation and iron accumulation in Alzheimer's disease using quantitative susceptibility mapping MRI. <i>NeuroImage</i> , 2019, 191, 176-185.	2.1	122

#	ARTICLE	IF	CITATIONS
1135	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , 2019, 9, 561.	1.6	42
1136	Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset. <i>Alzheimer's and Dementia</i> , 2019, 15, 506-514.	0.4	28
1137	The Role of Biomarkers in Alzheimer's Disease Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 29-61.	0.8	84
1138	Expression of telomere repeat binding factor 1 and TRF2 in Alzheimer's disease and correlation with clinical parameters. <i>Neurological Research</i> , 2019, 41, 504-509.	0.6	8
1139	M/EEG-Based Bio-Markers to Predict the MCI and Alzheimer's Disease: A Review From the ML Perspective. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 2924-2935.	2.5	60
1140	Physical Activity as a Moderator of Alzheimer Pathology: A Systematic Review of Observational Studies. <i>Current Alzheimer Research</i> , 2019, 16, 362-378.	0.7	30
1141	Current state of research on non-human primate models of Alzheimer's disease. <i>Animal Models and Experimental Medicine</i> , 2019, 2, 227-238.	1.3	29
1142	Demencias degenerativas: ¿un dilema de síndromes o de enfermedades?. <i>Neurología</i> , 2019, , .	0.3	0
1143	Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 48, 180-195.	0.7	25
1144	Two weeks of a computerized cognitive training may produce beneficial effects in Alzheimer's disease patients. , 2019, , .		0
1145	Evaluación preliminar de una versión pictórica y abreviada del Free and Cued Selective Reminding Test. <i>Neurología</i> , 2019, , .	0.3	1
1146	Reciprocal Incremental Value of 18F-FDG-PET and Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment Patients Suspected for Alzheimer's Disease and Inconclusive First Biomarker. <i>Journal of Alzheimer's Disease</i> , 2019, 72, 1193-1207.	1.2	5
1147	A Copper Complex of a Thiosemicarbazone-Pyridylhydrazone Ligand Containing a Vinylpyridine Functional Group as a Potential Imaging Agent for Amyloid- $\beta$ Plaques. <i>Australian Journal of Chemistry</i> , 2019, 72, 827.	0.5	10
1148	Are Linear Measurements of the Nucleus Basalis of Meynert Suitable as a Diagnostic Biomarker in Mild Cognitive Impairment and Alzheimer Disease?. <i>American Journal of Neuroradiology</i> , 2019, 40, 2039-2044.	1.2	8
1149	The clinico-metabolic correlates of language impairment in corticobasal syndrome and progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102009.	1.4	15
1151	Is semantic learning strategy an early clinical marker for amnesic mild cognitive impairment and Alzheimer's disease?. <i>International Psychogeriatrics</i> , 2019, 31, 1695-1697.	0.6	3
1152	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	1.7	13
1153	Parkinsonism in genetic and sporadic Alzheimer's disease. <i>International Review of Neurobiology</i> , 2019, 149, 237-247.	0.9	2

#	ARTICLE	IF	CITATIONS
1154	Blood-based biomarkers for Alzheimer's disease and related dementias: Keys to success and things to consider. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 784-786.	1.2	1
1155	Hemodynamics Analysis of Patients With Mild Cognitive Impairment During Working Memory Tasks. , 2019, 2019, 4470-4473.		7
1156	Classification of healthy, Alzheimer's disease, and Parkinson's disease individuals with cortical generators of rsEEG rhythms. , 2019, , .		0
1157	Which MCI Patients Should be Included in Prodromal Alzheimer Disease Clinical Trials?. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 104-112.	0.6	12
1158	Role of Cerebrospinal Fluid Biomarkers and (18)F-florbetapir PET Imaging in the Diagnosis of Primary Progressive Aphasia. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 282-284.	0.6	3
1159	Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early-stage Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 111.	3.0	21
1160	Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer's Disease. , 2019, , .		5
1162	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ -Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , 2019, 8, 129-145.	1.4	8
1163	Retinal correlates of neurological disorders. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988220.	1.1	36
1164	Salivary Biomarkers for Alzheimer's Disease and Related Disorders. <i>Neurology and Therapy</i> , 2019, 8, 83-94.	1.4	54
1165	Progression to dementia in memory clinic patients with mild cognitive impairment and normal $\beta$ -amyloid. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 99.	3.0	23
1166	Cognitive Aging and Dementia: A Life-Span Perspective. <i>Annual Review of Developmental Psychology</i> , 2019, 1, 177-196.	1.4	94
1167	Zinc transporters in Alzheimer's disease. <i>Molecular Brain</i> , 2019, 12, 106.	1.3	41
1168	Sleep symptoms in syndromes of frontotemporal dementia and Alzheimer's disease: A proof-of-principle behavioural study. <i>ENeurologicalSci</i> , 2019, 17, 100212.	0.5	17
1169	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	3.0	21
1171	Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project. <i>Journal of Global Health</i> , 2019, 9, 020320.	1.2	17
1172	Plasma A $\beta$ 42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnesic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 37-48.	1.2	23
1173	Neuropsychology as a profession in Italy. <i>Applied Neuropsychology Adult</i> , 2019, 26, 543-557.	0.7	5



#	ARTICLE	IF	CITATIONS
1174	Research on Computer-Aided Diagnosis of Alzheimer's Disease Based on Heterogeneous Medical Data Fusion. <i>International Journal of Pattern Recognition and Artificial Intelligence</i> , 2019, 33, 1957001.	0.7	8
1175	Standardization of hippocampus volumetry using automated brain structure volumetry tool for an initial Alzheimer's disease imaging biomarker. <i>Acta Radiologica</i> , 2019, 60, 769-776.	0.5	44
1176	Nanotheranostics, a future remedy of neurological disorders. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 113-128.	2.4	41
1177	Neuroimaging markers of global cognition in early Alzheimer's disease: A magnetic resonance imaging-electroencephalography study. <i>Brain and Behavior</i> , 2019, 9, e01197.	1.0	20
1178	Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 21, 101632.	1.4	37
1179	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
1180	Dementia with Lewy bodies "from scientific knowledge to clinical insights. <i>Nature Reviews Neurology</i> , 2019, 15, 103-112.	4.9	49
1181	White matter in different regions evolves differently during progression to dementia. <i>Neurobiology of Aging</i> , 2019, 76, 71-79.	1.5	49
1182	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 1-9.	1.2	14
1183	Automated classification of Alzheimer's disease and mild cognitive impairment using a single MRI and deep neural networks. <i>NeuroImage: Clinical</i> , 2019, 21, 101645.	1.4	352
1184	Viscoelastic Properties of Human Autopsy Brain Tissues as Biomarkers for Alzheimer's Diseases. <i>IEEE Transactions on Biomedical Engineering</i> , 2019, 66, 1705-1713.	2.5	31
1185	Association of hippocampal volume with gait variability in pre-dementia and dementia stages of Alzheimer disease: Results from a cross-sectional study. <i>Experimental Gerontology</i> , 2019, 115, 55-61.	1.2	29
1186	Two-Year Longitudinal Monitoring of Amnesic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 15-35.	1.2	34
1187	A Preliminary Study of Clinical Trial Enrollment Decisions Among People With Mild Cognitive Impairment and Their Study Partners. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 322-332.	0.6	20
1188	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.4	60
1189	Impaired brain plasticity as a potential therapeutic target for treatment and prevention of dementia. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 21-28.	1.5	21
1190	High frequency of getting out of bed in patients with Alzheimer's disease monitored by non-wearable actigraphy. <i>Geriatrics and Gerontology International</i> , 2019, 19, 130-134.	0.7	16
1191	Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 7.	3.0	87

#	ARTICLE	IF	CITATIONS
1192	Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1152-1163.	3.3	30
1193	Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1117-1131.	3.3	18
1194	Proinflammatory and anti-inflammatory cytokines in the CSF of patients with Alzheimer's disease and their correlation with cognitive decline. <i>Neurobiology of Aging</i> , 2019, 76, 125-132.	1.5	121
1195	Associations between tau, A $\beta$ , and cortical thickness with cognition in Alzheimer disease. <i>Neurology</i> , 2019, 92, e601-e612.	1.5	196
1196	Blood-based biomarkers for Alzheimer's disease—An update. <i>Journal of Neuroscience Methods</i> , 2019, 319, 2-6.	1.3	87
1197	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. <i>Acta Neuropathologica</i> , 2019, 137, 71-88.	3.9	29
1198	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2019, 15, 106-152.	0.4	302
1199	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
1200	Biomarkers for tau pathology. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 18-33.	1.0	163
1201	Memories defining the self in Alzheimer's disease. <i>Memory</i> , 2019, 27, 698-704.	0.9	13
1202	In-Out-Test: A New Paradigm for Sorting the Wheat from the Chaff in Prodromal Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 265-277.	1.2	2
1203	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2019, 137, 279-296.	3.9	128
1204	Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 348-356.	3.3	41
1205	FDG-PET hypometabolism is more sensitive than MRI atrophy in Parkinson's disease: A whole-brain multimodal imaging meta-analysis. <i>NeuroImage: Clinical</i> , 2019, 21, 101594.	1.4	53
1206	Electroencephalography in primary progressive aphasia and apraxia of speech. <i>Aphasiology</i> , 2019, 33, 1410-1417.	1.4	9
1207	Extravascular fibrinogen in the white matter of Alzheimer's disease and normal aged brains: implications for fibrinogen as a biomarker for Alzheimer's disease. <i>Brain Pathology</i> , 2019, 29, 414-424.	2.1	24
1208	A Novel ELISA for the Measurement of Cerebrospinal Fluid SNAP-25 in Patients with Alzheimer's Disease. <i>Neuroscience</i> , 2019, 420, 136-144.	1.1	25
1209	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2019, 151, 417-434.	2.1	15

#	ARTICLE	IF	CITATIONS
1210	Diagnostic accuracy of dopaminergic imaging in prodromal dementia with Lewy bodies. <i>Psychological Medicine</i> , 2019, 49, 396-402.	2.7	51
1211	Randomized Controlled Trials for Diagnostic Imaging: Conceptual and Practical Problems. <i>Topoi</i> , 2019, 38, 395-400.	0.8	5
1212	Brain structural correlates of executive and social cognition profiles in behavioral variant frontotemporal dementia and elderly bipolar disorder. <i>Neuropsychologia</i> , 2019, 126, 159-169.	0.7	65
1213	Genetic data and cognitively defined late-onset Alzheimer's disease subgroups. <i>Molecular Psychiatry</i> , 2020, 25, 2942-2951.	4.1	57
1214	Influence of sex differences in interpreting learning and memory within a clinical sample of older adults. <i>Aging, Neuropsychology, and Cognition</i> , 2020, 27, 18-39.	0.7	26
1215	Studying the Manifold Structure of Alzheimer's Disease: A Deep Learning Approach Using Convolutional Autoencoders. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 17-26.	3.9	127
1216	Deep Residual Inception Encoder-Decoder Network for Medical Imaging Synthesis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2020, 24, 39-49.	3.9	43
1217	Changes in functional and structural brain connectome along the Alzheimer's disease continuum. <i>Molecular Psychiatry</i> , 2020, 25, 230-239.	4.1	78
1218	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020, 85, 58-73.	1.5	150
1219	Is the Cutoff of the MoCA too High? Longitudinal Data From Highly Educated Older Adults. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 155-160.	1.2	28
1220	Propagation of Tau Pathology: Integrating Insights From Postmortem and In Vivo Studies. <i>Biological Psychiatry</i> , 2020, 87, 808-818.	0.7	50
1221	Head-to-head comparison of tau positron emission tomography tracers [ <sup>18</sup> F]flortaucipir and [ <sup>18</sup> F]RO948. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 342-354.	3.3	61
1222	Validation of the Movement Disorder Society Criteria for the Diagnosis of Repeat Tauopathies. <i>Movement Disorders</i> , 2020, 35, 171-176.	2.2	37
1223	Prediction of Alzheimer's disease diagnosis within 14 years through A $\beta$ 2 misfolding in blood plasma compared to APOE4 status, and other risk factors. <i>Alzheimer's and Dementia</i> , 2020, 16, 283-291.	0.4	26
1224	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 270-280.	3.3	23
1225	Early restoration of parvalbumin interneuron activity prevents memory loss and network hyperexcitability in a mouse model of Alzheimer's disease. <i>Molecular Psychiatry</i> , 2020, 25, 3380-3398.	4.1	120
1226	Dementia in China: epidemiology, clinical management, and research advances. <i>Lancet Neurology</i> , The, 2020, 19, 81-92.	4.9	412
1227	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. <i>Neurobiology of Disease</i> , 2020, 134, 104645.	2.1	16

#	ARTICLE	IF	CITATIONS
1228	The striatum, the hippocampus, and short-term memory binding: Volumetric analysis of the subcortical grey matter's role in mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2020, 25, 102158.	1.4	29
1229	Biosensors on the road to early diagnostic and surveillance of Alzheimer's disease. <i>Talanta</i> , 2020, 211, 120700.	2.9	36
1230	Development of potent reversible selective inhibitors of butyrylcholinesterase as fluorescent probes. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 498-505.	2.5	16
1231	Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease. <i>Neurology and Clinical Neuroscience</i> , 2020, 8, 61-67.	0.2	6
1232	Mixed dementia: Neglected clinical entity or nosographic artifice?. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116662.	0.3	23
1233	Every-other-day feeding exacerbates inflammation and neuronal deficits in 5XFAD mouse model of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 136, 104745.	2.1	21
1234	Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimer's disease course. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 5.	3.0	39
1235	A future for PET imaging in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 231-234.	3.3	11
1236	Improved quantification of amyloid burden and associated biomarker cut-off points: results from the first amyloid Singaporean cohort with overlapping cerebrovascular disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 319-331.	3.3	16
1237	Antihypertensive agents in Alzheimer's disease: beyond vascular protection. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 175-187.	1.4	26
1238	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 2.	3.0	86
1239	Biomarkers of Alzheimer Disease. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 194-208.	0.6	29
1240	CSF cutoffs for MCI due to AD depend on APOE $\epsilon$ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
1241	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. <i>Brain</i> , 2020, 143, 650-660.	3.7	68
1242	Brain metabolic signatures across the Alzheimer's disease spectrum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 256-269.	3.3	27
1243	Galantamine Inhibits A $\beta$ 1-42-Induced Neurotoxicity by Enhancing $\beta$ 7nAChR Expression as a Cargo Carrier for LC3 Binding and A $\beta$ 1-42 Engulfment During Autophagic Degradation. <i>Neurotherapeutics</i> , 2020, 17, 676-689.	2.1	16
1244	An update on fluid biomarkers for neurodegenerative diseases: recent success and challenges ahead. <i>Current Opinion in Neurobiology</i> , 2020, 61, 29-39.	2.0	67
1245	Weighted network measures reveal differences between dementia types: An EEG study. <i>Human Brain Mapping</i> , 2020, 41, 1573-1590.	1.9	25

#	ARTICLE	IF	CITATIONS
1246	ABC Dementia Scale Classifies Alzheimer's Disease Patients into Subgroups Characterized by Activities of Daily Living, Behavioral and Psychological Symptoms of Dementia, and Cognitive Function. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 383-392.	1.2	4
1247	The antidepressant drug; trazodone inhibits Tau amyloidogenesis: Prospects for prophylaxis and treatment of AD. <i>Archives of Biochemistry and Biophysics</i> , 2020, 679, 108218.	1.4	18
1248	Upcoming diagnostic biomarkers with promising prospects in neurological disorders. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 347-356.	0.9	1
1249	White matter fiber density abnormalities in cognitively normal adults at risk for late-onset Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2020, 122, 79-87.	1.5	15
1250	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	3.0	33
1251	The Reversal of Memory Deficits in an Alzheimer's Disease Model Using Physical and Cognitive Exercise. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 152.	1.0	17
1252	The effect of insomnia on development of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 289.	3.1	48
1253	Quantitative Study of the Changes in Cerebral Blood Flow and Iron Deposition During Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 439-452.	1.2	27
1254	Recent advances in research on Alzheimer's disease in China. <i>Journal of Clinical Neuroscience</i> , 2020, 81, 43-46.	0.8	22
1255	Research on Cognition Disorders. , 2020, , .		0
1256	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254
1257	Î2-Secretase1 biological markers for Alzheimer's disease: state-of-art of validation and qualification. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 130.	3.0	16
1258	EEG microstate complexity for aiding early diagnosis of Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 17627.	1.6	77
1259	Therapeutic benefit of aripiprazole-olanzapine combination in the treatment of senile Alzheimer's disease complicated by mental disorders. <i>Tropical Journal of Pharmaceutical Research</i> , 2020, 19, 441-446.	0.2	2
1260	Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis. <i>Mechanisms of Ageing and Development</i> , 2020, 192, 111386.	2.2	6
1261	Parieto-occipital sulcus widening differentiates posterior cortical atrophy from typical Alzheimer disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102453.	1.4	11
1262	Bridging the Gap Between Fluid Biomarkers for Alzheimer's Disease, Model Systems, and Patients. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 272.	1.7	17
1263	Retinal biomarkers for Alzheimer's disease and vascular cognitive impairment and dementia (VCID): implication for early diagnosis and prognosis. <i>GeroScience</i> , 2020, 42, 1499-1525.	2.1	64

#	ARTICLE	IF	CITATIONS
1264	Autonomic function in amnesic and non-amnesic mild cognitive impairment: spectral heart rate variability analysis provides evidence for a brain-heart axis. <i>Scientific Reports</i> , 2020, 10, 11661.	1.6	27
1265	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. <i>Molecular Psychiatry</i> , 2021, 26, 5967-5976.	4.1	76
1267	Analysis of clinical application patterns in acupuncture-moxibustion treatment of Alzheimer disease. <i>Journal of Acupuncture and Tuina Science</i> , 2020, 18, 238-246.	0.1	3
1268	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020, 90, 43-59.	1.5	30
1269	Diagnostic Impact of CSF Biomarkers in a Local Hospital Memory Clinic Revisited. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 2-7.	0.7	4
1271	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 514136.	1.1	8
1272	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	1.1	20
1273	Extracellular Vesicles in Alzheimer's and Parkinson's Disease: Small Entities with Large Consequences. <i>Cells</i> , 2020, 9, 2485.	1.8	36
1274	Late-onset presentation and phenotypic heterogeneity of the rare R377W PSEN1 mutation. <i>European Journal of Neurology</i> , 2020, 27, 2630-2634.	1.7	3
1275	A Robust Discriminant Framework Based on Functional Biomarkers of EEG and Its Potential for Diagnosis of Alzheimer's Disease. <i>Healthcare (Switzerland)</i> , 2020, 8, 476.	1.0	9
1276	Association between Structural Connectivity and Generalized Cognitive Spectrum in Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 879.	1.1	11
1277	Endosomal Dysfunction Induced by Directly Overactivating Rab5 Recapitulates Prodromal and Neurodegenerative Features of Alzheimer's Disease. <i>Cell Reports</i> , 2020, 33, 108420.	2.9	58
1278	Patients with progranulin mutations overlap with the progressive dysexecutive syndrome: towards the definition of a frontoparietal dementia phenotype. <i>Brain Communications</i> , 2020, 2, fcaa126.	1.5	3
1279	The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 518-525.	0.7	19
1281	Late-onset vs nonmendelian early-onset Alzheimer disease. <i>Neurology: Genetics</i> , 2020, 6, e512.	0.9	82
1282	Neurogranin and VILIP-1 as Molecular Indicators of Neurodegeneration in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8335.	1.8	15
1283	Graph Theory Analysis Reveals Resting-State Compensatory Mechanisms in Healthy Aging and Prodromal Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 576627.	1.7	34
1284	Correlations of apathy with clinical symptoms of Alzheimer's disease and olfactory dysfunctions: a cross-sectional study. <i>BMC Neurology</i> , 2020, 20, 416.	0.8	10

#	ARTICLE	IF	CITATIONS
1285	Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 92.	3.0	18
1286	Different Clinical Contexts of Use of Blood Neurofilament Light Chain Protein in the Spectrum of Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2020, 57, 4667-4691.	1.9	33
1287	A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis. <i>Nature Communications</i> , 2020, 11, 3960.	5.8	20
1288	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. <i>EBioMedicine</i> , 2020, 57, 102834.	2.7	59
1289	Chromatic Pupillometry Findings in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 780.	1.4	15
1290	Effect of a Cognitive Training Program on the Platelet APP Ratio in Patients with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5110.	1.8	3
1291	Role of Magnetoencephalography in the Early Stages of Alzheimer Disease. <i>Neuroimaging Clinics of North America</i> , 2020, 30, 217-227.	0.5	9
1292	Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. <i>Neurobiology of Aging</i> , 2020, 95, 123-130.	1.5	15
1293	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
1294	Combining Visual Rating Scales for Medial Temporal Lobe Atrophy and Posterior Atrophy to Identify Amnesic Mild Cognitive Impairment from Cognitively Normal Older Adults: Evidence Based on Two Cohorts. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 323-337.	1.2	9
1295	MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2020, 57, 4408-4416.	1.9	23
1296	Brain-Derived Neurotrophic Factor (BDNF) Preserves the Functional Integrity of Neural Networks in the $\beta^2$ -Amyloidopathy Model in vitro. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 582.	1.8	17
1297	The existence of $\Delta^2$ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 142, 17-39.	3.9	35
1298	Tracking the potential involvement of metabolic disease in Alzheimer's disease "Biomarkers and beyond. <i>International Review of Neurobiology</i> , 2020, 154, 51-77.	0.9	6
1299	A European Academy of Neurology guideline on medical management issues in dementia. <i>European Journal of Neurology</i> , 2020, 27, 1805-1820.	1.7	52
1300	Increased Neurofilament Light Chain and YKL-40 CSF Levels in One Japanese IBMPFD Patient With VCP R155C Mutation: A Clinical Case Report With CSF Biomarker Analyses. <i>Frontiers in Neurology</i> , 2020, 11, 757.	1.1	2
1301	Zinc Therapy in Early Alzheimer's Disease: Safety and Potential Therapeutic Efficacy. <i>Biomolecules</i> , 2020, 10, 1164.	1.8	22
1302	Elevated matrix metalloproteinase-9 levels in neuronal extracellular vesicles in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1681-1691.	1.7	32

#	ARTICLE	IF	CITATIONS
1303	Changes Over Time of Diffusion MRI in the White Matter of Aging Brain, a Good Predictor of Verbal Recall. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 218.	1.7	9
1304	The Framing of "Alzheimer's Disease": Differences Between Scientific and Lay Literature and Their Ethical Implications. <i>Gerontologist</i> , The, 2021, 61, 746-755.	2.3	13
1305	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1023-1037.	4.0	48
1306	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 572-583.	0.7	12
1307	Locus Coeruleus and neurovascular unit: From its role in physiology to its potential role in Alzheimer's disease pathogenesis. <i>Journal of Neuroscience Research</i> , 2020, 98, 2406-2434.	1.3	38
1310	The health burden of non-communicable neurological disorders in the USA between 1990 and 2017. <i>Brain Communications</i> , 2020, 2, fcaa097.	1.5	4
1311	Amyloid PET imaging in clinical practice. <i>Practical Neurology</i> , 2020, 20, 451-462.	0.5	28
1312	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. , 2020, , 202-212.		0
1313	Epidemiology and Mental Health in Old Age. , 2020, , 5-23.		0
1315	Young-Onset Dementias. , 2020, , 38-49.		0
1316	Rare and Unusual Dementias. , 2020, , 50-77.		0
1317	Mania in Late Life. , 2020, , 78-91.		0
1318	Alcohol Misuse in Older People. , 2020, , 92-104.		0
1319	Drug Misuse in Older People. , 2020, , 105-115.		0
1320	Mental Health in Parkinson's Disease. , 2020, , 116-128.		0
1321	The Home Assessment in Old Age Psychiatry. , 2020, , 129-138.		0
1322	Driving in Dementia. , 2020, , 139-148.		0
1323	Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. , 2020, , 149-160.		0



#	ARTICLE	IF	CITATIONS
1324	Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. , 2020, , 161-172.		0
1325	To Scan or Not to Scan. , 2020, , 173-190.		0
1326	Supporting Self-Management in Early Dementia. , 2020, , 191-201.		0
1327	Psychosocial Interventions in Dementia. , 2020, , 213-222.		0
1328	Palliative Care in Dementia. , 2020, , 223-242.		0
1329	Review of Treatment for Late-Life Depression. , 2020, , 243-253.		0
1330	Reducing the Healthcare Burden of Delirium. , 2020, , 254-265.		0
1331	Controlling the Confusion. , 2020, , 266-278.		0
1332	Residence Capacity. , 2020, , 305-316.		0
1335	Impact of hearing loss and vestibular decline on cognition in Alzheimer's disease: a prospective longitudinal study protocol (Gehoor, Evenwicht en Cognitie, GECKO). BMJ Open, 2020, 10, e039601.	0.8	16
1336	A French-Greek Cross-Site Comparison Study of the Use of Automatic Video Analyses for the Assessment of Autonomy in Dementia Patients. Biosensors, 2020, 10, 103.	2.3	7
1338	Mental Health Laws from All UK Jurisdictions. , 2020, , 279-292.		0
1339	Deprivation of Liberty. , 2020, , 293-304.		0
1340	Understanding the Person with Dementia. , 2020, , 317-327.		0
1341	Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use. Medicinal Research Reviews, 2021, 41, 2775-2803.	5.0	39
1342	Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease. JAMA Network Open, 2020, 3, e2010372.	2.8	34
1343	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	1.1	26
1344	Fluid Biomarkers for Synaptic Dysfunction and Loss. Biomarker Insights, 2020, 15, 117727192095031.	1.0	74

#	ARTICLE	IF	CITATIONS
1345	New Long-Term Encoding in Severely Amnesic Alzheimer's Disease Patients Revealed Through Repeated Exposure to Artistic Items. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1567-1579.	1.2	1
1346	Assessment of <sup>18</sup> F-Pi-2620 as a Biomarker in Progressive Supranuclear Palsy. <i>JAMA Neurology</i> , 2020, 77, 1408.	4.5	145
1347	An analytic framework for conceptualisations of disease: nine structuring questions and how some conceptualisations of Alzheimer's disease can lead to "diseasisation". <i>Medicine, Health Care and Philosophy</i> , 2020, 23, 677-693.	0.9	2
1348	Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 935-947.	1.2	5
1349	Biomarkers for Alzheimer's Disease Early Diagnosis. <i>Journal of Personalized Medicine</i> , 2020, 10, 114.	1.1	58
1350	Current Biomarkers for Alzheimer's Disease: From CSF to Blood. <i>Journal of Personalized Medicine</i> , 2020, 10, 85.	1.1	42
1351	Practices and opinions about disclosure of the diagnosis of Alzheimer's disease to patients with MCI or dementia: a survey among Belgian medical experts in the field of dementia. <i>Acta Neurologica Belgica</i> , 2020, 120, 1157-1163.	0.5	3
1352	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
1353	Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study. <i>PLoS Medicine</i> , 2020, 17, e1003289.	3.9	39
1354	Chronic Traumatic Encephalopathy: A Comparison with Alzheimer's Disease and Frontotemporal Dementia. <i>Seminars in Neurology</i> , 2020, 40, 394-410.	0.5	7
1355	Association Analysis of Peripheral and CSF Biomarkers in Late Mild Cognitive Impairment. <i>Frontiers in Genetics</i> , 2020, 11, 834.	1.1	1
1356	Unraveling Early Signs of Navigational Impairment in APP <sup>swe</sup> /PS1 <sup>dE9</sup> Mice Using Morris Water Maze. <i>Frontiers in Neuroscience</i> , 2020, 14, 568200.	1.4	7
1357	Low Cerebrospinal Fluid Levels of Hemopexin Are Associated With Increased Alzheimer's Pathology, Hippocampal Hypometabolism, and Cognitive Decline. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 590979.	1.6	7
1358	Radiomics Analysis of Magnetic Resonance Imaging Facilitates the Identification of Preclinical Alzheimer's Disease: An Exploratory Study. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 605734.	1.8	27
1359	Validation and Norms for a Recognition Task for the Spanish Version of the Free and Cued Selective Reminding Test. <i>Archives of Clinical Neuropsychology</i> , 2020, 36, 954-964.	0.3	4
1360	Aggregation of Vascular Risk Factors Modulates the Amplitude of Low-Frequency Fluctuation in Mild Cognitive Impairment Patients. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 604246.	1.7	11
1361	Souvenaid for Alzheimer's disease. <i>The Cochrane Library</i> , 2020, 2020, CD011679.	1.5	4
1362	Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 168.	3.0	7

#	ARTICLE	IF	CITATIONS
1363	The Destiny of Multiple Domain Amnesic Mild Cognitive Impairment: Effect of Alternative Neuropsychological Definitions and Their Adjunctive Role in Respect of Memory Impairment. <i>Archives of Clinical Neuropsychology</i> , 2021, 36, 702-710.	0.3	3
1364	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12097.	1.2	5
1365	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. <i>Brain Communications</i> , 2020, 2, faaa192.	1.5	24
1366	Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer's disease. <i>Science Advances</i> , 2020, 6, .	4.7	52
1367	Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid- $\beta^2$ positivity. <i>Molecular Psychiatry</i> , 2021, 26, 5864-5874.	4.1	22
1368	Potential cost savings for selected non-pharmacological treatment strategies for patients with Alzheimer's disease in Finland. <i>Journal of Rehabilitation Medicine</i> , 2020, 52, jrm00106.	0.8	3
1369	Sleep and circadian rhythms in the treatment, trajectory, and prevention of neurodegenerative disease. <i>Neurobiology of Disease</i> , 2020, 145, 105075.	2.1	1
1370	The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 50.	3.0	68
1371	Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 891-902.	1.2	22
1372	Change in Expression of 5-HT6 Receptor at Different Stages of Alzheimer's Disease: A Postmortem Study with the PET Radiopharmaceutical [ $^{18}\text{F}$ ]2FNQ1P. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1329-1338.	1.2	1
1373	Comparison of Diagnostic Performances Between Cerebrospinal Fluid Biomarkers and Amyloid PET in a Clinical Setting. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 473-490.	1.2	19
1374	Discrimination ability of the Short Test of Mental Status (STMS) compared to the Mini Mental State Examination (MMSE) in the spectrum of normal cognition, mild cognitive impairment, and probable Alzheimer's disease dementia: The Turkish standardization study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2020, 42, 450-458.	0.8	9
1375	Evidence that levels of nine essential metals in post-mortem human-Alzheimer's-brain and <i>ex vivo</i> rat-brain tissues are unaffected by differences in post-mortem delay, age, disease staging, and brain bank location. <i>Metallomics</i> , 2020, 12, 952-962.	1.0	12
1376	Current role of 18F-FDG-PET in the differential diagnosis of the main forms of dementia. <i>Clinical and Translational Imaging</i> , 2020, 8, 127-140.	1.1	3
1377	The Use of a Virtual Reality Platform for the Assessment of the Memory Decline and the Hippocampal Neural Injury in Subjects with Mild Cognitive Impairment: The Validity of Smart Aging Serious Game (SASG). <i>Journal of Clinical Medicine</i> , 2020, 9, 1355.	1.0	23
1378	Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 949-958.	1.2	7
1379	The burden of chronic disease, multimorbidity, and polypharmacy in adults with Down syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 1735-1743.	0.7	14
1380	A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 60-70.	1.5	35

#	ARTICLE	IF	CITATIONS
1381	Accuracy of MRI Classification Algorithms in a Tertiary Memory Center Clinical Routine Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1157-1166.	1.2	19
1382	Effectiveness and Safety of Acupuncture for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 98.	1.7	37
1383	Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years. <i>Molecular Psychiatry</i> , 2021, 26, 5812-5822.	4.1	31
1384	Multimodal Coherent Imaging of Retinal Biomarkers of Alzheimer's Disease in a Mouse Model. <i>Scientific Reports</i> , 2020, 10, 7912.	1.6	16
1385	Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3158.	1.8	12
1386	Epilepsy and Alzheimer's Disease: Potential mechanisms for an association. <i>Brain Research Bulletin</i> , 2020, 160, 107-120.	1.4	45
1388	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. <i>Brain Communications</i> , 2020, 2, fcaa068.	1.5	81
1389	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. <i>Cells</i> , 2020, 9, 1443.	1.8	60
1390	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 74.	3.0	53
1391	Mini Nutritional Assessment May Identify a Dual Pattern of Perturbed Plasma Amino Acids in Patients with Alzheimer's Disease: A Window to Metabolic and Physical Rehabilitation?. <i>Nutrients</i> , 2020, 12, 1845.	1.7	19
1392	Clinical detection of neurodegenerative blood biomarkers using graphene immunosensor. <i>Carbon</i> , 2020, 168, 144-162.	5.4	30
1393	Towards a Redefinition of Cognitive Frailty. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 831-843.	1.2	27
1394	Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression. <i>Alzheimer's and Dementia</i> , 2020, 16, 965-973.	0.4	30
1395	TDP-43 Is Elevated in Plasma Neuronal-Derived Exosomes of Patients With Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 166.	1.7	21
1396	Logopenic aphasia due to Lewy body disease dramatically improved with donepezil. <i>ENeurologicalSci</i> , 2020, 19, 100241.	0.5	8
1397	Evidence-based Positron Emission Tomography. , 2020, , .		3
1398	Assessment of visually guided reaching in prodromal Alzheimer's disease: a cross-sectional study protocol. <i>BMJ Open</i> , 2020, 10, e035021.	0.8	3
1399	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 22-37.	0.7	5

#	ARTICLE	IF	CITATIONS
1400	IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment. <i>Journal of Neuroinflammation</i> , 2020, 17, 174.	3.1	36
1401	A typology of clinical conditions. <i>Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences</i> , 2020, 83, 101291.	0.8	12
1402	Capgras Delusion in Posterior Cortical Atrophy—A Quantitative Multimodal Imaging Single Case Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 133.	1.7	3
1403	Identification of a Rare PSEN1 Mutation (Thr119Ile) in Late-Onset Alzheimer's Disease With Early Presentation of Behavioral Disturbance. <i>Frontiers in Psychiatry</i> , 2020, 11, 347.	1.3	7
1405	Biochemical Markers in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1989.	1.8	67
1406	Relationships between amyloid levels, glucose metabolism, morphologic changes in the brain and clinical status of patients with Alzheimer's disease. <i>Annals of Nuclear Medicine</i> , 2020, 34, 337-348.	1.2	13
1407	Alzheimer-related genes show accelerated evolution. <i>Molecular Psychiatry</i> , 2021, 26, 5790-5796.	4.1	10
1408	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. <i>Clinica Chimica Acta</i> , 2020, 506, 55-66.	0.5	2
1409	Association between motoric cognitive risk syndrome and frailty among older Chinese adults. <i>BMC Geriatrics</i> , 2020, 20, 110.	1.1	12
1411	Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12005.	1.2	35
1412	Apolipoprotein A1 in Cerebrospinal Fluid Is Insufficient to Distinguish Alzheimer's Disease from Other Dementias in a Naturalistic, Clinical Setting. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 15-19.	1.2	5
1413	Applying deep learning models to structural MRI for stage prediction of Alzheimer's disease. <i>Turkish Journal of Electrical Engineering and Computer Sciences</i> , 2020, 28, 196-210.	0.9	28
1414	Revealing a Novel Landscape of the Association Between Blood Lipid Levels and Alzheimer's Disease: A Meta-Analysis of a Case-Control Study. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 370.	1.7	22
1415	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 22.	3.0	74
1416	Current clinical approaches in neurodegenerative diseases. , 2020, , 79-124.		1
1417	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020, 395, 1988-1997.	6.3	164
1418	A Novel Connectome-based Electrophysiological Study of Subjective Cognitive Decline Related to Alzheimer's Disease by Using Resting-state High-density EEG EGI GES 300. <i>Brain Sciences</i> , 2020, 10, 392.	1.1	17
1419	Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid- $\beta^2$ Load. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 291-301.	1.2	3

#	ARTICLE	IF	CITATIONS
1420	Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia. <i>Frontiers in Neurology</i> , 2020, 11, 560.	1.1	4
1421	Genetic Association Between Alzheimer's Disease Risk Variant of the PICALM Gene and EEG Functional Connectivity in Non-demented Adults. <i>Frontiers in Neuroscience</i> , 2020, 14, 324.	1.4	6
1422	[18F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5875-5887.	4.1	14
1423	Clinical and radiological differences between patients with probable cerebral amyloid angiopathy and mixed cerebral microbleeds. <i>Journal of Neurology</i> , 2020, 267, 3602-3608.	1.8	10
1424	Blood and cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Journal of Laboratory and Precision Medicine</i> , 0, 5, 15-15.	1.1	5
1425	Development, equivalence study, and normative data of version B of the Spanish-language Free and Cued Selective Reminding Test. <i>Neurología (English Edition)</i> , 2020, 36, 353-360.	0.2	3
1426	Design and Rationale of the PACT-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 733-751.	1.2	27
1427	Norms for Testing Visual Binding Using the Memory Associative Test (TMA-93) in Older Educationally-Diverse Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 871-878.	1.2	7
1428	Heavy Tau Burden with Subtle Amyloid $\beta^2$ Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer's Disease with APP Osaka Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4443.	1.8	9
1429	Initial Physician Experience with [18F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 165-174.	1.2	3
1430	Chemical sensing platforms for detecting trace-level Alzheimer's core biomarkers. <i>Chemical Society Reviews</i> , 2020, 49, 5446-5472.	18.7	56
1431	Neuropathologic features associated with basal forebrain atrophy in Alzheimer disease. <i>Neurology</i> , 2020, 95, e1301-e1311.	1.5	29
1432	Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 785-796.	1.2	6
1433	Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation. <i>Brain</i> , 2020, 143, 976-992.	3.7	16
1434	Cerebellar White Matter Disruption in Alzheimer's Disease Patients: A Diffusion Tensor Imaging Study. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 615-624.	1.2	21
1435	CLIC1 Protein Accumulates in Circulating Monocyte Membrane during Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1484.	1.8	19
1436	Traitement de la maladie d'Alzheimer: une lueur au bout du tunnel?. <i>Pratique Neurologique - FMC</i> , 2020, 11, 46-48.	0.1	0
1437	The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 421-441.	1.5	42

#	ARTICLE	IF	CITATIONS
1438	Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 90, 110-118.	1.5	19
1439	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course—a joint PhD student course at University College London and University of Gothenburg. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 20.	3.0	32
1440	Potential of PET/CT in assessing dementias with emphasis on cerebrovascular disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2493-2498.	3.3	23
1441	Fingerprinting Alzheimer's Disease by <sup>1</sup> H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , 2020, 19, 1696-1705.	1.8	32
1442	US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development. <i>Clinical and Translational Science</i> , 2020, 13, 652-664.	1.5	11
1443	Magnetic Resonance Texture Analysis in Alzheimer's disease. <i>Academic Radiology</i> , 2020, 27, 1774-1783.	1.3	32
1444	Plasma levels of Interleukin 18 but not amyloid- $\beta$ or Tau are elevated in female depressive patients. <i>Comprehensive Psychiatry</i> , 2020, 97, 152159.	1.5	7
1445	The Role of Free and Cued Selective Reminding Test in Predicting [18F]Florbetaben PET Results in Mild Cognitive Impairment and Mild Dementia. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1647-1659.	1.2	4
1446	Engineering Versatile Nanoparticles for Near-Infrared Light-Tunable Drug Release and Photothermal Degradation of Amyloid $\beta$ . <i>Advanced Functional Materials</i> , 2020, 30, 1908473.	7.8	38
1447	The characterisation of subjective cognitive decline. <i>Lancet Neurology</i> , The, 2020, 19, 271-278.	4.9	627
1448	A kinetics-based approach to amyloid PET semi-quantification. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2175-2185.	3.3	3
1449	Frontal variant of Alzheimer's disease with asymmetric presentation mimicking frontotemporal dementia: Case report and literature review. <i>Brain and Behavior</i> , 2020, 10, e01548.	1.0	18
1450	Cognitive impairment in Parkinson's disease is multifactorial: A neuropsychological study. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 500-508.	1.0	11
1451	Functional Connectivity of Default Mode Network Subsystems in the Presymptomatic Stage of Autosomal Dominant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1435-1444.	1.2	6
1452	Alzheimer's disease: review of current nanotechnological therapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 271-279.	1.4	22
1453	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. <i>Protein and Peptide Letters</i> , 2020, 27, 484-511.	0.4	25
1454	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 21-37.	1.2	30
1455	Memory impairment and Alzheimer's disease pathology in individuals with MCI who underestimate or overestimate their decline. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 581-588.	1.3	11

#	ARTICLE	IF	CITATIONS
1456	The neural bases of discourse semantic and pragmatic deficits in patients with frontotemporal dementia and Alzheimer's disease. <i>Cortex</i> , 2020, 128, 174-191.	1.1	15
1457	Altered Time Awareness in Dementia. <i>Frontiers in Neurology</i> , 2020, 11, 291.	1.1	10
1458	CSF Ubiquitin Levels Are Higher in Alzheimer's Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. <i>Biomolecules</i> , 2020, 10, 497.	1.8	8
1459	Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment. <i>Translational Psychiatry</i> , 2020, 10, 125.	2.4	48
1460	Advances in protein misfolding, amyloidosis and its correlation with human diseases. <i>3 Biotech</i> , 2020, 10, 193.	1.1	15
1461	Anesthésie et maladie d'Alzheimer: actualités. <i>Praticien En Anesthésie Réanimation</i> , 2020, 24, 10-15.	0.0	0
1462	Independent and reproducible hippocampal radiomic biomarkers for multisite Alzheimer's disease: diagnosis, longitudinal progress and biological basis. <i>Science Bulletin</i> , 2020, 65, 1103-1113.	4.3	70
1463	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. <i>Nature Communications</i> , 2020, 11, 1683.	5.8	252
1464	Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2020, 80, 313-317.	0.6	30
1465	A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 48.	1.6	5
1466	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 707-721.	1.7	17
1467	Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies. <i>Acta Neuropathologica</i> , 2020, 140, 49-62.	3.9	218
1468	Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. <i>Cell and Tissue Research</i> , 2020, 380, 273-286.	1.5	10
1469	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
1470	Age-Related Changes in Instrumental and Basic Activities of Daily Living Impairment in Older Adults with Very Mild Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2020, 10, 27-37.	0.6	24
1471	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	4.9	668
1472	Associations of urinary 8-iso-prostaglandin F <sub>2</sub> levels with all-cause dementia, Alzheimer's disease, and vascular dementia incidence: results from a prospective cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, 804-813.	0.4	15
1473	Early diagnosis of Alzheimer's disease: the role of biomarkers including advanced EEG signal analysis. Report from the IFCN-sponsored panel of experts. <i>Clinical Neurophysiology</i> , 2020, 131, 1287-1310.	0.7	123



#	ARTICLE	IF	CITATIONS
1474	New fluid biomarkers tracking non-amyloid- $\beta^2$ and non-tau pathology in Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 556-568.	3.2	57
1475	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 36.	3.0	39
1476	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 277-286.	1.2	13
1477	A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 456.	2.2	201
1478	Abnormal cortical regions and subsystems in whole brain functional connectivity of mild cognitive impairment and Alzheimer's disease: a preliminary study. <i>Ageing Clinical and Experimental Research</i> , 2021, 33, 367-381.	1.4	5
1479	Biomarkers for Alzheimer's disease—preparing for a new era of disease-modifying therapies. <i>Molecular Psychiatry</i> , 2021, 26, 296-308.	4.1	205
1480	Reply to comment on "An elderly patient with Alzheimer's disease, normal pressure hydrocephalus and traumatic brain injury: presented with behavioral symptoms similar to behavioral variant frontotemporal dementia?". <i>International Journal of Neuroscience</i> , 2021, 131, 317-318.	0.8	1
1481	Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. <i>Neuropharmacology</i> , 2021, 185, 108081.	2.0	27
1482	Desarrollo, estudio de equivalencia y datos normativos de la versión española B del Free and Cued Selective Reminding Test. <i>Neurología</i> , 2021, 36, 353-360.	0.3	6
1483	Neural Correlates of Temporal Presentness in the Precuneus: A Cross-linguistic fMRI Study based on Speech Stimuli. <i>Cerebral Cortex</i> , 2021, 31, 1538-1552.	1.6	2
1484	Analysis of the Human Plasma Proteome Using Multi-Particle Protein Corona for Detection of Alzheimer's Disease. <i>Advanced Healthcare Materials</i> , 2021, 10, e2000948.	3.9	19
1485	Clinical impact of 18F-FDG-PET among memory clinic patients with uncertain diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 612-622.	3.3	16
1486	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 375-383.	0.6	36
1487	Current strategies for the development of fluorescence-based molecular probes for visualizing the enzymes and proteins associated with Alzheimer's disease. <i>Coordination Chemistry Reviews</i> , 2021, 427, 213553.	9.5	39
1488	Remédiation de la reconnaissance des émotions faciales dans la maladie d'Alzheimer et effets sur les stratégies d'observation, les troubles du comportement et le fardeau de l'aidant. <i>NPG Neurologie - Psychiatrie - Geriatrie</i> , 2021, 21, 25-36.	0.1	2
1489	Sleep-disordered breathing and the risk of Alzheimer's disease. <i>Sleep Medicine Reviews</i> , 2021, 55, 101375.	3.8	79
1490	Predicting the progression of mild cognitive impairment using machine learning: A systematic, quantitative and critical review. <i>Medical Image Analysis</i> , 2021, 67, 101848.	7.0	50
1491	Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk. <i>Alzheimer's and Dementia</i> , 2021, 17, 407-416.	0.4	28

#	ARTICLE	IF	CITATIONS
1492	Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia. <i>European Journal of Neurology</i> , 2021, 28, 1142-1152.	1.7	11
1493	Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis. <i>Alzheimer's and Dementia</i> , 2021, 17, 755-767.	0.4	81
1494	Assessing natural metalinguistic skills in people with Alzheimer's disease and frontotemporal dementia. <i>Journal of Communication Disorders</i> , 2021, 89, 106058.	0.8	1
1495	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. <i>Brain</i> , 2021, 144, 325-339.	3.7	124
1496	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
1497	Alterations of Brain Networks in Alzheimer's Disease and Mild Cognitive Impairment: A Resting State fMRI Study Based on a Population-specific Brain Template. <i>Neuroscience</i> , 2021, 452, 192-207.	1.1	20
1498	Egocentric and Allocentric Spatial Memory in Mild Cognitive Impairment with Real-World and Virtual Navigation Tasks: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 95-116.	1.2	25
1499	Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 44-49.	1.1	13
1500	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
1501	How can dementia and disability be prevented in older adults: where are we today and where are we going?. <i>Journal of Internal Medicine</i> , 2021, 289, 807-830.	2.7	70
1502	Brevican and Neurocan Peptides as Potential Cerebrospinal Fluid Biomarkers for Differentiation Between Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 729-741.	1.2	10
1503	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. <i>Acta Neuropathologica</i> , 2021, 141, 217-233.	3.9	33
1504	Singular cases of Alzheimer's disease disclose new and old genetic "acquaintances". <i>Neurological Sciences</i> , 2021, 42, 2021-2029.	0.9	4
1505	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. <i>Clinical Neurophysiology</i> , 2021, 132, 232-245.	0.7	30
1506	Topographic Distribution of Amyloid- $\beta$ , Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021, 96, e81-e92.	1.5	31
1507	Association of PET-based stages of amyloid deposition with neuropathological markers of $A\beta$ pathology. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 29-42.	1.7	7
1508	Neurological examination: what do psychiatrists need to know?. <i>BJ Psych Advances</i> , 2021, 27, 313-319.	0.5	0
1509	A Meta-Analysis of Semantic Memory in Mild Cognitive Impairment. <i>Neuropsychology Review</i> , 2021, 31, 221-232.	2.5	15

#	ARTICLE	IF	CITATIONS
1510	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
1511	Gut microbiota interacts with intrinsic brain activity of patients with amnesic mild cognitive impairment. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 163-173.	1.9	51
1512	The Complex and Integral Roles of Pericytes Within the Neurovascular Unit in Health and Disease. <i>Pancreatic Islet Biology</i> , 2021, , 39-74.	0.1	1
1513	Recent advances in enzymeless-based electrochemical sensors to diagnose neurodegenerative diseases. <i>Journal of Materials Chemistry B</i> , 2021, 9, 1175-1188.	2.9	22
1514	The NGF Metabolic Pathway: New Opportunities for Biomarker Research and Drug Target Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1331, 31-48.	0.8	2
1515	Biomarcadores en la enfermedad de Alzheimer. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 39-50.	0.1	2
1516	Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 819-832.	1.2	6
1518	Plasma $\beta$ -Amyloid Levels Associated With Structural Integrity Based on Diffusion Tensor Imaging in Subjective Cognitive Decline: The SILCODE Study. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 592024.	1.7	4
1519	AD7c-NTP Impairs Adult Striatal Neurogenesis by Affecting the Biological Function of MeCP2 in APP/PS1 Transgenic Mouse Model of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 616614.	1.7	5
1520	Too narrow and too broad: Differentiating late-onset dementia from its historical entanglement with Alzheimer's disease. <i>Aging Brain</i> , 2021, 1, 100010.	0.7	0
1521	Alzheimer's disease drug development pipeline: 2021. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12179.	1.8	259
1522	What role do metals play in Alzheimer's disease?. <i>Journal of the Iranian Chemical Society</i> , 2021, 18, 2199-2213.	1.2	3
1523	Analysis of Risk Factors in Dementia Through Machine Learning. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 845-861.	1.2	5
1524	Disturbed temporal dynamics of episodic retrieval activity with preserved spatial activity pattern in amnesic mild cognitive impairment: A simultaneous EEG-fMRI study. <i>NeuroImage: Clinical</i> , 2021, 30, 102572.	1.4	4
1525	$\text{A}\beta$ misfolding in blood plasma measured by immuno-infrared sensor as an age-independent risk marker of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12151.	1.2	2
1526	Diagnostic Evaluation of Dementia. , 2021, , 31-55.		0
1527	Evaluation of Wearable Technology in Dementia: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2020, 7, 501104.	1.2	17
1528	Diagnóstico neuropsicológico diferencial en enfermedad de Alzheimer y demencia frontotemporal: una revisión sistemática cualitativa. <i>Neurology Perspectives</i> , 2021, 1, 82-97.	0.2	3

#	ARTICLE	IF	CITATIONS
1529	Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories. <i>NeuroImage: Clinical</i> , 2021, 31, 102713.	1.4	6
1530	Identification of biomarkers for diagnosing and monitoring therapy in the treatment of neurologic disorders. , 2021, , 291-310.		0
1531	Detection of the SQSTM1 Mutation in a Patient with Early-Onset Hippocampal Amnesic Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 477-481.	1.2	2
1532	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
1533	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	1.3	8
1534	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 2.	3.0	18
1535	Past, Present, and Future of Non-invasive Brain Stimulation Approaches to Treat Cognitive Impairment in Neurodegenerative Diseases: Time for a Comprehensive Critical Review. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 578339.	1.7	51
1536	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
1537	Abeta CSF LC-MS. <i>Neuromethods</i> , 2021, , 55-69.	0.2	0
1538	Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2021, 11, 1978.	1.6	11
1539	Management of Patients with Dementia: An Introduction. , 2021, , 1-18.		1
1540	Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-16.	1.5	90
1541	Head-to-head comparison of amplified plasmonic exosome A $\beta$ 42 platform and single-molecule array immunoassay in a memory clinic cohort. <i>European Journal of Neurology</i> , 2021, 28, 1479-1489.	1.7	11
1542	A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants. <i>Frontiers in Neurology</i> , 2020, 11, 571657.	1.1	11
1543	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12131.	1.2	19
1544	Lumbar Puncture: Consensus Guidelines. <i>Neuromethods</i> , 2021, , 129-135.	0.2	0
1545	Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12179.	1.2	35
1546	Plasma contact factors as novel biomarkers for diagnosing Alzheimer's disease. <i>Biomarker Research</i> , 2021, 9, 5.	2.8	11

#	ARTICLE	IF	CITATIONS
1547	Comprehensive review on design perspective of PET ligands based on $\beta$ -amyloids, tau and neuroinflammation for diagnostic intervention of Alzheimer's disease. <i>Clinical and Translational Imaging</i> , 2021, 9, 153-175.	1.1	3
1548	Preliminary analysis of a shortened picture version of the Free and Cued Selective Reminding Test. <i>Neurologia (English Edition)</i> , 2021, 37, 192-198.	0.2	1
1549	Moving fluid biomarkers for Alzheimer's disease from research tools to routine clinical diagnostics. <i>Molecular Neurodegeneration</i> , 2021, 16, 10.	4.4	101
1550	Plasma and cerebrospinal fluid A $\beta$ 42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. <i>The Cochrane Library</i> , 2021, 2021, CD010945.	1.5	15
1551	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	3.3	33
1552	Clinical validity of increased cortical uptake of [ $^{18}$ F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2097-2109.	3.3	34
1553	TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 638922.	1.7	7
1554	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. <i>Brain Sciences</i> , 2021, 11, 215.	1.1	58
1555	Multimodal deep learning models for early detection of Alzheimer's disease stage. <i>Scientific Reports</i> , 2021, 11, 3254.	1.6	243
1556	Comparison of 6-[ $^{18}$ F]FDOPA PET with Nigrosome 1 detection in patients with parkinsonism. <i>EJNMMI Research</i> , 2021, 11, 16.	1.1	3
1557	Altered Regional Cerebral Blood Flow and Brain Function Across the Alzheimer's Disease Spectrum: A Potential Biomarker. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 630382.	1.7	18
1558	MicroRNAs as Candidate Biomarkers for Alzheimer's Disease. <i>Non-coding RNA</i> , 2021, 7, 8.	1.3	10
1559	[ $^{18}$ F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer's disease. <i>European Journal of Neurology</i> , 2021, 28, 1511-1519.	1.7	8
1560	Sequence of clinical and neurodegeneration events in Parkinson's disease progression. <i>Brain</i> , 2021, 144, 975-988.	3.7	49
1561	Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment. <i>PLoS ONE</i> , 2021, 16, e0244180.	1.1	98
1562	Correlation of Frontal Atrophy and CSF Tau Levels With Neuropsychiatric Symptoms in Patients With Cognitive Impairment: A Memory Clinic Experience. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 595758.	1.7	10
1563	New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease. <i>Cerebral Cortex</i> , 2021, 31, 3363-3373.	1.6	4
1564	The Free and Cued Selective Reminding Test Predicts Braak Stage. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 175-183.	1.2	6

#	ARTICLE	IF	CITATIONS
1565	Following H.N. over 21 years: recency change and reduced retention predict later impairment in memory, and recency ratio may combine both effects. <i>Neurocase</i> , 2021, 27, 147-154.	0.2	4
1566	Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer's disease and cognitively unimpaired individuals. <i>Translational Neurodegeneration</i> , 2021, 10, 11.	3.6	17
1567	Evaluating cognitive profiles of patients undergoing clinical amyloid-PET imaging. <i>Brain Communications</i> , 2021, 3, fcab035.	1.5	5
1568	Neuroimaging Research on Dementia in Brazil in the Last Decade: Scientometric Analysis, Challenges, and Peculiarities. <i>Frontiers in Neurology</i> , 2021, 12, 640525.	1.1	4
1569	Comparison of the clinical impact of 2-[18F]FDG-PET and cerebrospinal fluid biomarkers in patients suspected of Alzheimer's disease. <i>PLoS ONE</i> , 2021, 16, e0248413.	1.1	5
1570	A Young Missionary with Problems Quoting the Bible. , 2021, , 1-5.		0
1572	The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 627931.	1.6	12
1573	A Comparison of Two Statistical Mapping Tools for Automated Brain FDG-PET Analysis in Predicting Conversion to Alzheimer's Disease in Subjects with Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2021, 17, 1186-1194.	0.7	4
1574	Sensitivity and specificity of the Bamberg Dementia Screening Test's (BDST) full and short versions: brief screening instruments for geriatric patients that are suitable for infectious environments. <i>BMC Medicine</i> , 2021, 19, 65.	2.3	5
1575	±-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 885-893.	1.2	9
1576	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2121-2139.	3.3	43
1577	Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 735-747.	1.2	1
1578	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2140-2156.	3.3	83
1579	Emotion Recognition Deficits in the Differential Diagnosis of Amnesic Mild Cognitive Impairment: A Cognitive Marker for the Limbic-Predominant Phenotype. <i>Journal of the International Neuropsychological Society</i> , 2021, , 1-7.	1.2	2
1580	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2086-2096.	3.3	11
1581	Comprehensive Visual Rating Scale on Magnetic Resonance Imaging: Application to Prodromal Alzheimer Disease. <i>Annals of Geriatric Medicine and Research</i> , 2021, 25, 39-44.	0.7	1
1582	Advances in computerized MRI-based biomarkers in Alzheimer's disease. <i>Brain Science Advances</i> , 2021, 7, 26-43.	0.3	6
1583	Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI) Tj ETQq1 1,0,784314,rgBT /Ove	2.7	77

#	ARTICLE	IF	CITATIONS
1584	Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. <i>Current Alzheimer Research</i> , 2021, 17, 1214-1220.	0.7	9
1586	New insights into atypical Alzheimer's disease in the era of biomarkers. <i>Lancet Neurology</i> , The, 2021, 20, 222-234.	4.9	214
1587	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 64.	3.0	6
1588	Blinded Clinical Evaluation for Dementia of Alzheimer's Type Classification Using FDG-PET: A Comparison Between Feature-Engineered and Non-Feature-Engineered Machine Learning Methods. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 715-726.	1.2	11
1589	Classification accuracy of TMS for the diagnosis of mild cognitive impairment. <i>Brain Stimulation</i> , 2021, 14, 241-249.	0.7	35
1590	Value-Generating Exploratory Trials in Neurodegenerative Dementias. <i>Neurology</i> , 2021, 96, 944-954.	1.5	14
1591	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2070-2085.	3.3	22
1592	Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. <i>Frontiers in Neurology</i> , 2021, 12, 653267.	1.1	35
1593	Finding our way through the labyrinth of dementia biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2320-2324.	3.3	5
1594	Simultaneous Detection of Six Isoforms of Tau Protein in Human Cerebrospinal Fluid by Multidimensional Mass Spectrometry-Based Targeted Proteomics. <i>Journal of Proteome Research</i> , 2021, 20, 2299-2307.	1.8	7
1595	The MCP-1 A-2518G polymorphism increases the risk of Alzheimer's disease: A case-control study. <i>Neuroscience Letters</i> , 2021, 749, 135710.	1.0	5
1597	Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 75.	3.0	24
1598	Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. <i>Alzheimer's and Dementia</i> , 2021, 17, 1879-1891.	0.4	5
1599	Analysis of C9orf72 Intermediate Alleles in a Retrospective Cohort of Neurological Patients: Risk Factors for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1445-1451.	1.2	6
1600	A method for diagnosis support of mild cognitive impairment through EEG rhythms source location during working memory tasks. <i>Biomedical Signal Processing and Control</i> , 2021, 66, 102499.	3.5	3
1601	Diagnosis of Alzheimer's Disease by Time-Dependent Power Spectrum Descriptors and Convolutional Neural Network Using EEG Signal. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-17.	0.7	24
1602	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. <i>Neurobiology of Disease</i> , 2021, 151, 105247.	2.1	3
1603	SORL1 mutations are associated with parkinsonian and psychiatric features in Alzheimer disease. <i>Medicine (United States)</i> , 2021, 100, e25585.	0.4	1

#	ARTICLE	IF	CITATIONS
1605	Serum Levels of Clusterin, PKR, and RAGE Correlate with Amyloid Burden in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1067-1077.	1.2	7
1606	Novel noninvasive biomarkers of prodromal Alzheimer disease: The role of optical coherence tomography and optical coherence tomography-angiography. <i>European Journal of Neurology</i> , 2021, 28, 2185-2191.	1.7	11
1607	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 872-880.	0.9	17
1608	Characterization of the initial complaint and care pathways prior to diagnosis in very young sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 90.	3.0	2
1609	Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 203-209.	0.3	5
1610	Cerebral Microbleeds, Cerebrospinal Fluid, and Neuroimaging Markers in Clinical Subtypes of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 543866.	1.1	7
1611	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021, 17, 1528-1553.	0.4	64
1612	Vestibular Function in Older Adults With Cognitive Impairment: A Systematic Review. <i>Ear and Hearing</i> , 2021, 42, 1119-1126.	1.0	11
1613	Biomarqueurs du liquide c��brospinal. <i>Pratique Neurologique - FMC</i> , 2021, 12, 165-179.	0.1	1
1614	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 19-32.	1.2	3
1615	Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 263-272.	1.2	6
1616	Genetic Counselling Improves the Molecular Characterisation of Dementing Disorders. <i>Journal of Personalized Medicine</i> , 2021, 11, 474.	1.1	2
1617	TMA-93 Validation by Alzheimer's Disease Biomarkers: A Comparison with the Free and Cued Selective Reminding Test on a Biobank Sample. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 401-410.	1.2	4
1618	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
1619	Cerebrospinal Fluid C18 Ceramide Associates with Markers of Alzheimer's Disease and Inflammation at the Pre- and Early Stages of Dementia. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 231-244.	1.2	19
1620	Tau-Targeted Multifunctional Nanoinhibitor for Alzheimer's Disease. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 23328-23338.	4.0	24
1621	Alzheimer's disease diagnosis method based on convolutional neural network using key slices voting. , 2021, , .		2
1622	History in perspective: How Alzheimer's Disease came to be where it is?. <i>Brain Research</i> , 2021, 1758, 147342.	1.1	8



#	ARTICLE	IF	CITATIONS
1623	Functional connectivity differences in Alzheimer's disease and amnesic mild cognitive impairment associated with AT(N) classification and anosognosia. <i>Neurobiology of Aging</i> , 2021, 101, 22-39.	1.5	15
1624	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.4	5
1625	Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 1407-1414.	1.7	17
1626	Binding characteristics of [ <sup>18</sup> F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2957-2972.	2.4	30
1627	Genetic predisposition, A $\beta$ misfolding in blood plasma, and Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 261.	2.4	4
1629	Astrocyte Biomarkers in Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	70
1630	A blood-based diagnostic test incorporating plasma A $\beta$ <sub>42/40</sub> ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. <i>Molecular Neurodegeneration</i> , 2021, 16, 30.	4.4	98
1631	Old age genetically confirmed frontotemporal lobar degeneration with TDP $\epsilon$ 43 has limbic predominant TDP $\epsilon$ 43 deposition. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1050-1059.	1.8	10
1632	The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2021, 128, 589-613.	1.4	14
1633	State of the art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177.	0.4	33
1634	Degenerative dementias: a question of syndrome or disease?. <i>Neurologia (English Edition)</i> , 2021, , .	0.2	0
1635	The effect and pharmacology of Yizhi Sheng Hui decoction on Alzheimer's disease. <i>Annals of Palliative Medicine</i> , 2021, 10, 45-45.	0.5	0
1636	VEGF counteracts amyloid- $\beta$ -induced synaptic dysfunction. <i>Cell Reports</i> , 2021, 35, 109121.	2.9	19
1637	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 241-252.	2.5	30
1638	Re-emphasizing early Alzheimer's disease pathology starting in select entorhinal neurons, with a special focus on mitophagy. <i>Ageing Research Reviews</i> , 2021, 67, 101307.	5.0	62
1639	IRM encéphalique: quelle place dans le bilan des maladies neurologiques à expression cognitive?. <i>Pratique Neurologique - FMC</i> , 2021, 12, 158-164.	0.1	0
1640	Language Network Connectivity Increases in Early Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 447-460.	1.2	20
1641	Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. <i>Current Neuropharmacology</i> , 2022, 20, 713-737.	1.4	8

#	ARTICLE	IF	CITATIONS
1642	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 624330.	1.7	39
1643	Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 949-962.	1.2	4
1644	A longitudinal observation of brain structure between AD and FTL. <i>Clinical Neurology and Neurosurgery</i> , 2021, 205, 106604.	0.6	5
1645	Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers. <i>Acta Neuropathologica</i> , 2021, 142, 259-278.	3.9	8
1646	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. <i>Lancet Neurology</i> , The, 2021, 20, 484-496.	4.9	396
1647	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
1648	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	1.2	59
1649	Biological diagnosis of Alzheimer's disease and the issue of stigma. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 195-207.	0.2	1
1651	Norms for Automatic Estimation of Hippocampal Atrophy and a Step Forward for Applicability to the Italian Population. <i>Frontiers in Neuroscience</i> , 2021, 15, 656808.	1.4	4
1652	Multi-cohort profiling reveals elevated CSF levels of brain-enriched proteins in Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1456-1470.	1.7	19
1653	±-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?. <i>Biomolecules</i> , 2021, 11, 931.	1.8	14
1655	Role of a Heat Shock Transcription Factor and the Major Heat Shock Protein Hsp70 in Memory Formation and Neuroprotection. <i>Cells</i> , 2021, 10, 1638.	1.8	27
1656	Repurposing bromocriptine for A $\beta$ metabolism in Alzheimer's disease (REBRAND) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations. <i>BMJ Open</i> , 2021, 11, e051343.	0.8	9
1657	Amyloid PET in the diagnostic workup of neurodegenerative disease. <i>Clinical and Translational Imaging</i> , 2021, 9, 383-397.	1.1	1
1658	New Frontiers in the Prevention, Diagnosis, and Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S51-S63.	1.2	42
1659	Copper Imbalance in Alzheimer's Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants. <i>Biomolecules</i> , 2021, 11, 960.	1.8	33
1660	Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 356.	2.4	34
1661	The changing definition of Alzheimer's disease. <i>Lancet Neurology</i> , The, 2021, 20, 414-415.	4.9	7

#	ARTICLE	IF	CITATIONS
1662	Diagnostic Value of the CSF $\beta$ -Synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , 2021, 97, e930-e940.	1.5	51
1663	Cognitively unimpaired individuals with a low burden of $A\beta$ pathology have a distinct CSF biomarker profile. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 134.	3.0	8
1665	Decreased Glucose Metabolism and Glutamine Synthesis in the Retina of a Transgenic Mouse Model of Alzheimer's Disease. <i>Cellular and Molecular Neurobiology</i> , 2021, , 1.	1.7	4
1666	Coupling relationship between glucose and oxygen metabolisms to differentiate preclinical Alzheimer's disease and normal individuals. <i>Human Brain Mapping</i> , 2021, 42, 5051-5062.	1.9	13
1667	Application of Near-Infrared Spectroscopy for Evidence-Based Psychotherapy. <i>Frontiers in Psychology</i> , 2021, 12, 527335.	1.1	3
1668	The approval of a disease-modifying treatment for Alzheimer's disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036.	3.3	6
1669	Artificial intelligence in neurodegenerative diseases: A review of available tools with a focus on machine learning techniques. <i>Artificial Intelligence in Medicine</i> , 2021, 117, 102081.	3.8	53
1670	The complexity of Alzheimer's disease: an evolving puzzle. <i>Physiological Reviews</i> , 2021, 101, 1047-1081.	13.1	110
1671	Novel Insight in Idiopathic Normal Pressure Hydrocephalus (iNPH) Biomarker Discovery in CSF. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8034.	1.8	10
1672	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. <i>Neurobiology of Aging</i> , 2021, 103, 78-97.	1.5	9
1673	Amyloid- $\beta$ : A double agent in Alzheimer's disease?. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111575.	2.5	32
1674	White matter hyperintensity topography in Alzheimer's disease and links to cognition. <i>Alzheimer's and Dementia</i> , 2022, 18, 422-433.	0.4	59
1675	Soluble APP- $\beta$ and APP- $\beta$ in cerebrospinal fluid as potential biomarkers for differential diagnosis of mild cognitive impairment. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 341-347.	1.4	2
1676	ECOCAPTURE@HOME: Protocol for the Remote Assessment of Apathy and Its Everyday-Life Consequences. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7824.	1.2	2
1677	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
1678	The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer's Disease: A Review Study. <i>Life</i> , 2021, 11, 712.	1.1	9
1679	Robust EEG Based Biomarkers to Detect Alzheimer's Disease. <i>Brain Sciences</i> , 2021, 11, 1026.	1.1	11
1680	Repetitive Transcranial Magnetic Stimulation of the Dorsolateral Prefrontal Cortex Modulates Electroencephalographic Functional Connectivity in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 679585.	1.7	7

#	ARTICLE	IF	CITATIONS
1681	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	4.9	144
1682	Complexity of EEG Dynamics for Early Diagnosis of Alzheimer's Disease Using Permutation Entropy Neuromarker. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 206, 106116.	2.6	37
1683	Diagnostic Validity of the Smart Aging Serious Game: An Innovative Tool for Digital Phenotyping of Mild Neurocognitive Disorder. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1789-1801.	1.2	5
1684	The Utility of Next-Generation Sequencing for Identifying the Genetic Basis of Dementia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8520.	1.2	1
1686	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
1687	Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer's and other neurodegenerative diseases. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 949-967.	1.4	4
1688	White matter hyperintensities segmentation using the ensemble U-Net with multi-scale highlighting foregrounds. <i>NeuroImage</i> , 2021, 237, 118140.	2.1	18
1689	Association between handgrip strength and cognition in a Chinese population with Alzheimer's disease and mild cognitive impairment. <i>BMC Geriatrics</i> , 2021, 21, 459.	1.1	15
1691	Differences in Multimodal Electroencephalogram and Clinical Correlations Between Early-Onset Alzheimer's Disease and Frontotemporal Dementia. <i>Frontiers in Neuroscience</i> , 2021, 15, 687053.	1.4	8
1692	Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer's disease. <i>Metabolic Brain Disease</i> , 2022, 37, 39-50.	1.4	37
1693	Use of Hormone Therapy in Postmenopausal Women with Alzheimer's Disease: A Systematic Review. <i>Drugs and Aging</i> , 2021, 38, 769-791.	1.3	10
1694	Supporting behaviour change in younger-onset dementia: mapping the needs of family carers in the community. <i>Aging and Mental Health</i> , 2022, 26, 2252-2261.	1.5	8
1696	The Role of Age on Beta-Amyloid <sup>42</sup> Plasma Levels in Healthy Subjects. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 698571.	1.7	8
1697	A <sup>β</sup> 2 misfolding in blood plasma is inversely associated with body mass index even in middle adulthood. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 145.	3.0	3
1698	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
1699	The Amyloid- <sup>β</sup> 2 Pathway in Alzheimer's Disease. <i>Molecular Psychiatry</i> , 2021, 26, 5481-5503.	4.1	478
1700	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 68-74.	0.9	39
1701	Diagnosi clinicolaboratoristica della malattia di Alzheimer. <i>EMC - Neurologia</i> , 2021, 21, 1-15.	0.0	0

#	ARTICLE	IF	CITATIONS
1704	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	4.9	29
1705	Objective Assessment of Hyposmia in Alzheimer's Disease From Image and Behavior by Combining Pleasant Odor With Unpleasant Odor. <i>Frontiers in Neurology</i> , 2021, 12, 697487.	1.1	2
1706	A multimodal, longitudinal study of cognitive heterogeneity in early-onset Alzheimer's disease. <i>European Journal of Neurology</i> , 2021, 28, 3990-3998.	1.7	3
1707	Improved automated synthesis of [18F]FINH-Me via direct radio-fluorination and quality control for A $\beta$ -amyloid imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 65, 276-281.	0.4	1
1708	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 623-639.	1.2	7
1709	Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 741-751.	1.2	2
1710	Laughter as a paradigm of socio-emotional signal processing in dementia. <i>Cortex</i> , 2021, 142, 186-203.	1.1	3
1711	Epigenetic treatment of behavioral and physiological deficits in a tauopathy mouse model. <i>Aging Cell</i> , 2021, 20, e13456.	3.0	15
1712	Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1313-1323.	1.2	5
1713	Levels of Receptor for Advanced Glycation End Products and Glyoxalase-1 in the Total Circulating Extracellular Vesicles from Mild Cognitive Impairment and Different Stages of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 227-237.	1.2	5
1714	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. <i>Brain Sciences</i> , 2021, 11, 1258.	1.1	3
1715	Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnesic syndrome of the hippocampal type. <i>Translational Psychiatry</i> , 2021, 11, 498.	2.4	8
1716	A machine learning approach to screen for preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 105, 205-216.	1.5	18
1718	Concordance of Intrinsic Brain Connectivity Measures Is Disrupted in Alzheimer's Disease. <i>Brain Connectivity</i> , 2021, , .	0.8	2
1719	Estimation of Discrete Survival Function through Modeling Diagnostic Accuracy for Mismeasured Outcome Data. <i>Statistics in Biosciences</i> , 2022, 14, 105-138.	0.6	0
1720	Changes in the language system as amyloid- $\beta$ accumulates. <i>Brain</i> , 2021, 144, 3756-3768.	3.7	9
1721	A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1367-1377.	1.2	0
1722	Handwriting graphical parameters analysis in Posterior Cortical Atrophy: A case report. <i>Clinical Neurology and Neurosurgery</i> , 2021, 208, 106876.	0.6	1

#	ARTICLE	IF	CITATIONS
1723	Case Report: Usefulness of Biomarkers for Alzheimer's Disease in Two Cases With Very-Late-Onset Schizophrenia-Like Psychosis. <i>Frontiers in Psychiatry</i> , 2021, 12, 742659.	1.3	4
1725	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. <i>Clinical Neurophysiology</i> , 2021, 132, 2568-2607.	0.7	85
1726	Evaluation of aquaporins in the cerebrospinal fluid in patients with idiopathic normal pressure hydrocephalus. <i>PLoS ONE</i> , 2021, 16, e0258165.	1.1	4
1727	Association of plasma A $\beta$ <sup>240</sup> /A $\beta$ <sup>242</sup> ratio and brain A $\beta$ <sup>2</sup> accumulation: testing a whole-brain PLS-VIP approach in individuals at risk of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 107, 57-69.	1.5	5
1728	Small nucleolar RNAs in plasma extracellular vesicles and their discriminatory power as diagnostic biomarkers of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2021, 159, 105481.	2.1	17
1729	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , 2021, 108, 99-109.	1.5	13
1730	Resting-state functional magnetic resonance imaging in a randomized clinical trial for Alzheimer's disease. <i>NeuroImage Reports</i> , 2021, 1, 100055.	0.5	1
1731	Circulating extracellular vesicles: friends and foes in neurodegeneration. <i>Neural Regeneration Research</i> , 2022, 17, 534.	1.6	20
1732	Using Virtual Reality for Assessment and Rehabilitation of AD and MCI Patients. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2022, , 217-241.	0.3	0
1733	Impact of APOE $\epsilon$ 4 genotype on initial cognitive symptoms differs for Alzheimer's $\tau$ and Lewy body neuropathology. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 31.	3.0	10
1734	Multifunctional peptide-assembled micelles for simultaneously reducing amyloid- $\beta$ and reactive oxygen species. <i>Chemical Science</i> , 2021, 12, 6449-6457.	3.7	15
1735	<i>Neurological Disease</i> . , 2021, , 717-749.		0
1736	Identification of Cathepsin D as a Plasma Biomarker for Alzheimer's Disease. <i>Cells</i> , 2021, 10, 138.	1.8	16
1737	Preliminary Validation of the Triana Test: A New Story Recall Test Based on Emotional Material. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752110259.	0.9	1
1738	Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model. <i>Scientific Reports</i> , 2021, 11, 2275.	1.6	21
1739	Cerebrospinal Fluid $\alpha$ -Synuclein Species in Cognitive and Movements Disorders. <i>Brain Sciences</i> , 2021, 11, 119.	1.1	14
1740	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
1741	Disclosure of Diagnosis in MCI and Dementia. , 2021, , 57-72.		1

#	ARTICLE	IF	CITATIONS
1742	The contribution of mamillary body damage to Wernicke's encephalopathy and Korsakoff's syndrome. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2021, 180, 455-475.	1.0	13
1743	Matching Clinical Diagnosis and Amyloid Biomarkers in Alzheimer's Disease and Frontotemporal Dementia. Journal of Personalized Medicine, 2021, 11, 47.	1.1	9
1744	Alzheimer's disease: neuropathology, neuropsychological differential diagnosis, and treatment. , 2021, , 57-128.		0
1745	Brain Resources: How Semantic Cueing Works in Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD). Diagnostics, 2021, 11, 108.	1.3	3
1746	Deep brain stimulation in Alzheimer's disease. International Review of Neurobiology, 2021, 159, 69-87.	0.9	5
1747	Decoding expectation and surprise in dementia: the paradigm of music. Brain Communications, 2021, 3, fcab173.	1.5	8
1748	Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Frontiers in Neurology, 2020, 11, 592302.	1.1	23
1749	Quantification of the Trans-Synaptic Partners Neuroligin-Neurexin in CSF of Neurodegenerative Diseases by Parallel Reaction Monitoring Mass Spectrometry. SSRN Electronic Journal, 0, , .	0.4	0
1750	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. Translational Psychiatry, 2021, 11, 27.	2.4	207
1752	Changes in the use of psychotropic drugs during the course of Alzheimer's disease: A large-scale longitudinal study of French medical records. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12210.	1.8	0
1753	Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment. The Cochrane Library, 2019, 2019, CD011905.	1.5	78
1754	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12062.	1.2	12
1755	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20
1756	Epidemiology and Risk Factors of Alzheimer's Disease: A Focus on Diet. Neuromethods, 2018, , 15-42.	0.2	7
1757	Amyloid PET Imaging: Standardization and Integration with Other Alzheimer's Disease Biomarkers. Methods in Molecular Biology, 2018, 1750, 203-212.	0.4	8
1758	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. Methods in Molecular Biology, 2018, 1750, 231-251.	0.4	18
1759	Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials. Methods in Molecular Biology, 2018, 1750, 31-66.	0.4	36
1760	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. Methods in Molecular Biology, 2018, 1750, 139-155.	0.4	12

#	ARTICLE	IF	CITATIONS
1761	Assessment of Competence in Older Adults. Handbooks in Health, Work, and Disability, 2018, , 433-459.	0.0	1
1762	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
1765	Demenz, Wahn und bloÄyes Altsein: Regeln und Besonderheiten der Schuldfähigkeitsbegutachtung Älterer StraftÄter. , 2015, , 167-192.		2
1766	Demenz. , 2017, , 1377-1465.		1
1767	Neurodegenerative Diseases: Alzheimer Disease (AD). , 2019, , 897-931.		2
1768	Diagnostics and Treatments of Iron-Related CNS Diseases. Advances in Experimental Medicine and Biology, 2019, 1173, 179-194.	0.8	9
1769	Therapy for Insomnia and Circadian Rhythm Disorder in Alzheimer Disease. Current Treatment Options in Neurology, 2020, 22, 4.	0.7	23
1770	Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 131-138.	1.2	93
1772	ACR Appropriateness Criteria® Dementia. Journal of the American College of Radiology, 2020, 17, S100-S112.	0.9	11
1773	Artificial intelligence and neuropsychological measures: The case of Alzheimerâ€™s disease. Neuroscience and Biobehavioral Reviews, 2020, 114, 211-228.	2.9	51
1774	Differential effects of cognition-focused interventions for people with Alzheimerâ€™s disease: A meta-analysis.. Neuropsychology, 2018, 32, 664-679.	1.0	14
1775	Mental-orientation: A new approach to assessing patients across the Alzheimerâ€™s disease spectrum.. Neuropsychology, 2018, 32, 690-699.	1.0	13
1776	Performance on neuropsychological assessment and progression to dementia: A meta-analysis.. Psychology and Aging, 2019, 34, 954-977.	1.4	22
1777	Bridging Integrator 1 (BIN1) Genotype Effects on Working Memory, Hippocampal Volume, and Functional Connectivity in Young Healthy Individuals. , 0, .		1
1778	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
1779	Profiles in paint: contrasting responses to a common artistic exercise by people with different dementias. Arts and Health, 2019, 11, 79-86.	0.6	9
1780	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	3.7	89
1781	OUP accepted manuscript. Brain, 2021, 144, 434-449.	3.7	54



#	ARTICLE	IF	CITATIONS
1782	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
1783	Modeling Alzheimer Disease Through Functional Independence and Participation. <i>Alzheimer Disease and Associated Disorders</i> , 2017, 31, 218-224.	0.6	6
1791	European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment. <i>European Journal of Neurology</i> , 2021, 28, 2147-2155.	1.7	20
1792	Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias. <i>Functional Neurology</i> , 2016, 31, 205-215.	1.3	35
1793	Biparietal variant of Alzheimer's disease: a rare presentation of a common disease. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014207011-bcr2014207011.	0.2	4
1794	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 349-356.	0.9	31
1795	Pathobiological Subtypes of Alzheimer Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 321-333.	0.7	33
1796	Amyloid- $\beta$ misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 169.	3.0	31
1797	Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 615-618.	0.4	5
1798	Mild Cognitive Impairment. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 404-418.	0.4	377
1799	Posterior Cortical Atrophy. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 52-75.	0.4	24
1800	Late-onset Alzheimer Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 14-33.	0.4	70
1801	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e671-e683.	1.5	84
1802	Fine-mapping of the human leukocyte antigen locus as a risk factor for Alzheimer disease: A case-control study. <i>PLoS Medicine</i> , 2017, 14, e1002272.	3.9	67
1803	Prefrontal Lobe Brain Reserve Capacity with Resistance to Higher Global Amyloid Load and White Matter Hyperintensity Burden in Mild Stage Alzheimer's Disease. <i>PLoS ONE</i> , 2016, 11, e0149056.	1.1	8
1804	High prevalence of cognitive impairment after intracerebral hemorrhage. <i>PLoS ONE</i> , 2017, 12, e0178886.	1.1	28
1805	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2014, 1, 1-22.	1.5	48
1806	ENDPOINTS FOR PRE-DEMENTIA AD TRIALS: A REPORT FROM THE EU/US/CTAD TASK FORCE. <i>Journal of prevention of Alzheimer's disease</i> , The, 2015, 2, 1-8.	1.5	35

#	ARTICLE	IF	CITATIONS
1807	ETHICAL ISSUES IN THE DEVELOPMENT OF READINESS COHORTS IN ALZHEIMER'S DISEASE RESEARCH. <i>Journal of prevention of Alzheimer's disease, The</i> , 2017, 4, 1-7.	1.5	17
1808	ALZHEIMER'S DISEASE COMPOSITE SCORE: A POST-HOC ANALYSIS USING DATA FROM THE LIPIDIET TRIAL IN PRODROMAL ALZHEIMER'S DISEASE. <i>Journal of prevention of Alzheimer's disease, The</i> , 2019, 6, 1-5.	1.5	10
1809	Overtreating Alzheimer's Disease. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-3.	1.5	4
1810	Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer's Disease. , 2019, 10, 1075.		9
1811	Biomarkers in Alzheimer's disease. <i>Advances in Laboratory Medicine / Avances En Medicina De Laboratorio</i> , 2021, 2, 27-37.	0.1	13
1812	Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. <i>ENeuro</i> , 2019, 6, ENEURO.0439-18.2019.	0.9	9
1813	Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. <i>Molecular Systems Biology</i> , 2020, 16, e9356.	3.2	157
1814	Behavioral variant of frontotemporal dementia or frontal variant of Alzheimer's disease? A case study. <i>Dementia E Neuropsychologia</i> , 2019, 13, 356-360.	0.3	10
1815	Biomarkers in Alzheimer's disease: Evaluation of platelets, hemoglobin and vitamin B12. <i>Dementia E Neuropsychologia</i> , 2020, 14, 35-40.	0.3	9
1816	Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what". <i>Dementia E Neuropsychologia</i> , 2020, 14, 237-242.	0.3	13
1818	What makes a good biomarker?. <i>Advances in Precision Medicine</i> , 2016, 1, 66.	0.1	21
1819	STARD1 and NPC1 expression as pathological markers associated with astrogliosis in post-mortem brains from patients with Alzheimer's disease and Down syndrome. <i>Aging</i> , 2020, 12, 571-592.	1.4	13
1820	Mediation of episodic memory performance by the executive function network in patients with amnesic mild cognitive impairment: a resting-state functional MRI study. <i>Oncotarget</i> , 2016, 7, 64711-64725.	0.8	23
1821	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	0.8	51
1822	Careful neuropsychological testing reveals a novel genetic marker, <i>GSTO1*C</i> , linked to the pre-stage of Alzheimer's disease. <i>Oncotarget</i> , 2016, 7, 39108-39117.	0.8	10
1823	Toward precision medicine in neurological diseases. <i>Annals of Translational Medicine</i> , 2016, 4, 104-104.	0.7	27
1824	Hyphenated Mass Spectrometry Techniques in the Diagnosis of Amyloidosis. <i>Current Medicinal Chemistry</i> , 2019, 26, 104-120.	1.2	2
1825	[18F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APP <sup>swe</sup> /PS1 <sup>dE9</sup> . <i>Current Alzheimer Research</i> , 2018, 16, 49-55.	0.7	9

#	ARTICLE	IF	CITATIONS
1826	Connected Speech Deficit as an Early Hallmark of CSF-defined Alzheimer's Disease and Correlation with Cerebral Hypoperfusion Pattern. <i>Current Alzheimer Research</i> , 2019, 16, 483-494.	0.7	14
1827	Biomarkers for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 518-528.	0.7	55
1828	Plasma Clusterin as a Potential Biomarker for Alzheimer's Disease-A Systematic Review and Meta-analysis. <i>Current Alzheimer Research</i> , 2019, 16, 1018-1027.	0.7	5
1829	MRI Radiomics Classification and Prediction in Alzheimer's Disease and Mild Cognitive Impairment: A Review. <i>Current Alzheimer Research</i> , 2020, 17, 297-309.	0.7	45
1830	A Conceptual Framework for Research on Cognitive Impairment with no Dementia in Memory Clinic. <i>Current Alzheimer Research</i> , 2020, 17, 517-525.	0.7	10
1831	Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. <i>Current Neuropharmacology</i> , 2019, 17, 563-579.	1.4	48
1832	MicroRNA Landscape in Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 168-175.	0.8	22
1834	Ongoing Electroencephalographic Rhythms Related to Exploratory Movements in Transgenic TASTPM Mice. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 291-308.	1.2	2
1835	Aberrant Hippocampal Functional Connectivity Is Associated with Fornix White Matter Integrity in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1153-1168.	1.2	14
1836	Improving the Diagnosis of the Frontal Variant of Alzheimer's Disease with the DAPHNE Scale. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1735-1745.	1.2	9
1837	Quality Reporting of Radiomics Analysis in Mild Cognitive Impairment and Alzheimer's Disease: A Roadmap for Moving Forward. <i>Korean Journal of Radiology</i> , 2020, 21, 1345.	1.5	29
1838	Medical Informatics Platform (MIP): A Pilot Study Across Clinical Italian Cohorts. <i>Frontiers in Neurology</i> , 2020, 11, 1021.	1.1	10
1839	Accurate BAPL Score Classification of Brain PET Images Based on Convolutional Neural Networks with a Joint Discriminative Loss Function. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 965.	1.3	7
1840	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 1252.	1.8	8
1841	Role of Body-Fluid Biomarkers in Alzheimer's Disease Diagnosis. <i>Diagnostics</i> , 2020, 10, 326.	1.3	12
1842	Computer-Aided Diagnosis of Alzheimer's Disease through Weak Supervision Deep Learning Framework with Attention Mechanism. <i>Sensors</i> , 2021, 21, 220.	2.1	37
1844	Post-stroke cognitive impairment: epidemiology, mechanisms and management. <i>Annals of Translational Medicine</i> , 2014, 2, 80.	0.7	289
1845	Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnesic MCI. <i>Neurology India</i> , 2019, 67, 1310.	0.2	8

#	ARTICLE	IF	CITATIONS
1846	Blocking beta 2-adrenergic receptor inhibits dendrite ramification in a mouse model of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2017, 12, 1499.	1.6	15
1847	Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer's disease. <i>Neural Regeneration Research</i> , 2019, 14, 2147.	1.6	15
1848	Fully automated discrimination of Alzheimer's disease using resting-state electroencephalography signals. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 1063-1078.	1.1	16
1849	Differentiating comorbidities and predicting prognosis in idiopathic normal pressure hydrocephalus using cerebrospinal fluid biomarkers. <i>Croatian Medical Journal</i> , 2021, 62, 387-398.	0.2	4
1850	Beta Amyloid, Tau Protein, and Neuroinflammation: An Attempt to Integrate Different Hypotheses of Alzheimer's Disease Pathogenesis. <i>Molecular Biology</i> , 2021, 55, 670-682.	0.4	10
1851	Demencia preventív: A korai diagnózis a személyre szabott intervencióig. <i>Scientia Et Securitas</i> , 2021, 2, 207-219.	0.1	0
1852	Decreased Global EEG Synchronization in Amyloid Positive Mild Cognitive Impairment and Alzheimer's Disease Patients' Relationship to APOE ε4. <i>Brain Sciences</i> , 2021, 11, 1359.	1.1	8
1853	Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers. <i>Frontiers in Neurology</i> , 2021, 12, 619388.	1.1	1
1854	Voice processing for COVID-19 scanning and prognostic indicator. <i>Heliyon</i> , 2021, 7, e08134.	1.4	7
1855	The Diagnostic Value of a Short Memory Test: The TNI-93. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-11.	1.2	1
1856	Altered intrinsic default mode network functional connectivity in patients with remitted geriatric depression and amnesic mild cognitive impairment. <i>International Psychogeriatrics</i> , 2022, 34, 703-714.	0.6	6
1857	Disturbance of phylogenetic layer-specific adaptation of human brain gene expression in Alzheimer's disease. <i>Scientific Reports</i> , 2021, 11, 20200.	1.6	1
1858	Global cognitive dysfunction and $\beta$ -amyloid neuropathology in late-life and treatment-resistant major depression. <i>Psychological Medicine</i> , 2022, 52, 4116-4126.	2.7	1
1859	Non-Ceruloplasmin Copper as a Stratification Biomarker of Alzheimer's Disease Patients: How to Measure and Use It. <i>Current Alzheimer Research</i> , 2021, 18, 533-545.	0.7	8
1860	Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- positive vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Current Alzheimer Research</i> , 2021, 18, 523-532.	0.7	6
1861	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 746982.	1.7	12
1862	Meta-analysis of cerebrospinal fluid neuron-specific enolase levels in Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 163.	3.0	12
1863	Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology. <i>Acta Neuropathologica</i> , 2021, 142, 937-950.	3.9	45

#	ARTICLE	IF	CITATIONS
1864	From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. <i>Biomedicines</i> , 2021, 9, 1376.	1.4	3
1865	Short Digital Spatial Memory Test Detects Impairment in Alzheimer's Disease and Mild Cognitive Impairment. <i>Brain Sciences</i> , 2021, 11, 1350.	1.1	6
1866	Adaptation and Validation of the Memory Alteration Test (M@T) in Greek Middle-Aged, Older, and Older-Old Population with Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1-14.	1.2	2
1867	Electroencephalography as a Non-Invasive Biomarker of Alzheimer's Disease: A Forgotten Candidate to Substitute CSF Molecules?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10889.	1.8	11
1868	Resting-state functional reorganisation in Alzheimer's disease and amnesic mild cognitive impairment: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e049798.	0.8	4
1869	Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services"part 4 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 171.	3.0	37
1870	Breakdown of specific functional brain networks in clinical variants of Alzheimer's disease. <i>Ageing Research Reviews</i> , 2021, 72, 101482.	5.0	21
1871	Methods (1): Participants and Test Methods. , 2015, , 19-44.		0
1872	Methods (2): Statistical Methods. , 2015, , 45-71.		1
1876	Atypical Early-Onset Alzheimer's Disease Dementia Diagnosed by Biomarker Study. <i>Dementia and Neurocognitive Disorders</i> , 2015, 14, 168.	0.4	0
1878	Imaging Agent Binding to Amyloid Protofibrils. <i>Springer Theses</i> , 2016, , 43-61.	0.0	0
1879	(Neurobiology of) Dementia: Causes, Presentation and Management. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-20.	0.1	0
1880	Demenz. , 2016, , 1-89.		0
1881	Biomarkers in Mild Stages of Alzheimer's disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. <i>Functional Foods in Health and Disease</i> , 2016, 6, 627.	0.3	0
1882	Cerebrospinal fluid in Alzheimer's: A precious tool. <i>Oncotarget</i> , 2017, 8, 3770-3770.	0.8	0
1883	Atypical Alzheimer's Disease, Mixed Dementia, and Amyloid Angiopathy. , 2017, , 39-47.		0
1884	(Neurobiology of) Dementia: Causes, Presentation, and Management. <i>Mental Health and Illness Worldwide</i> , 2017, , 85-104.	0.1	0
1885	Glemsk og glemmt. <i>Tidsskrift for Den Norske Lægeforening</i> , 2017, 137, 339-339.	0.2	1

#	ARTICLE	IF	CITATIONS
1886	The Dementia Experience: Sociological Observations on the Construction of Cognition in Care Homes. , 2017, , 73-104.		0
1887	Clinical Features, Diagnostic Criteria, and Possible Variants of TGA. , 2017, , 9-25.		0
1889	E-Infrastructures for Neuroscientists: The GAAIN and neuGRID Examples. Springer INdAM Series, 2017, , 161-176.	0.4	0
1890	Proteomic Approaches for Diagnostics of Canine and Feline Dementia. , 2017, , 113-127.		0
1892	Editorial. Functional Neurology, 2017, 37, 117.	1.3	0
1894	Clinical efficacy of oral Souvenaid® as a non-pharmacological support in Alzheimer's disease – a review. Aktualnosci Neurologiczne, 2017, 17, 115-120.	0.1	1
1896	Assessing robustness of hazard ratio estimates to outcome misclassification in longitudinal panel studies with application to Alzheimer's disease. PLoS ONE, 2017, 12, e0190107.	1.1	2
1899	Biomarqueurs du liquide cÃ©rÃ©brospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
1900	Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer's Disease. , 2018, , .		0
1901	Brain Morphometry: Alzheimer's Disease. Neuromethods, 2018, , 217-240.	0.2	1
1902	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. Neuromethods, 2018, , 235-248.	0.2	0
1903	Longitudinal Follow-Up of a Population with MCI: Predictive Value of the MIS Test with Delayed Recall for Progression to Dementia. Advances in Alzheimer's Disease, 2018, 07, 183-196.	0.3	0
1904	Que penser de l'approche mÃ©dicamenteuse prÃ©ventive de la maladie d'Alzheimer ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 679-690.	0.0	0
1905	Alzheimerio ligos gydymo metodÅ³ paieÅ¼ka: klinikiniÅ³ tyrimÅ³ kryptys. Neurologijos Seminarai, 2018, 22, 21-30.	0.0	0
1908	Imagerie mÃ©tabolique et molÃ©culaire : l'exemple des maladies neurodÃ©gÃ©nÃ©ratives. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1511-1521.	0.0	0
1909	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: Comparing Different Approaches. Biosystems and Biorobotics, 2019, , 977-981.	0.2	1
1910	Posterior Cortical Atrophy. , 2019, , 223-237.		0
1912	Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. Journal of Psychiatry and Brain Science, 2019, 4, .	0.3	3

#	ARTICLE	IF	CITATIONS
1913	Methods (2): Statistical Methods. , 2019, , 51-93.		0
1914	Methods (1): Participants and Test Methods. , 2019, , 21-49.		0
1916	Emerging topics and practical aspects for an appropriate use of amyloid PET in the current Italian context. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 83-92.	0.4	0
1917	A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. Journal of the Korean Neurological Association, 2019, 37, 1-7.	0.0	2
1920	Genome-wide association study identifies <i>CBFA2T3</i> affecting the rate of CSF A $\beta$ 242 decline in non-demented elders. Aging, 2019, 11, 5433-5444.	1.4	5
1925	Mild Cognitive Impairment and Early Dementia. , 2020, , 215-236.		0
1928	Intelligent environment for advanced brain imaging: multi-agent system for an automated Alzheimer diagnosis. Evolutionary Intelligence, 2021, 14, 1523-1538.	2.3	2
1931	Biomarcadores en la demencia tipo alzheimer: sistema sanitario y edadismo. International Journal of Developmental and Educational Psychology Revista INFAD De Psicología, 2020, 1, 247-254.	0.0	0
1932	Neocortical Type Alzheimer's Disease : Logopenic Progressive Aphasia and Posterior Cortical Atrophy. Higher Brain Function Research, 2020, 40, 171-180.	0.0	0
1935	Demenzkerkrankungen. , 2020, , 295-321.		0
1936	Diagnostic précoce et biomarqueurs biologiques de la maladie d'Alzheimer. NPG Neurologie - Psychiatrie - Geriatrie, 2020, 20, 120S7-120S10.	0.1	0
1937	PET-Amyloid After Inconclusive Cerebrospinal Fluid Biomarkers in Clinical Practice. Is it Necessary to Duplicate Procedures?. Current Alzheimer Research, 2020, 17, 698-708.	0.7	1
1939	Psychiatric Disorders in Dementia. , 2021, , 317-385.		0
1940	PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. Environmental Pollution, 2022, 292, 118320.	3.7	52
1941	Psychometric Properties of the Clinical Dementia Rating " Sum of Boxes and Other Cognitive and Functional Outcomes in a Prodromal Alzheimer's Disease Population. Journal of Prevention of Alzheimer's Disease, The, 2021, 8, 1-10.	1.5	12
1942	Correlation Between Donepezil and QTc Prolongation and Torsades de Pointes: A Very Rare Phenomenon. Cureus, 2019, 11, e6451.	0.2	7
1943	Informatics and Cognitive Assessment: A RUDAS Scale Paradigm. Advances in Experimental Medicine and Biology, 2020, 1194, 285-291.	0.8	0
1945	Evidence-Based PET for Neurological Diseases. , 2020, , 125-136.		0

#	ARTICLE	IF	CITATIONS
1947	Alzheimer's disease and other dementias. , 2020, , C24.4.2-C24.4.2.P126.		1
1948	Cerebrospinal Fluid Biomarkers for the Diagnosis and Classification of Alzheimer's Disease Spectrum. Journal of Korean Medical Science, 2020, 35, e361.	1.1	13
1949	CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12098.	1.8	5
1950	Progression of symptoms in Parkinson's disease. , 2020, , 3-20.		1
1951	Addenbrooke's Cognitive Examination. , 2020, , 379-393.		1
1954	Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid- $\beta$ Positron Emission Tomography. Journal of Alzheimer's Disease, 2020, 74, 101-112.	1.2	2
1958	Dementia in Aging Migrants. Sustainable Development Goals Series, 2022, , 283-295.	0.2	1
1959	Examining Delayed Recall in Cochlear Implant Users Using the Montreal Cognitive Assessment, California Verbal Learning Test, Third Edition, and Item Specific Deficit Approach: Preliminary Results. Frontiers in Psychology, 2021, 12, 749045.	1.1	0
1960	Symptomatic, Genetic, and Mechanistic Overlaps between Autism and Alzheimer's Disease. Biomolecules, 2021, 11, 1635.	1.8	16
1961	Alzheimer's disease associated with Down syndrome: a genetic form of dementia. Lancet Neurology, The, 2021, 20, 930-942.	4.9	93
1962	Cerebral amyloid load determination in a clinical setting: interpretation of amyloid biomarker discordances aided by tau and neurodegeneration measurements. Neurological Sciences, 2021, , 1.	0.9	0
1963	“Brain Fog” by COVID-19 or Alzheimer's Disease? A Case Report. Frontiers in Psychology, 2021, 12, 7240221		19
1964	Longitudinal Analysis of Brain-Predicted Age in Amnesic and Non-amnesic Sporadic Early-Onset Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 729635.	1.7	7
1965	Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnesic Mild Cognitive Impairment and Alzheimer's Disease. ACS Chemical Neuroscience, 2021, 12, 4257-4264.	1.7	5
1966	Old Age Dementia: Clinical Patterns of Progression. Part 1. Psychiatry, 2020, 18, 108-120.	0.2	1
1968	Neuroimaging Findings in Mild Cognitive Impairment. , 2021, , 367-425.		1
1969	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451.		0
1970	Perfusion SPECT: Its Role in the Diagnosis and Differential Diagnosis of Alzheimer's Disease, with Particular Emphasis on Guidelines. , 2021, , 453-468.		0



#	ARTICLE	IF	CITATIONS
1974	Are the revised diagnostic criteria for Alzheimer's disease useful in low- and middle-income countries?. Shanghai Archives of Psychiatry, 2015, 27, 119-23.	0.7	4
1975	Dementia. Ulster Medical Journal, 2015, 84, 79-87.	0.2	44
1976	The presenilin 1 p.Gly206Ala mutation is a frequent cause of early-onset Alzheimer's disease in Hispanics in Florida. American Journal of Neurodegenerative Disease, 2016, 5, 94-101.	0.1	4
1977	The Clinical and Health Economic Value of Clinical Laboratory Diagnostics. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 47-62.	0.7	7
1978	Diagnostic performance of an automated analysis software for the diagnosis of Alzheimer's dementia with F FDG PET. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 12-23.	1.0	9
1979	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. Innovations in Clinical Neuroscience, 2017, 14, 22-29.	0.1	34
1980	The borderland between normal aging and dementia. , 2017, 29, 65-71.		6
1981	Detection of Alzheimer's Disease. Yale Journal of Biology and Medicine, 2018, 91, 291-300.	0.2	21
1982	Exploring Potential Biomarkers Underlying Pathogenesis of Alzheimer's Disease by Differential Co-expression Analysis. Avicenna Journal of Medical Biotechnology, 2018, 10, 233-241.	0.2	2
1983	Language Breakdown in Primary Progressive Aphasias. Annals of Indian Academy of Neurology, 2020, 23, S67-S72.	0.2	1
1984	Clinical features and brain structural changes in magnetic resonance imaging in Alzheimer's disease patients with apathy. Aging, 2020, 12, 19083-19094.	1.4	1
1985	More Atypical than Atypical Alzheimer's Disease Phenotypes: A Treviso Dementia (TREDem) Registry Case Report. Journal of Alzheimer's Disease Reports, 2021, 5, 365-374.	1.2	1
1986	Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts. NeuroImage: Clinical, 2022, 33, 102900.	1.4	8
1987	Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment. Neuroscience and Behavioral Physiology, 2021, 51, 1033-1039.	0.2	0
1988	Case 2: Alzheimer's Disease [18F]FDG, Tau, and Amyloid PET. , 2022, , 9-13.		1
1989	Cortical Auditory Evoked Potentials in Cognitive Impairment and Their Relevance to Hearing Loss: A Systematic Review Highlighting the Evidence Gap. Frontiers in Neuroscience, 2021, 15, 781322.	1.4	4
1990	Prodromal frontotemporal dementia: clinical features and predictors of progression. Alzheimer's Research and Therapy, 2021, 13, 188.	3.0	8
1991	Amyloid- $\beta$ , p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease. Brain Communications, 2021, 3, fcab281.	1.5	12

#	ARTICLE	IF	CITATIONS
1992	Machine Learning to Predict Brain Amyloid Pathology in Pre-dementia Alzheimer's Disease Using QEEG Features and Genetic Algorithm Heuristic. <i>Frontiers in Computational Neuroscience</i> , 2021, 15, 755499.	1.2	10
1993	Ultrasensitive Detection of Alzheimer's Amyloids on a Plasmonic-Gold Platform. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 57036-57042.	4.0	7
1995	It Is Time to Study Overlapping Molecular and Circuit Pathophysiologies in Alzheimer's and Lewy Body Disease Spectra. <i>Frontiers in Systems Neuroscience</i> , 2021, 15, 777706.	1.2	8
1996	Whole Blood Expression Pattern of Inflammation and Redox Genes in Mild Alzheimer's Disease. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 6085-6102.	1.6	9
1997	Cerebral Hemodynamics and Carotid Atherosclerosis in Patients With Subcortical Ischemic Vascular Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 741881.	1.7	3
1998	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 191.	3.0	21
1999	Association of Superficial White Matter Alterations with Cerebrospinal Fluid Biomarkers and Cognitive Decline in Neurodegenerative Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 431-442.	1.2	2
2000	Disrupted White Matter Integrity and Cognitive Functions in Amyloid- $\beta^2$ Positive Alzheimer's Disease with Concomitant Lobar Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2021, , 1-12.	1.2	3
2001	White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, 111, 54-63.	1.5	22
2002	MicroRNA-Target Interaction Regulatory Network in Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2021, 11, 1275.	1.1	11
2003	Path integration in normal aging and Alzheimer's disease. <i>Trends in Cognitive Sciences</i> , 2022, 26, 142-158.	4.0	21
2004	BARRIERS FOR PREVENTION AND PRODROMAL AD TRIALS. <i>Journal of prevention of Alzheimer's disease</i> , The, 2016, 3, 1-2.	1.5	6
2005	Neuroimaging correlates of Stages of Objective Memory Impairment (SOMI) system. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12224.	1.2	5
2006	A Practical Alzheimer Disease Classifier via Brain Imaging-Based Deep Learning on 85,721 Samples: A Multicentre, Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2008	Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. <i>Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova</i> , 2021, 121, 6.	0.1	31
2009	Combined Structural MR and Diffusion Tensor Imaging Classify the Presence of Alzheimer's Disease With the Same Performance as MR Combined With Amyloid Positron Emission Tomography: A Data Integration Approach. <i>Frontiers in Neuroscience</i> , 2021, 15, 638175.	1.4	5
2010	Quantification of the trans-synaptic partners neurexin-neuroligin in CSF of neurodegenerative diseases by parallel reaction monitoring mass spectrometry. <i>EBioMedicine</i> , 2022, 75, 103793.	2.7	4
2011	Brain FDG PET for Short- to Medium-Term Prediction of Further Cognitive Decline and Need for Assisted Living in Acutely Hospitalized Geriatric Patients With Newly Detected Clinically Uncertain Cognitive Impairment. <i>Clinical Nuclear Medicine</i> , 2022, 47, 123-129.	0.7	2

#	ARTICLE	IF	CITATIONS
2012	An Evaluation of the Studies on the Therapeutic Effects of Yoga in People with Dementia. <i>European Medical Journal Neurology</i> , 0, , 64-66.	0.0	0
2013	Clinical features and brain structural changes in magnetic resonance imaging in Alzheimer&#x2019;s disease patients with apathy. <i>Aging</i> , 2020, 12, 19083-19094.	1.4	4
2014	Cognitive tasks modelization and description in VR environment for Alzheimer&#x2019;s disease state identification. , 2020, , .		2
2016	Psychedelics as Novel Therapeutics in Alzheimer&#x2019;s Disease: Rationale and Potential Mechanisms. <i>Current Topics in Behavioral Neurosciences</i> , 2021, , 287-317.	0.8	11
2018	Executive Dysfunction and the Prefrontal Cortex. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 1586-1601.	0.4	44
2019	Experiences of Participation in a Multimodal Preventive Trial MIND-ADMINI Among Persons with Prodromal Alzheimer&#x2019;s Disease: A Qualitative Study. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 219-234.	1.1	3
2020	Suspected Dementia in Young Adults: Cognitive Screening Tools for Use in Primary Care. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 333-341.	1.2	2
2021	Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
2022	An Argument for Simple Tests of Treatment of Alzheimer&#x2019;s Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-4.	1.2	9
2023	The Outcome of Patients with Amyloid-Negative Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 629-640.	1.2	2
2024	Deep Learning-Based Prediction of Alzheimer&#x2019;s Disease from Magnetic Resonance Images. <i>Studies in Autonomic, Data-driven and Industrial Computing</i> , 2022, , 145-151.	0.4	13
2025	Structural Alteration of Medial Temporal Lobe Subfield in the Amnesic Mild Cognitive Impairment Stage of Alzheimer&#x2019;s Disease. <i>Neural Plasticity</i> , 2022, 2022, 1-11.	1.0	4
2026	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer&#x2019;s disease. <i>Journal of Neurochemistry</i> , 2023, 164, 309-324.	2.1	43
2027	Corticobasal Syndrome as Alzheimer&#x2019;s Disease Subtype: A Case Report. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2023, 29, 220-223.	0.1	0
2028	Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 802501.	1.7	7
2029	Can the entorhinal cortex help distinguish healthy aging brains from pathological aging brains?. <i>Aging Brain</i> , 2022, 2, 100026.	0.7	0
2030	Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2021, 12, 792227.	1.1	17
2031	Plasma Lipocalin 2 in Alzheimer&#x2019;s disease: potential utility in the differential diagnosis and relationship with other biomarkers. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 9.	3.0	2

#	ARTICLE	IF	CITATIONS
2032	The behavioral variant of Alzheimer's disease does not show a selective loss of Von Economo and phylogenetically related neurons in the anterior cingulate cortex. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 11.	3.0	3
2033	Deciphering the Roles of Metformin in Alzheimer's Disease: A Snapshot. <i>Frontiers in Pharmacology</i> , 2021, 12, 728315.	1.6	26
2034	Peripheral reaching in Alzheimer's disease and mild cognitive impairment. <i>Cortex</i> , 2022, 149, 29-43.	1.1	4
2035	Associations Between Oral Health Status, Perceived Stress, and Neuropsychiatric Symptoms Among Community Individuals With Alzheimer's Disease: A Mediation Analysis. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 801209.	1.7	4
2036	Diagnostic Blood Biomarkers in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 169.	1.4	13
2037	Multimodal Preventive Trial for Alzheimer's Disease: MIND-ADmini Pilot Trial Study Design and Progress. <i>Journal of Prevention of Alzheimer's Disease</i> , 2022, 9, 1-10.	1.5	5
2038	Research on Frequent Itemset Mining of Imaging Genetics GWAS in Alzheimer's Disease. <i>Genes</i> , 2022, 13, 176.	1.0	1
2039	Unclassified fluent variants of primary progressive aphasia: distinction from semantic and logopenic variants. <i>Brain Communications</i> , 2022, 4, .	1.5	8
2040	The role of Memory Clinics in the assessment and management of dementia, now and into the future. <i>Current Opinion in Psychiatry</i> , 2022, 35, 118-122.	3.1	4
2041	Multiplexed immunosensors for point-of-care diagnostic applications. <i>Biosensors and Bioelectronics</i> , 2022, 203, 114050.	5.3	69
2042	Unravelling the Association Between Amyloid-PET and Cerebrospinal Fluid Biomarkers in the Alzheimer's Disease Spectrum: Who Really Deserves an A+?. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1009-1020.	1.2	5
2043	Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1143-1151.	1.2	7
2044	The A $\beta$ <sub>1-42</sub> /A $\beta$ <sub>1-40</sub> ratio in CSF is more strongly associated to tau markers and clinical progression than A $\beta$ <sub>1-42</sub> alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
2045	Blood $\beta$ -Synuclein and Neurofilament Light Chain During the Course of Prion Disease. <i>Neurology</i> , 2022, , 10.1212/WNL.000000000200002.	1.5	11
2046	Neuroprotective Effect of HIIT against GFAP Hypertrophy through Mitochondrial Dynamics in APP/PS1 Mice. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-14.	1.9	3
2047	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. <i>Journal of Nuclear Medicine</i> , 2022, 63, 981-985.	2.8	9
2048	Impact of Current Alcohol Consumption on Cognitive Function in Patients with Self-Perceived Memory Decline: A Comparative Study of Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer-Type Dementia Groups. <i>Journal of the Korean Neurological Association</i> , 2022, 40, 29-38.	0.0	0
2049	Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 33.	3.0	9

#	ARTICLE	IF	CITATIONS
2052	Identification of recurrent genetic patterns from targeted sequencing panels with advanced data science: a case-study on sporadic and genetic neurodegenerative diseases. BMC Medical Genomics, 2022, 15, 26.	0.7	4
2053	Early Diagnosis of Alzheimer's Disease Using Cerebral Catheter Angiogram Neuroimaging: A Novel Model Based on Deep Learning Approaches. Big Data and Cognitive Computing, 2022, 6, 2.	2.9	20
2054	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
2055	Subtyping of mild cognitive impairment using a deep learning model based on brain atrophy patterns. Cell Reports Medicine, 2021, 2, 100467.	3.3	15
2056	Lifestyle Variables Such as Daily Internet Use, as Promising Protective Factors against Cognitive Impairment in Patients with Subjective Memory Complaints. Preliminary Results. Journal of Personalized Medicine, 2021, 11, 1366.	1.1	4
2057	A three-range approach enhances the prognostic utility of CSF biomarkers in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12270.	1.8	3
2058	OUP accepted manuscript. Archives of Clinical Neuropsychology, 2022, , .	0.3	1
2059	Blood-brain barrier dysfunction and reduced cerebrospinal fluid levels of soluble amyloid precursor protein <sup>2</sup> in patients with subcortical small-vessel disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12296.	1.2	5
2060	Alzheimer's Disease Assessments Optimized for Diagnostic Accuracy and Administration Time. IEEE Journal of Translational Engineering in Health and Medicine, 2022, 10, 1-9.	2.2	6
2063	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases. Journal of Neurology, 2022, 269, 4110-4128.	1.8	7
2064	Correlates of Conversion from Mild Cognitive Impairment to Dementia with Lewy Bodies: Data from the National Alzheimer's Coordinating Center. Journal of Alzheimer's Disease, 2022, 86, 1643-1654.	1.2	6
2065	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	1.4	7
2066	Diagnosing Alzheimer's Disease from Circulating Blood Leukocytes Using a Fluorescent Amyloid Probe. Journal of Alzheimer's Disease, 2022, 85, 1721-1734.	1.2	3
2067	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. Neurology, 2022, 98, .	1.5	10
2069	Structural (dys)connectivity associates with cholinergic cell density in Alzheimer's disease. Brain, 2022, 145, 2869-2881.	3.7	15
2070	Association of Variation in Behavioral Symptoms With Initial Cognitive Phenotype in Adults With Dementia Confirmed by Neuropathology. JAMA Network Open, 2022, 5, e220729.	2.8	11
2071	Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years. Neurology, 2022, 98, .	1.5	10
2072	Eye-gaze Strategies During Facial Emotion Recognition in Neurodegenerative Diseases and Links With Neuropsychiatric Disorders. Cognitive and Behavioral Neurology, 2022, 35, 14-31.	0.5	5

#	ARTICLE	IF	CITATIONS
2073	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 40.	3.0	30
2074	Dopamine transporter SPECT imaging in corticobasal syndrome: A peak into the underlying pathology?. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 762-769.	1.0	4
2075	Fluid Biomarkers in Alzheimer's Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments. <i>Diagnostics</i> , 2022, 12, 796.	1.3	4
2076	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
2077	A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer's Disease. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 386-399.	0.6	3
2078	Automatized FACEmemory <sup>®</sup> scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 43.	3.0	8
2079	Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review. <i>European Journal of Neuroscience</i> , 2022, 56, 5650-5713.	1.2	4
2081	The Role of Tau beyond Alzheimer's Disease: A Narrative Review. <i>Biomedicines</i> , 2022, 10, 760.	1.4	12
2082	Central Auditory Functions of Alzheimer's Disease and Its Preclinical Stages: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2022, 11, 1007.	1.8	12
2083	Predictive Diagnostic Approach to Dementia and Dementia Subtypes Using Wireless and Mobile Electroencephalography: A Pilot Study. <i>Bioelectricity</i> , 2022, 4, 3-11.	0.6	1
2084	Characterization of Vitamin D Status in Older Persons with Cognitive Impairment. <i>Nutrients</i> , 2022, 14, 1142.	1.7	6
2085	Expert Consensus on Cognitive Dysfunction in Diabetes. <i>Current Medical Science</i> , 2022, 42, 286-303.	0.7	2
2086	Evaluation of the Accuracy of Cognitive Screening Tests in Detecting Dementia Associated with Alzheimer's Disease: A Hierarchical Bayesian Latent Class Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 285-304.	1.2	5
2087	Validity of cingulate-precuneus-temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer's Disease. <i>Journal of Neurology</i> , 2022, 269, 4440-4451.	1.8	3
2088	Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years. <i>Alzheimer's and Dementia</i> , 2023, 19, 25-35.	0.4	26
2089	Plasma neurofilament light chain as a biomarker of Alzheimer's disease in Subjective Cognitive Decline and Mild Cognitive Impairment. <i>Journal of Neurology</i> , 2022, 269, 4270-4280.	1.8	30
2090	VAMP2 Expression and Genotype Are Possible Discriminators in Different Forms of Dementia. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 858162.	1.7	2
2091	Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Neurology International</i> , 2022, 14, 357-367.	1.3	2

#	ARTICLE	IF	CITATIONS
2092	Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1061-1072.	1.2	1
2093	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34
2094	Exploring Network Properties Across Preclinical Stages of Alzheimer's Disease Using a Visual Short-Term Memory and Attention Task with High-Density Electroencephalography: A Brain-Connectome Neurophysiological Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 643-664.	1.2	4
2095	Mechanism of Tripeptide Trimming of Amyloid $\beta$ -Peptide 49 by $\beta$ -Secretase. <i>Journal of the American Chemical Society</i> , 2022, 144, 6215-6226.	6.6	26
2096	Early dementia diagnosis, MCI to dementia risk prediction, and the role of machine learning methods for feature extraction from integrated biomarkers, in particular for EEG signal analysis. <i>Alzheimer's and Dementia</i> , 2022, 18, 2699-2706.	0.4	23
2097	Decreased Electroencephalography Global Field Synchronization in Slow-Frequency Bands Characterizes Synaptic Dysfunction in Amnesic Subtypes of Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 755454.	1.7	2
2098	Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications. <i>Cells</i> , 2022, 11, 1279.	1.8	11
2099	The Free and Cued Selective Reminding Test: Discriminative Values in a Naturalistic Cohort. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 887-899.	1.2	1
2100	Behavior of olfactory-related frontal lobe oscillations in Alzheimer's disease and MCI: A pilot study. <i>International Journal of Psychophysiology</i> , 2022, 175, 43-53.	0.5	5
2101	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
2102	Inorganic Nanomaterial for Biomedical Imaging of Brain Diseases. <i>Molecules</i> , 2021, 26, 7340.	1.7	8
2103	Neuroimaging alterations in dementia with Lewy bodies and neuroimaging differences between dementia with Lewy bodies and Alzheimer's disease: An activation likelihood estimation meta-analysis. <i>CNS Neuroscience and Therapeutics</i> , 2022, 28, 183-205.	1.9	8
2104	Association of rs3027178 polymorphism in the circadian clock gene PER1 with susceptibility to Alzheimer's disease and longevity in an Italian population. <i>GeroScience</i> , 2022, 44, 881-896.	2.1	6
2105	A peripheral lipid sensor GPR120 remotely contributes to suppression of PGD <sub>2</sub> -microglia-provoked neuroinflammation and neurodegeneration in the mouse hippocampus. <i>Journal of Neuroinflammation</i> , 2021, 18, 304.	3.1	10
2106	Impaired performances on the category cued memory test in mild Alzheimer's disease and dementia with Lewy bodies: A comparative validity study. <i>Applied Neuropsychology Adult</i> , 2021, , 1-6.	0.7	3
2107	Structural Covariance Network as an Endophenotype in Alzheimer's Disease-Susceptible Single-Nucleotide Polymorphisms and the Correlations With Cognitive Outcomes. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 721217.	1.7	5
2108	Genetically modified large animal models for investigating neurodegenerative diseases. <i>Cell and Bioscience</i> , 2021, 11, 218.	2.1	14
2109	Cyral hinges account for the highest cost and the highest communication capacity in a corticocortical network. <i>Cerebral Cortex</i> , 2022, 32, 3359-3376.	1.6	6

#	ARTICLE	IF	CITATIONS
2110	Oxidative Stress Biomarkers and Mitochondrial DNA Copy Number Associated with APOE4 Allele and Cholinesterase Inhibitor Therapy in Patients with Alzheimer's Disease. <i>Antioxidants</i> , 2021, 10, 1971.	2.2	8
2111	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	3.3	122
2112	Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid- $\beta$ peptides 1-42 and 1-40 in CSF. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 198-206.	1.4	2
2113	The borderland between normal aging and dementia. <i>Tzu Chi Medical Journal</i> , 2017, 29, 65.	0.4	24
2114	Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer's disease: a meta-analysis and systematic review. <i>Neural Regeneration Research</i> , 2022, 17, 2381.	1.6	22
2115	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. <i>Frontiers in Neurology</i> , 2022, 13, 870799.	1.1	4
2116	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1058-1063.	1.4	4
2117	Alzheimer's Disease-Related Psychosis: An Overview of Clinical Manifestations, Pathogenesis, and Current Treatment. <i>Current Alzheimer Research</i> , 2022, 19, 285-301.	0.7	1
2118	Brain pathological changes during neurodegenerative diseases and their identification methods: How does QSM perform in detecting this process?. <i>Insights Into Imaging</i> , 2022, 13, 74.	1.6	9
2119	A Tau Pathogenesis-Based Network Pharmacology Approach for Exploring the Protections of Chuanxiong Rhizoma in Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2022, 13, 877806.	1.6	10
2169	Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline. <i>Neurological Sciences</i> , 2022, 43, 4107-4124.	0.9	37
2170	The spatial layout of doorways and environmental boundaries shape the content of event memories. <i>Cognition</i> , 2022, 225, 105091.	1.1	2
2173	Language breakdown in primary progressive aphasias. <i>Annals of Indian Academy of Neurology</i> , 2020, 23, 67.	0.2	1
2174	The management of dementia worldwide: A review on policy practices, clinical guidelines, end-of-life care, and challenge along with aging population. <i>BioScience Trends</i> , 2022, 16, 119-129.	1.1	7
2175	Theranostic nanoagents: Future of personalized nanomedicine. , 2022, , 349-378.		0
2176	Is the Brain Undernourished in Alzheimer's Disease?. <i>Nutrients</i> , 2022, 14, 1872.	1.7	7
2177	Correlation Between Brain Structure Atrophy and Plasma Amyloid- $\beta$ and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnesic Mild Cognitive Impairment Explored by Surface-Based Morphometry. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 816043.	1.7	10
2178	Acquisition and consolidation of verbal learning and episodic memory as predictors of the conversion from mild cognitive impairment to probable Alzheimer's disease. <i>Aging, Neuropsychology, and Cognition</i> , 2023, 30, 638-653.	0.7	1



#	ARTICLE	IF	CITATIONS
2179	Functional Imaging for Neurodegenerative Diseases. <i>Presse Medicale</i> , 2022, 51, 104121.	0.8	3
2181	Classical Cerebrospinal Fluid Biomarkers in Dementia with Lewy Bodies. <i>Medicina (Lithuania)</i> , 2022, 58, 612.	0.8	1
2182	Sex Differences in Memory: Do Female Reproductive Factors Explain the Differences?. <i>Frontiers in Endocrinology</i> , 2022, 13, 837852.	1.5	1
2184	AD and its comorbidities: An obstacle to develop a clinically efficient treatment?. <i>Revue Neurologique</i> , 2022, , .	0.6	3
2185	Rapidly progressive dementias " aetiologies, diagnosis and management. <i>Nature Reviews Neurology</i> , 2022, 18, 363-376.	4.9	30
2186	Phonemic restoration in Alzheimer's disease and semantic dementia: a preliminary investigation. <i>Brain Communications</i> , 2022, 4, .	1.5	3
2187	Effects of different kinds of anti-Alzheimer's disease drugs on cognitive improvement: protocol for a systematic review and network meta-analysis of phase III clinical trials. <i>Systematic Reviews</i> , 2022, 11, 84.	2.5	2
2188	Biomarker A+T: is this Alzheimer's disease or not? A combined CSF and pathology study. <i>Brain</i> , 2023, 146, 1166-1174.	3.7	12
2189	Increase in Mitochondrial D-Loop Region Methylation Levels in Mild Cognitive Impairment Individuals. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5393.	1.8	9
2190	The course of primary progressive aphasia diagnosis: a cross-sectional study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 64.	3.0	4
2192	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	4.9	99
2193	The Current Landscape of Prevention Trials in Dementia. <i>Neurotherapeutics</i> , 2022, 19, 228-247.	2.1	10
2194	Epilepsy in neurodegenerative diseases. <i>Epileptic Disorders</i> , 2022, 24, 249-273.	0.7	20
2195	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	2.8	47
2196	Testing Visual Binding by the TMA-93 in People Aged 75 and Over. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	1.2	2
2197	Cerebral Iron Deposition in Neurodegeneration. <i>Biomolecules</i> , 2022, 12, 714.	1.8	38
2198	Shared pathophysiology: Understanding stroke and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2022, 218, 107306.	0.6	9
2199	A Prospective Viewpoint on Neurological Diseases and Their Biomarkers. <i>Molecules</i> , 2022, 27, 3516.	1.7	9

#	ARTICLE	IF	CITATIONS
2200	Evaluation of Alpha-Synuclein Cerebrospinal Fluid Levels in Several Neurological Disorders. <i>Journal of Clinical Medicine</i> , 2022, 11, 3139.	1.0	3
2201	Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	16
2202	Decreased Cerebral Amyloid- $\beta$ Depositions in Patients With a Lifetime History of Major Depression With Suspected Non-Alzheimer Pathophysiology. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
2203	Is the pathology of posterior cortical atrophy clinically predictable?. <i>Reviews in the Neurosciences</i> , 2022, 33, 849-858.	1.4	2
2204	Global estimates on the number of persons across the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2023, 19, 658-670.	0.4	146
2207	Outils d'imagerie dans les maladies neurodégénératives. , 2022, , 73-85.		0
2210	Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	2
2212	Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer's Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
2213	Establishment of combined diagnostic models of Alzheimer's disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS). <i>Translational Psychiatry</i> , 2022, 12, .	2.4	4
2214	Decreased Frontal Gamma Activity in Alzheimer Disease Patients. <i>Annals of Neurology</i> , 2022, 92, 464-475.	2.8	24
2215	Alzheimer's Disease with Epileptiform EEG Activity: Abnormal Cortical Sources of Resting State Delta Rhythms in Patients with Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-29.	1.2	2
2216	Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions?. <i>Neuroepidemiology</i> , 2022, 56, 309-318.	1.1	13
2217	Phosphorylated Tau 181 Serum Levels Predict Alzheimer's Disease in the Preclinical Stage. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	6
2218	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	1.8	13
2219	Abnormal Functional Connectivity of Thalamic Subdivisions in Alzheimer's Disease: A Functional Magnetic Resonance Imaging Study. <i>Neuroscience</i> , 2022, 496, 73-82.	1.1	6
2220	A Metallomic Approach to Assess Associations of Plasma Metal Levels with Amnesic Mild Cognitive Impairment and Alzheimer's Disease: An Exploratory Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 3655.	1.0	1
2221	Machine Learning for Alzheimer's Disease Detection Based on Neuroimaging techniques: A Review. , 2022, , .		0
2222	A Dichotomous Role for FABP7 in Sleep and Alzheimer's Disease Pathogenesis: A Hypothesis. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	6

#	ARTICLE	IF	CITATIONS
2223	Tau as a Biomarker of Neurodegeneration. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7307.	1.8	28
2224	Contribution of Memory Tests to Early Identification of Conversion from Amnesic Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1397-1409.	1.2	5
2225	Bioinspired Self-assembly Nanochaperone Inhibits Tau-Derived PHF6 Peptide Aggregation in Alzheimer's Disease. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2022, 40, 1062-1070.	2.0	3
2226	A Validation Study of the Hong Kong Brief Cognitive Test for Screening Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1523-1532.	1.2	3
2227	Characteristic of process analysis on instrumental activities of daily living according to the severity of cognitive impairment in community-dwelling older adults with Alzheimer's disease. <i>International Psychogeriatrics</i> , 0, , 1-12.	0.6	4
2228	The perspectives of family caregivers of people with Alzheimer's disease regarding advance care planning in China: a qualitative research. <i>BMC Psychiatry</i> , 2022, 22, .	1.1	2
2229	Modulation of Brain Activity and Functional Connectivity by Acupuncture Combined With Donepezil on Mild-to-Moderate Alzheimer's Disease: A Neuroimaging Pilot Study. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4
2230	Convergent functional changes of the episodic memory impairment in mild cognitive impairment: An ALE meta-analysis. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	7
2231	The road to precision medicine: Eliminating the "One Size Fits All" approach in Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113337.	2.5	17
2232	Update on the Cognitive Presentations of iNPH for Clinicians. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
2233	Grey matter changes on brain MRI in subjective cognitive decline: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	8
2234	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. <i>Pharmaceutics</i> , 2022, 14, 1532.	2.0	3
2236	Amyloid-beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years. <i>Alzheimer's and Dementia</i> , 2023, 19, 1020-1028.	0.4	23
2237	Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer's disease. <i>European Radiology</i> , 2023, 33, 184-195.	2.3	9
2238	Alzheimer's disease: a scoping review of biomarker research and development for effective disease diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 681-703.	1.5	5
2239	Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4589-4600.	3.3	4
2240	A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	1
2241	Alzheimer disease and neuroinflammation in Down syndrome. , 2022, , 321-367.		0

#	ARTICLE	IF	CITATIONS
2242	The Clinical Use of Alzheimer's Disease Biomarkers in Patients with Mild Cognitive Impairment: A European Alzheimer's Disease Consortium Survey. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 535-551.	1.2	7
2243	MRI-based model for MCI conversion using deep zero-shot transfer learning. <i>Journal of Supercomputing</i> , 0, , .	2.4	1
2244	Blood levels of circulating methionine components in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
2245	Frequency of Parkinson's Disease Genes and Role of PARK2 in Amyotrophic Lateral Sclerosis: An NGS Study. <i>Genes</i> , 2022, 13, 1306.	1.0	4
2246	Early diagnosis of Alzheimer's disease using machine learning: a multi-diagnostic, generalizable approach. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	24
2247	Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8598.	1.8	9
2248	Proteomic Discovery and Validation of Novel Fluid Biomarkers for Improved Patient Selection and Prediction of Clinical Outcomes in Alzheimer's Disease Patient Cohorts. <i>Proteomes</i> , 2022, 10, 26.	1.7	9
2249	A comparison of the composition and functions of the oral and gut microbiotas in Alzheimer's patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	11
2250	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	16
2251	CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 1059-1065.	0.9	13
2252	Amyloid- $\beta$ levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy. <i>Brain</i> , 2022, 145, 4032-4041.	3.7	12
2253	Clinical and metabolic imaging features of late-onset and early-onset posterior cortical atrophy. <i>European Journal of Neurology</i> , 0, , .	1.7	2
2254	Is liquid biopsy mature enough for the diagnosis of Alzheimer's disease?. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	9
2255	Effect of cognitive reserve on amnesic mild cognitive impairment due to Alzheimer's disease defined by fluorodeoxyglucose-positron emission tomography. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	1
2256	Disfluency patterns in Alzheimer's disease and frontotemporal lobar degeneration. <i>Clinical Linguistics and Phonetics</i> , 0, , 1-14.	0.5	0
2257	Association Plasma A $\beta$ 242 Levels with Alzheimer's Disease and Its Influencing Factors in Chinese Elderly Population. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 18, 1831-1841.	1.0	1
2258	Biological determinants of blood-based cytokines in the Alzheimer's disease clinical continuum. <i>Journal of Neurochemistry</i> , 0, , .	2.1	2
2259	Plasma P-Tau181 for the Discrimination of Alzheimer's Disease from Other Primary Dementing and/or Movement Disorders. <i>Biomolecules</i> , 2022, 12, 1099.	1.8	3

#	ARTICLE	IF	CITATIONS
2260	GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network. <i>Computational Intelligence and Neuroscience</i> , 2022, 2022, 1-15.	1.1	4
2261	Effect of acupuncture with donepezil based on syndrome differentiation on cognitive function in patients with mild-to-moderate Alzheimer's disease: a study protocol for a multicenter randomized controlled trial. <i>Trials</i> , 2022, 23, .	0.7	0
2262	Alzheimer's disease classification based on graph kernel SVMs constructed with 3D texture features extracted from MR images. <i>Expert Systems With Applications</i> , 2023, 211, 118633.	4.4	11
2263	Dementia Disease Detection from Psychiatric Disorders Based on Automatic Speech Analysis. <i>Advanced Technologies and Societal Change</i> , 2023, , 95-102.	0.8	1
2264	Effects of age, sex, and education on California Verbal Learning Test-II performance in a Chinese-speaking population. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	2
2265	Designing the next-generation clinical care pathway for Alzheimer's disease. <i>Nature Aging</i> , 2022, 2, 692-703.	5.3	44
2266	Genetic association of apolipoprotein E genotype with EEG alpha rhythm slowing and functional brain network alterations during normal aging. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	4
2267	Network synchronization deficits caused by dementia and Alzheimer's disease serve as topographical biomarkers: a pilot study. <i>Brain Structure and Function</i> , 2022, 227, 2957-2969.	1.2	8
2268	Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1879.	1.4	1
2269	Biomarker and therapeutic potential of peripheral extracellular vesicles in Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2022, 190, 114486.	6.6	14
2270	Exploring Early Physical Examination Diagnostic Biomarkers for Alzheimer's Disease Based on Least Absolute Shrinkage and Selection Operator. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-10.	0.7	2
2271	Longitudinal Clinical and Cognitive Changes Along the Alzheimer Disease Continuum in Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2225573.	2.8	11
2272	Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease. <i>Human Brain Mapping</i> , 2023, 44, 327-340.	1.9	2
2273	The New Zealand Parkinson's progression programme. <i>Journal of the Royal Society of New Zealand</i> , 2023, 53, 466-488.	1.0	2
2274	Validation of the Alzheimer's disease-resemblance atrophy index in classifying and predicting progression in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
2276	Iron in Alzheimer's Disease: From Physiology to Disease Disabilities. <i>Biomolecules</i> , 2022, 12, 1248.	1.8	18
2277	OMICS in Schizophrenia and Alzheimer's Disease. , 2022, , 109-119.		0
2278	The temporal lobe in typical and atypical Alzheimer disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2022, , 449-466.	1.0	5

#	ARTICLE	IF	CITATIONS
2279	What is new in nuclear medicine imaging for dementia. <i>Noropsikiyatri Arsivi</i> , 2022, , .	0.2	1
2280	White matter hyperintensity distribution differences in aging and neurodegenerative disease cohorts. <i>NeuroImage: Clinical</i> , 2022, 36, 103204.	1.4	9
2281	Characterizing TMS-EEG perturbation indexes using signal energy: initial study on Alzheimer's Disease classification. , 2022, , .		0
2282	A Retrospective Study on Clinical Assessment of Cognitive Impairment in a Swedish Cohort: Is There Inequality Between Natives and Foreign-Born?. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	1.2	0
2283	Experiences of Active Everyday Life Among Persons with Prodromal Alzheimerâ€™s Disease: A Qualitative Study. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 15, 1921-1932.	1.1	1
2284	Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1179.	0.8	4
2285	Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimerâ€™s disease: protocol for the ExPlas study. <i>BMJ Open</i> , 2022, 12, e056964.	0.8	2
2286	Evaluation of Synaptic and Axonal Dysfunction Biomarkers in Alzheimerâ€™s Disease and Mild Cognitive Impairment Based on CSF and Bioinformatic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10867.	1.8	3
2287	Optimal MoCA cutoffs for detecting biologically-defined patients with MCI and early dementia. <i>Neurological Sciences</i> , 2023, 44, 159-170.	0.9	7
2288	Dementia-related genetic variants in an Italian population of early-onset Alzheimerâ€™s disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
2290	Neuropsychological, Metabolic, and Connectivity Underpinnings of Semantic Interference Deficits Using the LASSI-L. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-18.	1.2	1
2291	Case Report: A neurolinguistic and neuroimaging study on a Chinese follow-up case with logopenic-variant of primary progressive aphasia. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	0
2292	Cognitive and Brain Metabolism Profiles of Mild Cognitive Impairment in Prodromal Alpha-Synucleinopathy. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 433-444.	1.2	2
2293	TREM2 risk variants are associated with atypical Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2022, 144, 1085-1102.	3.9	7
2294	Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 761-773.	1.2	5
2295	Characteristics of Drawing Process Differentiate Alzheimerâ€™s Disease and Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 693-704.	1.2	3
2296	Aquaporin-4 cerebrospinal fluid levels are higher in neurodegenerative dementia: looking at glymphatic system dysregulation. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	18
2297	<scp>Magnetic resonance imaging</scp> Locus Coeruleus abnormality in amnesic Mild Cognitive Impairment is associated with future progression to dementia. <i>European Journal of Neurology</i> , 2023, 30, 32-46.	1.7	13

#	ARTICLE	IF	CITATIONS
2298	Associations of Stages of Objective Memory Impairment with Cerebrospinal Fluid and Neuroimaging Biomarkers of Alzheimer's Disease. <i>Journal of prevention of Alzheimer's disease</i> , The, 0, , .	1.5	2
2299	Speech and language characteristics differentiate Alzheimer's disease and dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	8
2300	Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-9.	1.2	1
2302	Early-stage differentiation between Alzheimer's disease and frontotemporal lobe degeneration: Clinical, neuropsychology, and neuroimaging features. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
2303	Neuropsychological profiles and neural correlates in typical and atypical variants of Alzheimer disease: A systematic qualitative review. <i>Neurology Perspectives</i> , 2022, , .	0.2	0
2304	Randomized, sham-controlled, clinical trial of repetitive transcranial magnetic stimulation for patients with Alzheimer's dementia in Japan. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	8
2305	Developing a Danish version of the LASSI-L test – reliability and predictive value in patients with mild cognitive impairment, mild dementia due to AD and subjective cognitive decline. <i>Aging, Neuropsychology, and Cognition</i> , 2024, 31, 174-186.	0.7	0
2306	Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1381-1393.	1.2	2
2307	A practical Alzheimer's disease classifier via brain imaging-based deep learning on 85,721 samples. <i>Journal of Big Data</i> , 2022, 9, .	6.9	21
2308	Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	33
2309	How Do Our Brains Change as We Age?. <i>Frontiers for Young Minds</i> , 0, 10, .	0.8	0
2310	Cerebrospinal Fluid Biomarker Profile in TDP-43-Related Genetic Frontotemporal Dementia. <i>Journal of Personalized Medicine</i> , 2022, 12, 1747.	1.1	4
2311	Social cognition deficits and biometric signatures in the behavioural variant of Alzheimer's disease. <i>Brain</i> , 2023, 146, 2163-2174.	3.7	4
2312	Preclinical Alzheimer's dementia: a useful concept or another dead end?. <i>European Journal of Ageing</i> , 2022, 19, 997-1004.	1.2	5
2313	A Novel Automated Chemiluminescence Method for Detecting Cerebrospinal Fluid Amyloid-Beta 1-42 and 1-40, Total Tau and Phosphorylated-Tau: Implications for Improving Diagnostic Performance in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 2667.	1.4	8
2314	Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial. <i>Brain</i> , 2022, 145, 3776-3786.	3.7	58
2315	Investigating Tissue-Specific Abnormalities in Alzheimer's Disease with Multi-Shell Diffusion MRI. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1771-1791.	1.2	2
2316	CSF p-tau as a potential cognition impairment biomarker in ALS. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	4

#	ARTICLE	IF	CITATIONS
2317	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. <i>Fundamental Research</i> , 2023, 3, 505-519.	1.6	4
2318	Characterization of the logopenic variant of Primary Progressive Aphasia: A systematic review and meta-analysis. <i>Ageing Research Reviews</i> , 2022, 82, 101760.	5.0	15
2319	Elevated hippocampal copper in cases of type 2 diabetes. <i>EBioMedicine</i> , 2022, 86, 104317.	2.7	6
2320	AChE as a spark in the Alzheimer's blaze – Antagonizing effect of a cyclized variant. <i>Ageing Research Reviews</i> , 2023, 83, 101787.	5.0	4
2321	Alzheimer's Disease: Treatment Strategies and Their Limitations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13954.	1.8	66
2322	A distribution-free smoothed combination method to improve discrimination accuracy in multi-category classification. <i>Statistical Methods in Medical Research</i> , 0, , 096228022211377.	0.7	1
2323	Brain metabolic correlates of Locus Coeruleus degeneration in Alzheimer's disease: a multimodal neuroimaging study. <i>Neurobiology of Aging</i> , 2023, 122, 12-21.	1.5	3
2324	PET molecular imaging for pathophysiological visualization in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 765-783.	3.3	18
2325	Genistein effect on cognition in prodromal Alzheimer's disease patients. The GENIAL clinical trial. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	11
2327	Blood Selenium and Serum Glutathione Peroxidase Levels Were Associated with Serum $\beta$ -Amyloid in Older Adults. <i>Biological Trace Element Research</i> , 2023, 201, 3679-3687.	1.9	5
2328	Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	10
2329	Hyperconnectivity matters in early-onset Alzheimer's disease: a resting-state EEG connectivity study. <i>Neurophysiologie Clinique</i> , 2022, 52, 459-471.	1.0	3
2330	Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges. <i>Revue Neurologique</i> , 2023, 179, 161-172.	0.6	12
2331	Toward the Identification of Neurophysiological Biomarkers for Alzheimer's Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis. , 2022, .		2
2332	Distinct reserve capacity impacts on default-mode network in response to left angular gyrus-navigated repetitive transcranial magnetic stimulation in the prodromal Alzheimer disease. <i>Behavioural Brain Research</i> , 2023, 439, 114226.	1.2	2
2333	The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, .	1.5	0
2334	Cerebrospinal fluid levels of fatty acid-binding protein 3 are associated with likelihood of amyloidopathy in cognitively healthy individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, .	1.2	3
2336	Visinin-like protein 1 levels in blood and CSF as emerging markers for Alzheimer's and other neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	5



#	ARTICLE	IF	CITATIONS
2337	Differential compartmentalization of myeloid cell phenotypes and responses towards the CNS in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, .	5.8	7
2338	Remote versus face-to-face neuropsychological testing for dementia research: a comparative study in people with Alzheimer's disease, frontotemporal dementia and healthy older individuals. <i>BMJ Open</i> , 2022, 12, e064576.	0.8	8
2339	Serum unsaturated phosphatidylcholines predict longitudinal basal forebrain degeneration in Alzheimer's disease. <i>Brain Communications</i> , 2022, 4, .	1.5	3
2340	Liver Enzymes in a Cohort of Community-Dwelling Older Persons: Focus on Sex Contribution. <i>Nutrients</i> , 2022, 14, 4973.	1.7	7
2341	Plasma phosphorylated tau181 predicts cognitive and functional decline. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 18-31.	1.7	7
2342	Bipolar spectrum disorders in neurologic disorders. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	2
2343	Hippocampal subfield volumetry in corticobasal syndrome of diverse underlying pathologies. <i>Journal of Neurology</i> , 2023, 270, 2059-2068.	1.8	1
2344	Cognitive Decline Related to Diet Pattern and Nutritional Adequacy in Alzheimer's Disease Using Surface-Based Morphometry. <i>Nutrients</i> , 2022, 14, 5300.	1.7	2
2345	SOBA: Development and testing of a soluble oligomer binding assay for detection of amyloidogenic toxic oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
2346	Association of Brain Volume and Retinal Thickness in the Early Stages of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 743-752.	1.2	3
2347	Novel Algorithm of Network Calcium Dynamics Analysis for Studying the Role of Astrocytes in Neuronal Activity in Alzheimer's Disease Models. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15928.	1.8	4
2348	Trajectories of Cognitive Impairment in Adults Bearing Vascular Risk Factors, with or without Diagnosis of Mild Cognitive Impairment: Findings from a Longitudinal Study Assessing Executive Functions, Memory, and Social Cognition. <i>Diagnostics</i> , 2022, 12, 3017.	1.3	1
2349	Inhibition of mGluR5/PI3K-AKT Pathway Alleviates Alzheimer's Disease-Like Pathology Through the Activation of Autophagy in 5XFAD Mice. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 1197-1214.	1.2	4
2351	Recognizing Atypical Presentations of Alzheimer's Disease: The Importance of CSF Biomarkers in Clinical Practice. <i>Diagnostics</i> , 2022, 12, 3011.	1.3	2
2352	CSF biomarkers for early-onset Alzheimer's disease in Chinese population from PUMCH dementia cohort. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
2353	Altered delay discounting in neurodegeneration: insight into the underlying mechanisms and perspectives for clinical applications. <i>Neuroscience and Biobehavioral Reviews</i> , 2023, , 105048.	2.9	2
2354	The expression pattern of GDF15 in human brain changes during aging and in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
2355	Adversarially-Regularized Mixed Effects Deep Learning (ARMED) Models Improve Interpretability, Performance, and Generalization on Clustered (non-iid) Data. <i>IEEE Transactions on Pattern Analysis and Machine Intelligence</i> , 2023, , 1-13.	9.7	0

#	ARTICLE	IF	CITATIONS
2356	Home-based transcranial direct current stimulation in mild neurocognitive disorder due to possible Alzheimer's disease. A randomised, single-blind, controlled-placebo study. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	3
2357	Neuropsychological Assessment in the Distinction Between Biomarker Defined Frontal-Variant of Alzheimer's Disease and Behavioral-Variant of Frontotemporal Dementia. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 1303-1312.	1.2	1
2358	Localization, induction, and cellular effects of tau phosphorylated at threonine 217 <sup>1</sup> . <i>Alzheimer's and Dementia</i> , 2023, 19, 2874-2887.	0.4	6
2359	Wechsler memory scale—fourth edition (WMS—IV) in the neuropsychological evaluation of patients diagnosed with probable Alzheimer's disease. <i>Applied Neuropsychology Adult</i> , 0, , 1-8.	0.7	2
2360	Visuoconstructional Abilities of Patients With Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 0, , 089198872211355.	1.2	0
2361	Differences in structural MRI and diffusion tensor imaging underlie visuomotor performance declines in older adults with an increased risk for Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
2362	Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia. <i>Diagnostics</i> , 2023, 13, 332.	1.3	1
2363	A Note on Changing Approach to Diagnosis of Alzheimer's Disease. <i>European Medical Journal Neurology</i> , 0, , 87-94.	0.0	1
2365	How an Intergenerational Book Club Can Prevent Cognitive Decline in Older Adults: A Pilot Study. <i>Gerontology and Geriatric Medicine</i> , 2023, 9, 233372142211500.	0.8	0
2366	The Future of Precision Medicine in the Cure of Alzheimer's Disease. <i>Biomedicines</i> , 2023, 11, 335.	1.4	7
2367	Infection-specific PET imaging with 18F-fluorodeoxysorbitol and 2-[18F]F- $\beta$ -aminobenzoic acid: An extended diagnostic tool for bacterial and fungal diseases. <i>Frontiers in Microbiology</i> , 0, 14, .	1.5	0
2369	Corneal nerve loss predicts dementia in patients with mild cognitive impairment. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	1.7	1
2371	Steeper memory decline after COVID-19 lockdown measures. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	3
2372	Neuronal Hyperactivation in EEG Data during Cognitive Tasks Is Related to the Apolipoprotein J/Clusterin Genotype in Nondemented Adults. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6790.	1.8	0
2373	Auditory Event-Related Potentials in Older Adults with Subjective Memory Complaints. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1093-1109.	1.2	1
2374	Cortical hyperexcitability and plasticity in Alzheimer's disease: developments in understanding and management. <i>Expert Review of Neurotherapeutics</i> , 2022, 22, 981-993.	1.4	1
2375	Plasma microglial-derived extracellular vesicles are increased in frail patients with Mild Cognitive Impairment and exert a neurotoxic effect. <i>GeroScience</i> , 2023, 45, 1557-1571.	2.1	8
2377	The Amyloid-Beta Clearance: From Molecular Targets to Glial and Neural Cells. <i>Biomolecules</i> , 2023, 13, 313.	1.8	8

#	ARTICLE	IF	CITATIONS
2378	Revisiting the intersection of microglial activation and neuroinflammation in Alzheimer's disease from the perspective of ferroptosis. <i>Chemico-Biological Interactions</i> , 2023, 375, 110387.	1.7	12
2379	The architecture of abnormal reward behaviour in dementia: multimodal hedonic phenotypes and brain substrate. <i>Brain Communications</i> , 2023, 5, .	1.5	2
2380	Neuropsychiatric Symptoms and Caregiver Stress in Parkinson's Disease with Cognitive Impairment, Alzheimer's Disease, and Frontotemporal Dementia. <i>Journal of Parkinson's Disease</i> , 2023, 13, 243-254.	1.5	0
2381	Forecasting the Prevalence of Alzheimer's Disease at Mild Cognitive Impairment and Mild Dementia Stages in France in 2022. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, .	1.5	0
2382	Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging. <i>Brain and Behavior</i> , 2023, 13, .	1.0	4
2383	What happens when people develop dementia whilst working? An exploratory multiple case study. <i>International Journal of Qualitative Studies on Health and Well-being</i> , 2023, 18, .	0.6	1
2384	CSF A $\beta$ 42 and A $\beta$ 42/A $\beta$ 40 Ratio in Alzheimer's Disease and Frontotemporal Dementias. <i>Diagnostics</i> , 2023, 13, 783.	1.3	4
2385	PASSED: Brain atrophy in non-demented individuals in a long-term longitudinal study from two independent cohorts. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	1
2386	A Review on Garlic as a Supplement for Alzheimer's Disease: A Mechanistic Insight into its Direct and Indirect Effects. <i>Current Pharmaceutical Design</i> , 2023, 29, 519-526.	0.9	1
2387	The use of virtual reality in screening for preclinical Alzheimer's disease: A scoping review protocol. <i>PLoS ONE</i> , 2023, 18, e0282436.	1.1	0
2388	Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	12
2389	Clinical Features and Classification of Neuronal Intranuclear Inclusion Disease. <i>Neurology: Genetics</i> , 2023, 9, .	0.9	10
2390	Dementia Disease Detection from Psychiatric Disorders Based on Automatic Speech Analysis. <i>Advanced Technologies and Societal Change</i> , 2023, , 123-130.	0.8	0
2391	The Future: Moving from Phenotypically Defined Diseases Toward Pathophysiological Systems. <i>Canadian Journal of Neurological Sciences</i> , 2024, 51, 110-112.	0.3	0
2393	Decoding the Roles of Amyloid- $\beta$ (1-42) Key Oligomerization Domains toward Designing Epitope-Specific Aggregation Inhibitors. <i>Jacs Au</i> , 2023, 3, 1065-1075.	3.6	7
2394	Machine Learning-Assisted Nanoenzyme/Bioenzyme Dual-Coupled Array for Rapid Detection of Amyloids. <i>Analytical Chemistry</i> , 2023, 95, 4605-4611.	3.2	8
2395	$\beta$ -Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid: A Systematic Review and Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2023, 10, 737-747.	0.8	9
2396	Cure of Alzheimer's Dementia Requires Addressing All of the Affected Brain Cell Types. <i>Journal of Clinical Medicine</i> , 2023, 12, 2049.	1.0	6

#	ARTICLE	IF	CITATIONS
2397	Cellular response to $\beta$ -amyloid neurotoxicity in Alzheimer's disease and implications in new therapeutics. <i>Animal Models and Experimental Medicine</i> , 2023, 6, 3-9.	1.3	6
2398	Visual atrophy rating scales and amyloid $\langle$ sc $\rangle$ PET $\langle$ /sc $\rangle$ status in an Alzheimer's disease clinical cohort. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 619-631.	1.7	2
2399	Two Routes to Alzheimer's Disease Based on Differential Structural Changes in Key Brain Regions. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1399-1412.	1.2	0
2401	Metal-Organic Frameworks as Sensors for Human Amyloid Diseases. <i>ACS Sensors</i> , 2023, 8, 1033-1053.	4.0	14
2403	The Global Deterioration Scale for Down Syndrome Population (GDS-DS): A Rating Scale to Assess the Progression of Alzheimer's Disease. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 5096.	1.2	1
2404	Contribution of clinical information to the predictive performance of plasma $\beta$ -amyloid levels for amyloid positron emission tomography positivity. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	1
2405	Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
2406	Cortical tau is associated with microstructural imaging biomarkers of neurite density and dendritic complexity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 2750-2754.	0.4	1
2408	The Progression of Current Biomarkers for the Diagnosis of Alzheimer's Disease. , 0, 36, 621-627.		0
2409	Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. <i>Neuropsychiatric Disease and Treatment</i> , 0, Volume 19, 647-660.	1.0	4
2410	Early Alzheimer's Disease Diagnosis Using Wearable Sensors and Multilevel Gait Assessment: A Machine Learning Ensemble Approach. <i>IEEE Sensors Journal</i> , 2023, 23, 10041-10053.	2.4	3
2411	Natural language processing techniques for studying language in pathological ageing: A scoping review. <i>International Journal of Language and Communication Disorders</i> , 2024, 59, 110-122.	0.7	2
2412	Visual deep learning of unprocessed neuroimaging characterises dementia subtypes and generalises across non-stereotypic samples. <i>EBioMedicine</i> , 2023, 90, 104540.	2.7	9
2414	Non-Ceruloplasmin Copper Identifies a Subtype of Alzheimer's Disease (CuAD): Characterization of the Cognitive Profile and Case of a CuAD Patient Carrying an RGS7 Stop-Loss Variant. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6377.	1.8	8
2415	Tau accumulates differently in four subtypes of Alzheimer's disease. <i>Neurology and Clinical Neuroscience</i> , 2023, 11, 231-238.	0.2	0
2416	Tau positron emission tomography in tauopathies: A narrative review. <i>Precision and Future Medicine</i> , 2023, 7, 7-24.	0.5	0
2417	The Use of Diffusion Kurtosis Imaging for the Differential Diagnosis of Alzheimer's Disease Spectrum. <i>Brain Sciences</i> , 2023, 13, 595.	1.1	2
2419	Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	0

#	ARTICLE	IF	CITATIONS
2420	The identification and cognitive correlation of perfusion patterns measured with arterial spin labeling MRI in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	1
2421	Compensatory Mechanisms in Early Alzheimer's Disease and Clinical Setting: The Need for Novel Neuropsychological Strategies. <i>Journal of Alzheimer's Disease Reports</i> , 0, , 1-13.	1.2	2
2422	Apraxia and dementia severity in Alzheimer's disease: a systematic review. <i>Journal of Clinical and Experimental Neuropsychology</i> , 0, , 1-20.	0.8	2
2423	Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2023, 19, 3916-3925.	0.4	2
2425	Research progress on vestibular dysfunction and visual-spatial cognition in patients with Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 15, .	1.7	3
2426	Effects of storage conditions on the stability of blood-based markers for the diagnosis of Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1580-1589.	1.4	4
2429	Disambiguation of Cognitive Impairment Diagnosis with EEG-Based Dual-Contrastive Learning. , 2023, , .		0
2431	An updated overview of recent and ongoing deep brain stimulation (DBS) trials in patients with dementia: a systematic review. <i>Neurological Sciences</i> , 0, , .	0.9	0
2444	Electroencephalogram Analysis Using Convolutional Neural Networks in Order to Diagnose Alzheimer's Disease. <i>Cognitive Technologies</i> , 2023, , 127-142.	0.5	0
2452	Recent Advances in Photoelectrochemical Sensing of Alzheimer's Biomarkers. <i>Biochip Journal</i> , 2023, 17, 218-229.	2.5	0
2458	Copper, oxidative stress, Alzheimer's disease, and dementia. , 2023, , 65-85.		0
2476	Recent developments in the chemical biology of amyloid- $\beta$ oligomer targeting. <i>Organic and Biomolecular Chemistry</i> , 2023, 21, 4540-4552.	1.5	5
2478	Detection and treatment of Alzheimer's disease in its preclinical stage. <i>Nature Aging</i> , 2023, 3, 520-531.	5.3	12
2479	Applications of fMRI to Neurodegenerative Disease. , 2023, , 819-860.		0
2481	The role of brain noradrenaline in Alzheimer's disease: Implications for a precision medicine-oriented approach. , 2024, , 526-539.		0
2486	Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias. <i>Neurotherapeutics</i> , 2023, 20, 955-974.	2.1	2
2488	The GABAergic system in Alzheimer's disease: a systematic review with meta-analysis. <i>Molecular Psychiatry</i> , 0, , .	4.1	4
2492	AD-Care DPSS Design Based on EER and EDP Framework. <i>Lecture Notes in Computer Science</i> , 2023, , 449-462.	1.0	0

#	ARTICLE	IF	CITATIONS
2493	A Real-Time Neurophysiologic Stress Test for the Aging Brain: Novel Perioperative and ICU Applications of EEG in Older Surgical Patients. <i>Neurotherapeutics</i> , 2023, 20, 975-1000.	2.1	3
2497	Neuroprotective effects of flavonoids. , 2023, , 133-200.		1
2499	Computer-Aided Diagnosis and Prediction in Brain Disorders. <i>Neuromethods</i> , 2023, , 459-490.	0.2	0
2514	Photobiomodulation Therapy for Dementia. <i>Synthesis Lectures on Biomedical Engineering</i> , 2023, , 165-189.	0.1	0
2516	A Web-Based Application for Screening Alzheimer's Disease in the Preclinical Phase. , 2023, , .		0
2527	The Role of Clinical Assessment in the Era of Biomarkers. <i>Neurotherapeutics</i> , 2023, 20, 1001-1018.	2.1	1
2546	The application of saccades to assess cognitive impairment among older adults: a systematic review and meta-analysis. <i>Aging Clinical and Experimental Research</i> , 0, , .	1.4	0
2557	Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?. <i>Journal of Neurology</i> , 0, , .	1.8	0
2573	qEEG Methods to Probe Abnormal Brain Rhythms Related to Quiet Vigilance in Patients with Dementia Due to Alzheimer's, Parkinson's, and Lewy Body Diseases. <i>Neuromethods</i> , 2024, , 67-89.	0.2	0
2574	Biomarkers of Cognitive Decline and Dementia in Down Syndrome. , 2023, , 189-205.		0
2576	Exploring the Role of Locus Coeruleus in Alzheimer's Disease: a Comprehensive Update on MRI Studies and Implications. <i>Current Neurology and Neuroscience Reports</i> , 0, , .	2.0	0
2581	Developing an Intelligent Prediction Model for Dementia from Baseline and Time Series. <i>Lecture Notes in Networks and Systems</i> , 2023, , 167-180.	0.5	0
2602	Liquid-liquid phase separation in Alzheimer's disease. <i>Journal of Molecular Medicine</i> , 2024, 102, 167-181.	1.7	0
2636	Advances in Deep Learning for the Detection of Alzheimer's Disease Using MRI: A Review. <i>Studies in Computational Intelligence</i> , 2024, , 363-388.	0.7	0
2638	A Pilot Genome-Wide Association Study of Brain Glucose Metabolism Levels in Alzheimer's Disease Based on 18F-FDG PET. <i>Lecture Notes in Electrical Engineering</i> , 2024, , 549-556.	0.3	0
2642	Amyloid PET Imaging: Standard Procedures and Semiquantification. <i>Methods in Molecular Biology</i> , 2024, , 165-175.	0.4	0
2643	Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach. <i>Methods in Molecular Biology</i> , 2024, , 195-218.	0.4	0
2646	Case report: Rapidly progressive neurocognitive disorder with a fatal outcome in a patient with PU.1 mutated agammaglobulinemia. <i>Frontiers in Immunology</i> , 0, 15, .	2.2	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------